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1 Summary 
The development of stress-related psychiatric disorders involves the integration of 
genetic and environmental factors. How these factors are integrated on a molecular 
level to determine risk or resilience is far from being understood. The long-term 
integration of both factors is thought to be mediated by epigenetic adaptations. One 
molecular mechanism for a statistical gene x environment interaction has been 
described for the FKBP5 gene (Klengel et al., 2013). This thesis aims to further 
elaborate our understanding of this molecular mechanism.  
First, a new method - High accurate methylation measurements via targeted bisulfite 
sequencing (HAM-TBS) - was established to accurately and robustly measure DNA 
methylation (DNAm) levels of key regulatory sites within the FKBP5 locus in larger 
cohorts of patients (chapter 5.1 (Paper I), discussed in chapter 6.1). The new 
possibilities of this method have been used to better understand dynamic methylation 
changes in FKBP5 due to early life stress by monitoring dynamic glucocorticoid (GC)-
induced methylation changes in healthy individuals upon a GC challenge (chapter 5.2 
(Paper II) & chapter 5.3 (Paper III), discussed in chapter 6.2). The data obtained 
indicate that the exposure to high levels of GCs can be embedded onto DNAm 
levels. In addition, the underlying dynamics of these GC-induced methylation 
changes at distinct CpGs were observed to be genotype-dependent (rs1360780). 
The processes involved in this embedding of environmental signals are not yet fully 
understood. However there are several lines of evidence that these are active 
enzymatically driven leading to dynamic epigenetic changes centered around GR 
binding sites in the FKBP5 locus.  
Furthermore, lymphoblastoid cell lines carrying different alleles for a 3.3 kb large 
insertion / deletion (INDEL, esv3608688) in intron 1 of FKBP5 have been used to 
identify if and how this INDEL in the disease-associated haplotype contributes to 
shape GC-induced FKBP5 gene expression changes (chapter 5.4 (Manuscript II), 
discussed in chapter 6.3). We identified that the stabilization of architectural and 
enhancer-promoter loops is a common feature of the factors (T-allele, deletion and 
GR activation by GCs) leading to increased FKBP5 mRNA expression. This gene 
expression response is most likely the result of an increased activity of enhancers 
due to the stabilization of chromatin interactions. However, further experiments 
manipulating the DNA sequence and DNA methylation levels of FKBP5 key 
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regulatory sites will be necessary to obtain causality. Moreover, further analysis in 
patients will help to clarify the role of INDEL alleles in the development of stress-
related psychiatry phenotypes. Finally, thoughts on future perspectives and potential 
translations into the clinical routine of the mechanistic insights of FKBP5 gene 
expression regulation are discussed (chapter 6.4).  
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1 Zusammenfassung 
Die Entstehung von stressbedingten psychiatrischen Erkrankungen involviert die 
Integration von genetischen und Umweltfaktoren. Wie diese Faktoren auf der 
molekularen Ebene integriert und somit Risiko und Resilienz vermitteln, ist weit 
davon entfernt verstanden zu werden. Man vermutet, dass die dauerhafte Integration 
beider Faktoren durch epigenetische Anpassungen vermittelt wird. Ein molekularer 
Mechanismus für eine statistische Gen-Umweltinteraktion wurde für das FKBP5 Gen 
beschrieben (Klengel et al., 2013). Die vorliegende Doktorarbeit zielt darauf ab, 
unser Verständnis des molekularen Mechanismus, der genetische und 
Umweltfaktoren integriert, besser zu verstehen.  
Als erstes wurde eine neue Methode – Hochgradig akkurate 
Methylierungsmessungen anhand von zielgerichteter Bisulfit-Sequenzierung  (HAM-
TBS) – etabliert, um die DNA Methylierungslevel von wichtigen regulatorischen 
Regionen im FKBP5 Gen akkurat und robust in größeren Patientenkohorten messen 
zu können (Kapitel 5.1 (Publikation I), diskutiert in Kapitel 6.1). Die neuen 
Möglichkeiten dieser Methode wurden dazu genutzt dynamische 
Methylierungsveränderungen in FKBP5, die aufgrund von frühkindlichem Stress 
auftreten können, weiter zu untersuchen (Kapitel 5.2 (Publikation II), diskutiert in 
Kapitel 6.2). Hierbei wurde in gesunden Probanden, die mit Dexamethason 
behandelt wurden, die zugrunde liegenden Dynamik von Glukokortikoid-induzierten 
DNA Methylierungsveränderungen in FKBP5 betrachtet (Kapitel 5.3 (Manuskript I), 
diskutiert in Kapitel 6.2). Die ermittelten Daten deuten darauf hin, dass die Exposition 
mit hohen Glukokortikoidspiegeln sich auf das DNA Methylierungslevel niederlegen 
kann. Des Weiteren kann sich die Dynamik der Glukokortikoid-induzierten 
Methylierungsveränderungen an bestimmten CpGs aufgrund von unterschiedlichen 
Genotypen ändern (rs1360780). Die beteiligten  Einbettungsprozesse der 
Umweltsignale sind noch nicht in Gänze verstanden, aber einige Evidenzen deuten 
darauf hin, dass diese aktiv enzymatisch vermittelt sind und zu dynamischen 
epigenetischen Veränderungen führen, die um Glukokortikoidrezeptorbindestellen 
zentriert im FKBP5  Lokus auftreten.  
Zusätzlich wurden Lymphoblastoide Zelllinien mit unterschiedlichen Allelen für eine 
3.3 kb große insertion / deletion (INDEL, esv3608688) in Intron 1 des FKBP5 Gens 
verwendet, um herauszufinden inwiefern die INDEL Allele im krankheitsassoziertem 
Zusammenfassung	
	 - 6 - 
Haplotyp daran beteiligt ist, die glukokorticoid-indizierten FKBP5 
Genexpressionsveränderungen zu gestalten (Kapitel 5.4 (Manuskript II), diskutiert in 
Kapitel 6.3). Wir konnten feststellen, dass die Stabilisierung von architektonischen 
und Enhancer-Promotor Loops ein gemeinsames Merkmal von Faktoren (T-allele, 
deletion und Glukokortikoidrezeptoraktivierung durch Glukokortikoide) ist, die zu 
einer erhöhten FKBP5 Expression führen. Diese Genexpressionsantwort ist 
wahrscheinlich ein Ergebnis einer erhöhten Enhanceraktivität aufgrund der 
Stabilisierung von Chromatininteraktionen. Nichtdestotrotz sind weitere Experimente 
notwendig welche die DNA Sequenz und DNA Methylierungslevel von regulatorisch 
wichtigen Regionen des FKBP5 Lokus manipulieren um Kausalität zu erlangen. 
Außerdem werden weitere Analysen von Patientendaten dazu beitragen, die Rolle 
der INDEL-allele innerhalb der Entwicklung von stressbedingten psychiatrischen 
Phänotypen aufzuklären. 
Abschließend, werden Zukunftsperspektiven und potenzielle Möglichkeiten der 
Translation in den klinischen Alltag diskutiert (Kapitel 6.4). 
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2 Abbreviations 
3C = Chromatin Conformation Capture 
4C = Circularized Chromosome Conformation Capture 
5C = Chromosome Conformation Capture Carbon Copy 
5caC = 5-Carboxylcytosine 
5fC = 5-Formylcytosine 
5hmC = 5-Hydroxymethylation 
5mC = 5-Methylcytosine 
ACTH = Adrenocorticotropin Hormone 
APOBEC = Apolipoprotein B mRNA Editing Enzyme 
AS = Angelman Syndrome 
AVP = Vasopressin 
BER = Base Excision Repair 
BWS = Beckwith-Wiedemann Syndrome 
CpGs = Cytosine Guanine Dinucleotides  
CRH = Corticotropin Releasing Hormone 
CRHR1 = Corticotropin Releasing Hormone Receptor 1  
CRISPR = Clustered Regularly Interspaced Short Palindromic Repeats  
CT = Chromosome Territory 
CTCF = CCCTC-Binding Factor 
DEX = Dexamethasone  
DNAm = DNA methylation 
DNMTs = DNA Methyltransferases 
ELS = Early-Life Stress 
eRNA = Enhancer RNA 
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EWAS = Epigenome-Wide Association Study 
FDA = Food and Drug Administration 
FISH = Fluorescence In Situ Hybridization 
FKBP5 = FK506 Binding Protein 5 
GC = Glucocorticoids 
GR = Glucocorticoid Receptor 
GRE = Glucocorticoid Responsive Element 
GWAS = Genome-Wide Association Study 
GxE = Gene-Environment Interaction 
H3K27ac = K27-acetylated Histone H3 
H3K36me3 = K36-trimethylated Histone H3 
H3K4me = K4-methylated Histone H3 
H3K4me3 = K4-trimethylated Histone H3 
HAM-TBS = High Accurate Methylation Measurements via Targeted Bisulfite 
Sequencing 
HPA axis = Hypothalamic-Pituitary-Adrenal axis 
HPCs = Hippocampal Progenitor Cells 
INDEL = Insertion / Deletion 
LAD = Lamina-Associated Domain 
LCLs = Lymphoblastoid Cell Lines 
LD = Linkage Disequilibrium 
MDD = Major Depressive Disorder 
MR = Mineralocorticoid Receptor 
mRNA = Messenger RNA 
PCR = Polymerase Chain Reaction 
PTSD = Post Traumatic Stress Disorder  
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PVN = Paraventricular Nucleus 
PWS = Prader-Willi Syndrome 
qPCR = Quantitative PCR 
RNAPII = RNA Polymerase II 
SINE = Short Interspersed Nuclear Elements 
SNP = Single-Nucleotide Polymorphism 
TAD = Topological Associating Domain 
TBS = Targeted Bisulfite Sequencing  
TET = Ten-Eleven Translocation Methylcytosine Dioxygenases 
TFs = Transcription Factors 
tRNA = Transfer RNA 
TSS = Transcription Start Site 
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3 Introduction 
3.1 GxE interaction and the relevance of FKBP5 in stress-
related diseases  
The vast success of Darwin´s evolutionary model and Mendelian genetics pushed 
the idea that traits can be acquired during life and transmitted to future generations 
into the background. “Epigenetics, or the study of heritable (mitotic and/or meiotic) 
changes in gene activity that are not brought about by changes in the DNA 
sequence…” (Van Soom et al., 2014) now refreshes the idea proposed by Lamarck. 
One method for identifying hypothesized gene-environment (GxE) interactions is 
epidemiological research. Epidemiology brought evidences that a GxE interactions 
are potentially involved in the development of diseases, but lack to explain the 
molecular mechanisms of GxE interactions (Caspi and Moffitt, 2006). Furthermore, 
twin studies (Bell and Spector, 2011; Bell et al., 2012; Petronis, 2006) and inbred 
mouse strains (Weaver et al., 2004) were used to investigate the influence of non-
genetic factors onto phenotypes due to the advantage that monozygotic twins and 
inbred mouse strains have identical genomes. In spite of the fact that some GxE 
interactions have been reported for mood and anxiety disorders (Binder et al., 2008; 
Caspi et al., 2010; Heim et al., 2009; Xie et al., 2010), the molecular link how genetic 
and environmental factors can interact together within specific mechanisms to alter 
cell function and more remote behavioral phenotypes remains largely unknown 
(Figure 1). Since epigenetic mechanisms are potentially playing a role in the etiology 
of various human diseases (Handel et al., 2010) such as depression (McGowan et 
al., 2009), major psychosis (Mill et al., 2008), autism (Schanen, 2006), cancer 
(Esteller, 2007; Varambally et al., 2008), asthma (Adcock et al., 2005) and obesity 
(Gerken et al., 2007), it has been proposed that epigenetic modifications and 
mechanisms such as DNA methylation, histone modifications, non-coding RNA and 
chromatin conformation changes (Levenson and Sweatt, 2005; Maddox et al., 2013; 
Mill and Petronis, 2007; Miller et al., 2008; Mitchell et al., 2014; Tsankova et al., 
2007) are involved in mediating GxE interactions by changing the expression of 
genes implicated in stress-related psychiatric diseases (Jaenisch and Bird, 2003; 
Yehuda and LeDoux, 2007). Epigenetic changes due to GxE interaction effects have 
been suggested to be installed during sensitive periods (e.g. development) and to 
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remain stable over time (Klengel et al., 2013; Klengel et al., 2014). It is discussed 
that molecular and behavioral adaptations due to epigenetic changes can be 
inherited across generations via gametes and maternal behavior (Bohacek et al., 
2013; Daxinger and Whitelaw, 2012; Franklin et al., 2010; Gapp et al., 2014; Yehuda 
et al., 2016).  
 
 
 
 
 
 
 
3.1.1 GxE interaction in stress-related psychiatric disorders  
It has been shown that the risk of developing a stress-related psychiatric disorder like 
Post Traumatic Stress Disorder (PTSD) or depression not only depends on genetic 
predisposition of having risk or protective genetic variants, but as well environmental 
factors like exposure to stressful or traumatic life events (Caspi and Moffitt, 2006; 
Kendler et al., 1999; Kendler et al., 1995; Klengel et al., 2013; Molnar et al., 2001). 
Genes which have shown to be part of GxE are often involved in the stress hormone 
system such as the glucocorticoid receptor (GR, NR3C1), corticotrophin releasing 
Figure 1: The development of stress-related psychiatric disorders involves the integration of genetic and 
environmental factors  
The importance of integrating genes and the environment when investigating stress-related psychiatric disorders has been 
shown in epidemiological & genetic studies. Both individuals (Person A and B) start with a different genetic predisposition 
to develop a stress disorder. After severe trauma during childhood person B does not develop clinical relevant symptoms 
when struggling under daily life hassles. Whereas person A does develop symptoms. The question is how genetic and 
environmental factors are integrated to determine risk and resilience and what are the molecular mechanisms, which 
prime the two persons onto different trajectories after early-life stress (ELS). It is believed that GCs are involved in this 
priming event and might mediate the impact of environmental factors under the background of genetic variants onto 
epigenetic layers. Source: Tobias Wiechmann, 2019 
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hormone receptor 1 (CRHR1) and FK506 binding protein 5 (FKBP5), which play a 
key role in the regulation of the hypothalamic-pituitary-adrenal (HPA) axis (Binder, 
2009; Bradley et al., 2008; Klengel and Binder, 2015; Klengel et al., 2013; Polanczyk 
et al., 2009; Zannas and Binder, 2014). A dysregulated stress hormone system is a 
strong risk factor for developing stress-related psychiatric disorders and therefore 
regulating factors of this system display promising therapeutic targets for the 
treatment of stress-regulated diseases like PTSD or depression (Binder, 2009; 
Klengel et al., 2013). An increasing number of studies have linked interactions 
between FKBP5 genotypes and stressors with diverse disease-related phenotypes 
(Zannas and Binder, 2014). Phenotypes examined to date include Major Depressive 
Disorder (MDD) or depressive symptoms (Appel et al., 2011; Dackis et al., 2012; 
Kohrt et al., 2015; VanZomeren-Dohm et al., 2015; Zimmermann et al., 2011), PTSD 
and related phenotypes (Binder et al., 2008; Boscarino et al., 2012; Klengel et al., 
2013; Koenen et al., 2005; Xie et al., 2010), suicidality (Roy et al., 2010; Roy et al., 
2012), aggression and violent behaviors (Bevilacqua et al., 2012), psychosis (Collip 
et al., 2013), cognitive performance (Hernaus et al., 2014), and general physical 
illness (Lessard and Holman, 2014). In total 31 independent studies comprising 39 
cohorts including a total of 31 000 subjects have been carried out so far, with the 
majority of them showing that the alleles associated with higher FKBP5 induction and 
prolonged cortisol responses are also the alleles associated with higher disease risk 
(Matosin et al., 2018). 
 
3.1.2 The role of FKBP5 in the stress system  
The HPA axis is a neuroendocrine system that controls reactions to stress in 
mammals (Sapolsky et al., 2000). During this process, the brain and the body need 
to be adjusted to successfully cope with stressful situations (e.g. make energy 
resources available to fight or flight). Exposure to a stressor induces the release of 
corticotrophin releasing hormone (CRH) and vasopressin (AVP) from the 
paraventricular nucleus (PVN) in the hypothalamus, which stimulates the release of 
adrenocorticotropin hormone (ACTH) from the anterior pituitary, in turn inducing the 
release of glucocorticoids (GC) from the cortex of the adrenal glands into the blood 
system. GCs act through two mostly intracellular receptors, the mineralocorticoid 
receptor (MR) and GR. The high affinity MR is mainly implicated in the appraisal 
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processes and the acute onset of the stress response, whereas the lower affinity GR 
promotes adaptation to recovery from the stress (De Kloet et al., 1998). GR is 
activated by cortisol, binds to the DNA at glucocorticoid responsive elements (GRE) 
and acts as a transcription factor to initiate the transcription of several genes, which 
can be involved in the regulation of the HPA axis in many tissues (Russell et al., 
2010) (Figure 2). In the brain (mainly the hypothalamus), the activation of GR by GCs 
induces a negative feedback loop repressing the HPA axis and results in the 
termination of the stress response. At the cellular level, the activity of GR is also 
regulated in the cytoplasm by a multi-protein complex including heat shock proteins 
and FK506 proteins such as FKBP51 and FKBP52 (Pratt and Toft, 1997). At 
baseline, in both humans and mice, FKBP5 expression levels differ across tissues, 
being markedly elevated in metabolically active tissues, such as adipocytes, 
peripheral blood cells as well as the hippocampus (http://biogps.org/). In the rodent 
brain, FKBP5 has the highest expression levels in the hippocampus, with much lower 
expression in other brain regions (Scharf et al., 2011). Substantial variability of 
FKBP5 expression is similarly observed in the human brain, with high levels noted, 
for example, in the hippocampus but low levels in the hypothalamus 
(http://human.brain-map.org/). FKBP5 gene expression is induced by GR via GREs 
located within the FKBP5 locus. A function of FKBP51 is to inactivate GR in the 
cytoplasm, constituting in an ultra-short negative feedback loop, which regulates GR 
sensitivity. FKBP5 induction can vary across individuals and has been proposed as a 
marker of GR sensitivity (Kelly et al., 2012; Menke et al., 2012; Vermeer et al., 2003). 
In humans, an eightfold increase in FKBP5 messenger RNA (mRNA) has been 
observed in peripheral blood cells 3 h after oral administration of 1.5 mg of the GR 
agonist dexamethasone (DEX). FKBP5 is the most robustly induced transcript 
(Menke et al., 2012). Similar robust induction by GR activation has been noted in 
omental and subcutaneous adipose tissues (Pereira et al., 2014). Following 
stimulation with dexamethasone or stress exposure, FKBP5 expression is 
dramatically increased in a number of brain regions (Scharf et al., 2011), with the 
largest changes observed in the amygdala and the PVN, whereas the hippocampus 
shows a much less pronounced FKBP5 induction. This likely reflects the high 
baseline levels of FKBP5 in this brain region that may confer relative GR resistance. 
By modulating GR signaling, FKBP5 has the potential to modulate the actions of 
Introduction 	
	 - 15 - 
glucocorticoids, which are hormones with pleiotropic effects that can affect 
essentially every tissue (Chrousos and Gold, 1992; Nicolaides et al., 2014)(Figure 2). 
 
 
 
 
 
 
 
 
 
3.1.3 FKBP5 genetic variations interact with childhood abuse during 
early life    
The human locus of FKBP5 (Nair et al., 1997) is located on the short arm of 
chromosome 6 (6p21.31), consists of 13 exons, 12 intron and spans around 155 kb 
Figure 2: Schematic representation of the molecular events involved in glucocorticoid-mediated FKBP5 
induction, the resulting intracellular negative feedback loop, and effects on other biological processes.  
Glucocorticoids enter the cytoplasm (a) and activate the glucocorticoid receptor (GR) complex. FKBP51 binding to the 
complex reduces affinity of glucocorticoids to the GR and delays translocation of the GR to the nucleus. However, 
exchange of FKBP51 (FKBP5) for FKBP52 (FKBP4) (b) results in GR translocation to the nucleus (c). The GR can either 
interact as a monomer with other transcription factors (d) or form a homodimer that binds to DNA at glucocorticoid 
response elements. Overall, GR functions result in transactivation or transrepression of a large number of genes. The 
FKBP5 gene is highly responsive to GR, but responsiveness depends on FKBP5 polymorphisms and methylation status 
(e). The synthesized FKBP5 mRNA translocates to the cytoplasm (f) where it is translated into FKBP51 protein. FKBP51 
then inhibits GR activity not only forming an ultra-short, intracellular negative feedback loop of GR signaling but also 
modulating several other biological pathways (g). Source: adopted from Zannas et al., 2015 
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(Figure 3). The gene transcription is steroid-regulated and mediated by binding of the 
GR to GREs, which are located in a region spanning over 100 kb and range from 
upstream of FKBP5 promoter to introns 2, 5, and 7 of the gene (Paakinaho et al., 
2010). With the use of tagging experiments and, more recently, next-generation 
sequencing, FKBP5 variants have been described in detail (Ellsworth et al., 2013a; 
Ellsworth et al., 2013b; Pelleymounter et al., 2011).  
 
 
 
 
 
 
 
The best-characterized polymorphisms comprise a haplotype that spans the whole 
gene, contains up to 18 single-nucleotide polymorphisms (SNPs) in strong linkage 
disequilibrium (LD) in Caucasians (r2 > 40.8, distance 4500 kb, 1000 genomes next- 
generation sequencing project), and is commonly tagged by rs3800373, rs9296158, 
or rs1360780. This haplotype has been associated with heightened induction of 
FKBP5 mRNA in response to GR activation (Binder et al., 2004) and interacts with 
childhood abuse to predict adult PTSD (Binder et al., 2008). This functionality was 
shown to be likely conferred by rs1360780, a SNP located in an enhancer region, 
488 base pairs (bp) away from a functional GRE in intron 2 of the gene, with the risk 
T-allele facilitating GR-mediated induction of FKBP5 mRNA (Klengel et al., 2013). 
However, other polymorphisms within or outside of this FKBP5 haplotype may also 
Figure 3: Schematic overview of key features of the FKBP5 locus.  
Shown tracks are from the UCSC genome browser (https://genome.ucsc.edu). FKBP5 splicing variants are derived from 
the RefSeq Genes Track. Bisulfite sequencing loci are shown as a custom track and are based on Klengel and Binder 
(2013) and Yehuda et al. (2013). As shown, these CpG sites are distinct from CpGs covered by the Illumina 450K array 
(shown for two blood cell lines and one neuroblastoma cell line based on ENCODE/HAIB; warm colors, high methylation; 
cold colors, low methylation levels). Glucocorticoid response elements (GREs) are displayed for A549 and ECC-1 cells 
and are derived from transcription factor (glucocorticoid receptor) ChIP-sequencing data of the ENCODE project. 
Conserved GREs are highlighted with red asterisk and are derived from the HMR Conserved Transcription Factor Binding 
Sites track (z-score cutoff: 1.64). GxE SNPs represent SNPs identified in gene–environment interaction studies and are 
mapped based on the Common SNPs(142) track. The H3K27Ac Mark and H3K4Me3 tracks show data from two different 
blood cells lines derived from the ENCODE project.  Source: adopted from Zannas et al., 2015 
Introduction 	
	 - 17 - 
have functional effects, either at baseline or following transcriptional induction 
(Ellsworth et al., 2013a; Roy et al., 2010).  
A mechanism for the interaction of childhood abuse and genetic variants of the 
FKBP5 gene, focusing on rs1360780 variants was proposed by Klengel et al. (2013). 
In this GxE mechanism, functional polymorphisms within GRE in intron 2 can alter 
the 3D chromatin structure of the FKBP5 locus and install childhood trauma 
dependent epigenetic modification. Here, demethylation of cytosine guanine 
dinucleotides (CpGs) within a GRE of intron 7, is leading to increased FKBP5 
expression and dysregulation of the stress hormone system resulting in increased 
risk of developing stress-related disorders like PTSD (Figure 2). By using chromatin 
conformation capture experiments (3C) it has been shown that the “risk allele” of 
rs1360780 enables the structural interaction of downstream enhancers located in 
GRE of intron 2 with the Transcription Start Site (TSS), but not in carriers of the 
“protective allele”. This structural interaction leads to a stronger FKBP5 mRNA 
expression by GR, possibly due to the fact that the “risk allele” generates a TATA-
box binding motive, which allows to bind more TATA-box binding proteins and 
subsequently facilitates the binding of enhancer regions to RNA polymerase II 
transcription complex. Even minor stressors would therefore result in a prolonged 
cortisol release in “risk” but not in “protective allele” carriers due to an impaired 
negative feedback loop. Upon childhood abuse, enhanced cortisol levels result in 
strong GR activation in risk allele carriers and can trigger demethylation of distal 
functional GREs in FKBP5 intron 7, further promoting the FKBP5 mRNA 
transcription. Demethylation of CpGs in GREs of FKBP5 due to childhood abuse and 
activation of GR was reported by Klengel et al. (2013) in peripheral blood cells and 
hippocampal progenitor cells. However, whether or not there is a change in 
methylation levels of CpGs in the FKBP5 locus around other GREs or functional DNA 
binding loci has not been investigated so far and has to be further tested. A multistep 
mechanism model how a targeted demethylation may be implemented in 
transcriptional activation by GR was proposed for GREs at the Tat gene by Grange 
et al. (2001). In this model, stable GR binding to GREs and transcriptional stimulation 
by exposure to GCs is achieved by chromatin remodeling, local demethylation of 
CpGs and at GREs and C/EBP recruitment. However, it remains unclear which 
proteins mediate CpG demethylation within this mechanism but the involvement of 
DNA repair proteins has been proposed (Kress et al., 2006). Transient demethylation 
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due to GR binding (Thomassin et al., 2001) can possibly change to a long term 
demethylation of the Fkbp5 gene displaying a potential mark to excessive stress and 
glucocorticoid exposure (Lee et al., 2011). The higher transcriptional activation of 
FKBP5 by GR in risk-allele carrier strengthens the intracellular negative feedback 
loop, which leads to GR resistance and a deregulated stress hormone system. 
Moreover, gene expression can be altered in GR responsive systems such as the 
immune system. Alteration of neuronal circuits as structural changes in the 
hippocampus, higher the risk for stress-related psychiatric diseases like PTSD. The 
same gene environment interaction, childhood abuse and FKBP5 polymorphisms, 
have been associated with other disorders implying to share the same molecular 
mechanisms reviewed by Zannas and Binder (2014). 
 
3.2 DNA methylation 
DNA methylation (DNAm) is the covalent addition of a methyl group at the 5-carbon 
ring of cytosine, resulting in 5-methylcytosine (5mC). In the mammalian genome, this 
occurs predominantly in the context of CpG dinucleotides (Bird, 2002). Non-CpG 
methylation are rarely detected in somatic mammalian tissues but have been 
observed in the context of CpNpG or CpA in mouse embryonic stem cells and plants 
(Tost, 2010). 5mC accounts for approximately 1% of total DNA bases with a high 
degree (70-80%) of CpGs being methylated (Ehrlich et al., 1982). In mammalian 
genomes CpGs are generally underrepresented most likely due to the increased 
mutation rates at CpG sites (10 - 50 times higher than other transitional mutations) 
which led to their depletion and gain of TpG / CpG dinucleotides during evolution 
(Bird, 1980; Swartz et al., 1962; Tost, 2010). A possible explanation for the increased 
mutation rates is the spontaneously occurring deamination of methylated CpGs to 
TpGs and imperfect repair mechanisms (Coulondre et al., 1978; Shin et al., 2014; 
Waters and Swann, 1998). CpG-rich clusters of 1 - 4 kb length known as CpG 
Islands, which are often found in the promoter region of genes, escaped from this 
evolutionary pressure most likely to their low degree in methylation and more efficient 
repair mechanisms when unmethylated cytosines are spontaneously deaminated to 
Uracil (Bird et al., 1985; Shin et al., 2014).  
A prerequisite to understand the functionality of DNAm is the distribution of DNAm 
patterns and that these patterns can vary in time (e.g. development) and space (cell-
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type-specific methylation patterns) (Bird, 2002; Luo et al., 2018). In general, DNAm 
fulfills its function in the context of several other epigenetic marks influencing gene 
expression and serving further purposes as genomic imprinting, X-chromosome 
imprinting, definition of cellular identity, aging, maintenance of genomic stability and 
is thought to be able to serve as a memory for environmental inputs even across 
generations (Ambrosi et al., 2017; Tost, 2010). Although an inverse correlation of 
DNAm at promoters and transcriptional activity has been observed, its causal role in 
suppressing gene expression alone or influence in transcription factor binding to DNA 
is still unclear and highly context-dependent (Ambrosi et al., 2017; Shin et al., 2014). 
DNAm at promoters is thought to act repressive either direct by blocking binding of 
transcription factors (TFs) (Iguchi-Ariga and Schaffner, 1989) or indirect by recruiting 
proteins with methyl-binding domains, which block TFs from binding via the 
introduction of repressing domains (Nan et al., 1998). The recent developments 
enabling a precise manipulation of DNAm at specific target sites using the Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR) / Cas9 System (Liu et 
al., 2016; Luo et al., 2018) has the potential to shed further light onto the causal 
function of DNAm.   
Key players in the establishment and maintenance of DNA methylation patterns are 
DNA methyltransferases (DNMTs). DNMTs can be divided into de novo 
methyltransferases (DNMT3 A, B) which prefer to methylate unmethylated DNA 
templates as substrates especially during the development and maintenance DNA, 
and methyltransferases (DNMT1) which prefer hemimethylated DNA templates as 
substrates during the replication process (Goll and Bestor, 2005). The erasure of 
DNA methylation patterns can be achieved during a passive demethylation process 
mainly observed in early development during embryogenesis and an active 
demethylation pathway, which either can be achieved via a direct DNA repair 
process (apolipoprotein B mRNA editing enzyme (APOBEC), not shown in 
mammalian cells) or the oxidation of 5mC to 5-hydroxymethylation (5hmC), 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC) via Ten-eleven translocation 
methylcytosine dioxygenases (TET) 1-3 (Ambrosi et al., 2017; Bergman and Cedar, 
2013; Shin et al., 2014; Wu and Zhang, 2014). These modifications are subsequently 
removed by glycosylases leaving an apyrimidinic acid, which is replaced by a base 
excision repair (BER). Whether these oxidized forms of 5mC are only intermediate 
steps of the demethylation pathway or have themselves distinct function as 
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epigenetic marks is current topic of investigation and debated (Shin et al., 2014; Wu 
and Zhang, 2014). It is also speculated that local demethylation can be introduced by 
specific transcription factor binding (Luo et al., 2018). In this model TFs lead to 
methylation depletion by acting as “pioneer TFs” to induce local epigenetic 
remodeling (Wapinski et al., 2013) or recruit cytosine demethylation machinery like 
TET enzymes. 
 
3.2.1 The relevance of DNA methylation in disease 
Diseases in which epigenetic modifications play a role often involve genes being 
epigenetically regulated or are part of the epigenetic machinery (reader / writer / 
eraser) to maintain and propagate epigenetic modifications during development and 
cell division (Tost, 2010). Therefore disease phenotypes can display aberrant 
methylation profiles at single genes but also be very complex and reveal global 
methylation changes (reviewed in Robertson (2005); Robertson and Wolffe (2000); 
Tost (2010)).  
The Fragile X syndrome is an example of a “repeat-instability disease”, in which 
aberrant methylation patterns are involved in the gene expression regulation of a 
single gene. In case of the Fragile X syndrome, the loss of FMR1 gene expression 
during the development is probably caused by a triplet-repeat expansion (CGG) and 
gain of methylation at the FMR1 promoter (Dor and Cedar, 2018; Robertson and 
Wolffe, 2000). Recently, it has been shown that the demethylation (introduced by the 
CRISPR/Cas9 system together with Tet1) of CGG repeats is sufficient to reactivate 
the FMR1 gene and rescue the FXS-related cellular phenotypes in in vitro-derived 
FXS neurons (Liu et al., 2018). 
Imprinting disorders like the Beckwith-Wiedemann syndrome (BWS), Prader-Willi 
syndrome (PWS) or Angelman syndrome (AS) are examples in which altered DNA 
methylation patterns in important regulatory regions can lead to the loss of normal 
allele-specific gene expression patterns. Diseases caused by a loss of imprinting are 
often phenotypically more variable due to the fact that the regulatory region controls 
several imprinted genes. The molecular rational for the allele-specific regulation of 
imprinted genes often include the access of distant enhancers to promoters, which 
can be regulated by the zinc-finger protein CCCTC-binding factor (CTCF) 
(Robertson, 2005). CTCF binding to its binding site is methylation sensitive and 
therefore can block the access of enhancers to promoters due to the methylation 
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status of the unmethylated allele and established allele-specific gene regulation from 
the maternal or paternal allele. For example, the molecular phenotype of the Rett 
syndrome involves the transcriptional deregulation of several hundreds of genes and 
is an example for defects of a methylation reader. This syndrome is caused by 
mutations in the methyl-binding protein MeCP2, which binds to methylated DNA and 
leads to repression of gene expression by recruiting transcriptional co-repressors 
(Klose and Bird, 2006).  
 
Cancer is one of the best-documented diseases with an epigenetic component and 
shown to exhibit the most complex aberrant methylation profiles. In general, tumor 
cells reveal global hypomethylation but also local hypermethylation of CpG islands at 
promoters (Baylin and Jones, 2011; Jones and Baylin, 2007). Recent studies better 
defined the monitored demethylation in cancer cells and linked them to regions 
associated to the nuclear envelop lamina (Berman et al., 2011). Although the 
underlying mechanisms of this demethylation are unknown, it is though that the 
maintenance machinery is too slow (abnormally high recruitment of Dnmt1 to de 
novo targeted CpG islands) and the replication rate is very high in cancer cells and 
therefore a passive demethylation might be observed (Bergman and Cedar, 2013; 
O'Hagan et al., 2011). The pathophysiological role of the DNA methylation changes 
in cancer are yet not clear, but it has been shown that de novo methylation may be 
installed in cancer cells to repress tumor-suppressor genes (Bender et al., 1998; 
Laird et al., 1995; Tsai et al., 2012). 
 
3.2.2 Techniques to measure DNA methylation levels 
In the beginning of the 1980s the earliest techniques to measure DNA methylation 
where based on the separation of methylated and unmethylated cytosines via 
chromatography and enabled to assess the total amount of 5mC of in genomes 
(Harrison and Parle-McDermott, 2011). Until the late 1990 various methods 
combined polymerase chain reaction (PCR) amplification with the use of methylation-
sensitive restriction enzymes, immunoprecipitation or bisulfite sequencing to detect 
DNA methylation. Nowadays, the most commonly used methods to measure DNA 
methylation at base pair resolution are based on the finding that sodium bisulfite can 
be used to convert unmethylated cytosine to uracil (Hayatsu et al., 1970) and that the 
conversion rate for 5mC is much slower (Wang et al., 1980). Frommer et al. (1992) 
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described that these different conversion rates can be used to analyze DNA 
methylation profiles of genomes. This realization revolutionized the way one could 
obtain DNAm levels (Harrison and Parle-McDermott, 2011). Classical whole genome 
DNA sequencing strategies were based on the cloning of DNA fragments into 
bacterial vectors, amplification and subsequent Sanger sequencing (Prober et al., 
1987). Pyrosequencing bypassed the time-consuming subcloning-step (Tost and 
Gut, 2007). The coupling of bisulfite conversion and subsequent detection of 5mC 
sites via microarrays/ beadchips and high-throughput sequencing increased the 
throughput genome-wide DNAm analysis. Today, there are a great variety of 
methods investigating DNAm in different dimensions of resolution and genomic 
regions covered ranging from genome wide assays to targeted approaches (Laird, 
2010; Masser et al., 2018; Shin et al., 2014). The strength and weaknesses of most 
of these approaches have been described by Barros-Silva et al. (2018); Laird (2010). 
The newest methods to analyze DNA methylation target challenges in the field to 
uncover the diversity of methylation patterns in single cells (Luo et al., 2018; Masser 
et al., 2018), detection of other types of DNA modifications (Shin et al., 2014) or to 
develop sequencing strategies to avoid the bisulfite conversion step e.g Nanopore 
sequencing (Burgess, 2017; Schatz, 2017). Major challenges in the development of 
DNA methylation assays for biomarker research and clinical application are 
robustness, accuracy and costs per sample. A community wide benchmark study by 
the Blueprint consortium showed that amplicon bisulfite sequencing and bisulfite 
pyrosequencing had the best all-around performance as DNA methylation assays for 
biomarker development and clinical applications (consortium, 2016). 
Targeted bisulfite sequencing (TBS) offers a candidate approach to perform such 
studies with high resolution by increasing depth of read coverage per CpG to detect 
small changes in DNA methylation in a cost-efficient manner. Recently, a few 
applications of TBS have been developed with differences in accuracy, throughput 
and library preparation (Bernstein et al., 2015; Chen et al., 2017; Masser et al., 2013; 
Masser et al., 2015; Tost and Gut, 2007). Assessing DNA modifications with high 
accuracy and sensitivity in candidate loci would increase the power to detect and 
replicate the embedding of GxE interactions onto epigenetic layers as well as 
perform time course experiments in large numbers of samples to understand the 
stability of the environmentally induced changes during development. In addition, 
changes related to environmental exposure such as adverse life events and 
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psychopathology are often only present in specific cell types, although most studies 
rely on more complex tissues such as post-mortem brain or blood samples. Detecting 
these effects in mixed tissues requires high accuracy in order to detect small 
changes emerging from a small number of cells. 
 
3.3 The 3D genome 
The genome contains heritable information of eukaryotic organisms and is stored in 
the nucleus of cells. In order to fit the human genome with an approximate size of 3 x 
109 bp into the space of a nucleus efficient compaction of the DNA is necessary. The 
organization of the DNA has not to only be efficiently condensed for chromosome 
separation during mitosis but also enable a dynamic access of its information for the 
specific expression of genes during the development and cell fate decisions (Sati and 
Cavalli, 2017). A vast amount of data suggests that the interphase genome is not 
randomly folded but rather is organized into at least 4 hierarchical layers of different 
scales (reviewed in Bonev and Cavalli, 2016; Buchwalter et al., 2019; Gibcus and 
Dekker, 2013; Krumm and Duan, 2018; Uhler and Shivashankar, 2017; Yu and Ren, 
2017). At the largest scale (ca. 100000 kb), each chromosome occupies a specific 
space in the nucleus, which is called chromosome territory (CT) (reviewed in Cremer 
and Cremer, 2010) and overlaps between chromosomes only appear at its borders 
(Branco and Pombo, 2006). CTs are not randomly distributed in the nucleus but 
follow specific rules. First, CT positions are partially conserved after mitosis (Parada 
et al., 2003). Second, CT´s have a radial positioning preference, in general small 
gene-rich chromosomes tend so be placed in the center, whereas larger gene-poor 
chromosomes are situated at the nuclear periphery (Croft et al., 1999). Third, early-
replicating loci and active genes have the tendency to be in the nuclear interior, while 
late-replicating loci and repressed genes preferably occupy the nuclear periphery 
(Grasser et al., 2008; Takizawa et al., 2008). Chromatin interacting with the lamina of 
the nucleus is referred to as lamina-associated domains (LADs) and consists mostly 
of transcriptionally silent chromatin enriched with marks of heterochromatin (reviewed 
in Buchwalter et al., 2019). Compartments (scale ca. 10000 kb) can be divided into A 
and B compartments, which reflect the general chromatin state of the loci and genes 
located within these separated regions (Lieberman-Aiden et al., 2009; Rao et al., 
2014; Wang et al., 2016). The A compartments harbor early replicating loci with a 
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high density of genes of which exhibit strong gene expression. Conversely, late 
replicating loci and loci often situated at LADs are found in the B compartment (Ryba 
et al., 2010). Interestingly, during stem cell differentiation around 60% of the human 
genome display an A/B compartment switch (Schmitt et al., 2016) and therefore 
partitioning in a compartment is to a certain degree cell type specific. Topological 
associating domains (TADs) partition the genome into blocks (scale 100 – 1000 kb), 
which are described as a region in which loci show a higher contact frequency 
compared to the rest of the genome which have been found in human, mouse (Dixon 
et al., 2012; Nora et al., 2012) and non-mammalian genomes like Drosophila (Sexton 
et al., 2012) zebrafish (Gomez-Marin et al., 2015), Caenorhabditis elegans (Crane et 
al., 2015) and yeast (Hsieh et al., 2015). In Arabidopsis thaliana (Wang et al., 2015) 
these domains were not found, indicating that in plants different mechanisms may be 
present to structure the chromatin. The positioning of the TADs in the human and 
mouse embryonic stem cells overlay in 50-70% of all cases, indicating that the 
location of TADs in mammalian genomes is evolutionary conserved (Crane et al., 
2015).  Although it is not fully understood how the boundaries of TADs are defined, 
they are enriched with multiple factors such as CTCF binding sites, housekeeping 
genes, transcription start sites, short interspersed nuclear elements (SINE), transfer 
RNA (tRNA), K4-trimethylated histone H3 (H3K4me3), K36-trimethylated histone H3 
(H3K36m3) (Yu and Ren, 2017). Especially interesting is the occurrence of CTCF, 
which is the case for 75% of all TADs in mouse embryonic stem cells (Dixon et al. 
2012). CTCF is known to be a key player in genome organization with the ability to 
form homodimers generating long-range looping which can enable or block promoter-
enhancer interactions (Phillips and Corces, 2009). The loop extrusion model tries to 
explain the formation of TADs with these CTCF-mediated long-range loopings and a 
chromatin motor complex such as the cohesion complex which loads onto the DNA 
and extrudes a loop until it is stalled by binding of CTCF at convergent oriented 
binding sites (Sanborn et al., 2015). It has to be noticed that a distinct mechanism 
independent of CTCF might be responsible for TADs lacking CTCF occupancy (Yu 
and Ren, 2017). TADs do not only act as structural but also functional units that 
possibly coordinate gene expression by blocking, guiding or facilitating promoter 
enhancer loops (Dekker and Heard, 2015; Dixon et al., 2015; Ma et al., 2015; Nora et 
al., 2012; Symmons et al., 2016; Symmons et al., 2014; Zhan et al., 2017). At the 
lowest level long-range chromatin interactions can connect genomic loci separated 
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by several 100 kb of distance. These loops can be classified into two types. The first 
type consists of structural loops associated with CTCF binding, which for example 
form TADs. The second type of loops consists of functional loops driving gene 
expression enabling to build complex networks of enhancer-promoter, promoter-
promoter or enhancer-enhancer interactions. These functional loops are often 
associated with enhancer-associated factors as well as the cohesion or mediator 
complex (Ji et al., 2016; Phillips-Cremins and Corces, 2013). Interestingly, there are 
indications that structural loops and functional loops can be organized in foci, which 
often appear to be spatially linked (Tang et al., 2015). The nuclear architecture can 
be dynamically regulated, which is key to fulfill its functional roles and some 
examples of reorganization occur within distinct biological processes such as mitosis, 
X-chromosome inactivation, circadian oscillating transcription, pluripotency and 
differentiation (Yu and Ren, 2017). The importance of time as the fourth dimension 
becomes clear when regarding the spatial and temporal organization of nuclear 
protein structures (reviewed in Hemmerich et al., 2011). Protein structures like DNA 
replication sites, the nucleolus, telomeres, centromeres and nuclear lamina can be 
stable for seconds up to several hours and that the stability can be modulated 
depending on the structures` function. 
 
3.3.1 The „C“-Techniques  
First insights into the organization of genomes were obtained with microscopy-based 
techniques e.g. fluorescence in situ hybridization (FISH), which allowed the direct 
observation of spatial distance between genomic loci and their dynamic movement in 
single cells. However, these microscopy-based imaging tools are limited in 
throughput (single cells), resolution (defined by the microscope, observation of higher 
order structures) and genome coverage (simulations observation of >30 genomic 
locations (Wang et al., 2016)). The second principal to investigate the 3D genome 
organization is a molecular-biology-based approach developed by Dekker et al. 
(2002). This technique is called chromosome conformation capture (3C) and the 
rational of 3C-based methods is the conversion of chromatin interactions into ligation 
products (reviewed by Dekker and Mirny, 2013). Loci in physical proximity in the 
genome (estimated range 10-100 nm) are stabilized by cross-linking DNA-Protein 
interactions with the use of cross-linking agents such as formaldehyde. 
Subsequently, the chromatin is fragmented by restriction digestion or sonication, 
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followed by ligation of cross-linked fragments. Afterwards the hybrid DNA is purified 
and the ligation events are quantified by PCR using locus specific primers or 
sequencing over the ligation site. Due to the fact that an individual cell can provide 
maximal 2 data points, populations of cells are used to obtain a mean interaction 
profile of the contacts in the genome. A plethora of 3C-based methods of have been 
developed (reviewed by Davies et al., 2017; Krumm and Duan, 2018; Li et al., 2018; 
Sajan and Hawkins, 2012; Simonis et al., 2007; van Steensel and Dekker, 2010) to 
detect chromatin interaction at different resolution (key factor: Fragmentation method 
of cross-linked chromatin e.g. 6 or 4-base pair restriction enzymes, MNase, DNase 
and sonication), sensitivity (key factor: number of observations needed to produce 
interaction profiles) but also with the focus on interactions mediated by specific 
proteins (e. g ChIA-PET; Enrichment of protein-mediated integrations ameliorated by 
immunoprecipitation using specific antibodies against factors of interest). High-
resolution interaction profiles from few target loci can be achieved using circularized 
chromosome conformation capture (4C) or Capture-C. If less information about a 
region of interest is known, chromosome conformation capture carbon copy (5C) can 
be used detecting all interactions among multiple selected loci. The 3D structure of 
whole mammalian genomes can be analyzed using Hi-C. The development of in situ 
ligation helped to increase the resolution of Hi-C approaches enabling to visualize 
chromatin loopings within TAD structures (Rao et al., 2014). Despite the fact, that 
3C-based assays have reached a level of maturity and approachability to use them 
as general tools, current limitations of this approach are the bias of interactions which 
can be analyzed due to formaldehyde cross-linking, uneven distribution of restriction 
sites in the genome and interpretation of 3D data visualized in 2D plots (Dekker, 
2006; Dekker and Mirny, 2013; Simonis et al., 2007).  
The two general approaches - microscopy and 3C - to study genome organization 
therefore complement each other and should be utilized simultaneously. While there 
is a good overlay of observations from both techniques onto nuclear organization, 
some discrepancies at single loci have been descripted (Dekker, 2016; Williamson et 
al., 2014). Recent developments in both fields such as STORM (Rust et al., 2006) 
and single cell 3C approaches (Nagano et al., 2015; Nagano et al., 2017; Ramani et 
al., 2017; Stevens et al., 2017) will help to disentangle the complexity and dynamics 
of the 3D genome organization but most promising will be multidisciplinary 
approaches like the 4D Nucleome project (Yu and Ren, 2017) and the 
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implementation of the CRISPR-Cas9 tools such as CRISPR-GO (Wang et al., 
2018b).   
  
3.3.2 The relevance of chromatin structure in disease 
The 3D architecture of the human genome is a hierarchically layered structure that 
undergoes dynamic restructuring to enable a healthy development. A disruption of 
the 3D genome at or across different scales can lead to disease and often involves 
the mutation in architectural important genes or regulatory elements of gene 
expression (Chakraborty and Ay, 2018; Li et al., 2018).  Studies investigating the 
molecular mechanisms of cancer formation show that alterations at chromosomal 
territories, compartments, TADs and chromatin loops are potentially involved to 
develop the disease phenotype (Chakraborty and Ay, 2018). At the level of CTs it 
has been indicated that the dynamic intermingling at the territorial boarders has been 
correlated with translocation frequencies in human cells, which may play a role in 
various cancers (Branco and Pombo, 2006). A change of compartments has been 
shown for important genes in breast cancer (Barutcu et al., 2015) and in a heart 
failure model (Rosa-Garrido et al., 2017). Moreover, there is evidence for higher 
mutation rates in the B over the A compartment in prostate cancer cells (Schuster-
Bockler and Lehner, 2012). Up to now most studies linking 3D architecture with 
disease reveal a disruption of architectural loops (CTCF-CTCF interactions forming 
TADs) or functional loops (e.g. enhancer-promoter loops reviewed in Chakraborty 
and Ay (2018); Krijger and de Laat (2016); Krumm and Duan (2018). The disruption 
of TADs due to structural variants (reviewed in Spielmann et al., 2018) generic 
disruption (Hnisz et al., 2016) or epigenetic inactivation (Flavahan et al., 2016; 
Victoria-Acosta et al., 2015) of architectural protein binding sites can lead to rewiring 
of enhancer-promoter interactions, which would normally be isolated from each other 
and therefore can alter the gene expression pattern of disease-relevant genes.  Intra-
TAD duplications can lead to duplications or loss of enhancer’s that can lead to a sex 
reversal phenotype (Cox et al., 2011) (enhancer duplications or loss in the SOX9 
TAD), B cell lymphoma (Chapuy et al., 2013) (Duplication of a super-enhancer in the 
BCL6 TAD) and Polydactyly (Lupianez et al., 2015) (Limb enhancer duplication in the 
SHH TAD). Digit abnormalities in the Cooks syndrome is an example in which a TAD 
boundary is duplicated forming a new regulatory unit called “Neo-TAD” (Cox et al., 
2011). The deletion of a TAD boundary can lead to the fusion of two TADs and 
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enables the rewiring of enhancer to gene promoters leading to abnormal gen 
expression patterns (e.g. congenital limb malformation caused by a CTCF-associated 
boundary loss at the EPHA4 (Lupianez et al., 2015)). The inversion or translocation 
of TAD boundaries can lead to a restructuring of TADs within the genome, which is 
called “TAD shuffling” causing the adaption or loss of enhancers to their target 
genes. Two diseases in which this TAD abnormality occurs, is the F-Syndrome 
(Lupianez et al., 2015) exhibiting syndactyly or atypical Rett syndrome (Goubau et 
al., 2013). Similar to architectural loops forming TADs, genetic variants can disrupt or 
establish functional loops and alter the gene expression of genes and potentially 
leading to disease phenotypes. The dysregulation of gene expression can be 
achieved by enhancer formation (T cell acute lymphoblastic leukemia (Mansour et 
al., 2014)), deletion (α-thalassemia (Fritsch et al., 1979), weakening  
(holoproencephaly (Jeong et al., 2006), strengthening (preaxial polydactyly type II 
(Lettice et al., 2003), duplicated (lung adenocarcinoma (Zhang et al., 2016). An 
example of a disease in which a SNP can lead to the introduction of a new promoter 
or deletion of a promoter is α-thalassemia (De Gobbi et al., 2006; Lower et al., 2009).  
The catalogue of known human disease-associated variants has dramatically 
expanded due to the advent of Genome-wide association studies (GWAS) (Visscher 
et al., 2017). Variants found linked to disease by GWAS are often located in non-
coding regions and 3C methods can be applied to identify candidate genes, which 
can be affected by the variant. A multi-omics strategy to discover the molecular 
mechanisms causing disease of associated variants has been proposed by Krijger 
and de Laat (2016). This approach uses all disease-associated variants and 
haplotype-based SNP imputation to identify all associated variants. Afterwards, the 
epigenetic data is used to co-localize candidate causal variants with potential 
regulatory sequences. Subsequently, genes are identified which are located in the 
same TAD using HI-C data and physical links of candidate variants to genes are 
monitored with high-resolution contact maps e.g obtained from 4C. The next step, is 
to establish a functional link of the variant to the gene by allele specific gene 
expression analysis. To finally confirm the molecular mechanism site-directed 
genome-editing is required and the use of a model organism can confirm that the 
effect of the variant is relevant for the disease. In order to better investigate 
molecular mechanisms in psychiatric disorders, the PsychENCODE Consortium has 
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generated a comprehensive resource integrating multi-omics data including Hi-C 
maps derived from the adult brain (Wang et al., 2018a).    
 
3.3.3 Steroid Hormones and the 3D chromatin structure of FKBP5 
The regulation of hormone responsive genes exhibits a shared mode of action. The 
sequence of hormone response elements like GREs are ubiquitously distributed in 
the genome, but the presence of the binding motif is not sufficient for GR binding but 
rather highly selective and cell type specific (John et al., 2011; Uhlenhaut et al., 
2013) mainly due to chromatin accessibility but also to a lesser extent by DNA 
methylation at GREs (Wiench et al., 2011). Upon activation hormone receptors like 
GR do not only bind directly to the proximal promoter regions of responsive genes 
but in the majority of cases, to intragenic and far distance sites that correspond to 
enhancer regions (John et al., 2011; Le Dily and Beato, 2018; Reddy et al., 2009). It 
has been shown that enhancers regulate GC-mediated activation or repression by 
the recruitment of transcription factors (reviewed by Grbesa and Hakim (2017)) and 
not only affect genes in close proximity but also in far distance by the formation of 
long-range chromatin loops (Biddie, 2011; Hakim et al., 2009; Harmston and 
Lenhard, 2013). This regulation can involve a complex network of multiple promoters 
and enhancers (Jin et al., 2013; Le Dily and Beato, 2015; Sanyal et al., 2012). Due to 
the promiscuous behavior of enhancers (Krijger and de Laat, 2016), TADs facilitate 
the correct organization of these structures by restraining their actions within a sub-
megabase scale (Le Dily and Beato, 2015).  It seems that the functional loopings are 
dynamically regulated upon hormone exposure but stay restricted within the stable 
TAD boundaries (Jin et al., 2013; Le Dily and Beato, 2015). Interestingly, pre-existing 
functional loops seem to favor the response to an external stimuli (Grbesa and 
Hakim, 2017; Jin et al., 2013), indicating that the gene expression response is not 
only regulated by the establishment and disintegration (Fullwood et al., 2009; Perillo 
et al., 2008; Quintin et al., 2014) but also by the stability of functional loops (Hakim et 
al., 2011; Le Dily et al., 2014). In this regard, a dysregulation of architectural proteins/ 
loops could lead to changes in the stability of functional interactions and lead to an 
altered response in gene expression (Antony et al., 2015; Quintin et al., 2014; Seitan 
et al., 2013). Therefore the picture emerges that the 3D genome structure is an 
important factor for the adaptation to an external stimulus and that the complex 
interplay of functional and architectural chromatin interactions is a dynamic 
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playground to integrate external changes in the light of previous experiences but also 
inherited genetic factors of the individual to enable an adequate reaction. 
FKBP5 is a glucocorticoid-regulated gene in which a molecular mechanism for the 
integration of genetic and environmental factors has been described (see section 
3.1.3). To understand how genotypes can influence the complex fine-tuning process 
of FKBP5 gene expression regulation in health and disease, one has to understand 
the molecular regulatory landscape of this gene. An in silico analysis comprising the 
key features of the FKBP5 locus structure using available literature and datasets 
(Consortium, 2004; Paakinaho et al., 2010; Rao et al., 2014; Tang et al., 2015) 
(Figure 4) showed that the topology of the FKBP5 locus is formed by CTCF, which 
generates an architectural chromatin loop, the TAD, in which RNA polymerase II 
(RNAPII) and other proteins like TFs (e.g. GR) further bind and substructures the 
locus to regulate FKBP5 gene expression. Active epigenetic marks, such as K4-
methylated histone H3 (H3K4me) and K27-acetylated histone H3 (H3K27ac) and 
H3K36me3 indicate that the locus conformation is already pre-existing before 
exposure to steroids in blood, prostate and lung epithelial cancer cells (Jaaskelainen 
et al., 2011) and therefore poised for transcription.  
In the same haplotype of FKBP5, which comprises the disease-associated functional 
SNP rs1360780, a larger structural variant esv3608688 can be found (Pelleymounter 
et al., 2011). This 3.3 kb large insertion/ deletion (INDEL) is located in intron 1 of the 
FKBP5 gene and the deletion was found in 65.385 % and the insertion 34.615% of all 
alleles screened by the 1000 genomes project. What is unknown so far, is how the 
combination of different genetic factors like rs1360780 and INDEL allele in intron 1 
affects the chromatin structure and therefore changes gene expression under basal 
and stress conditions and which chromatin status is more responsive to induction by 
glucocorticoids and possibly induce other epigenetic changes like methylation levels 
of functional elements in the FKBP5 locus. 
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Figure 4: In silico analysis of the 3D structure of the FKBP5 locus. 
Genome browser shot and HI-C profile illustrating the FKBP5 locus 3D structure (hg19 / chr6:35487554-35718452) and 
the location of the genetic variants rs1360780 & esv3608688 in relevance to key functional sites using reference data. 
ChiP-Seq – The binding of the Glucocorticoid receptor (GR; ENCODE GR HAIB TFBS track from A549 cells), CTCF 
and Cohesin (indicated by its subunit Rad21)(both ENCODE SYDH TFBS tracks from GM12878) at the FKBP5 locus. 
ChIA-PET – Chromatin interactions mediated by PolII and CTCF at the FKBP5 locus (Tang et al., 2015)). CTCF 
interactions are classified in convergent (loop formed by CTCF sites with opposing motif directions), complex 
convergent (loop formed by CTCF sites with opposing motif directions, between the interaction CTCF sites are other 
CTCF sites forming chromatin interactions) and tandem loops (loop formed by CTCF sites with the same motif 
directions) according to Tang et al. (2015). HI-C – The FKBP5 locus topologically associated domain structure (TAD) in 
GM12878 using data from Rao et al. (2014) (visualized by Juciebox from the Aiden-Lieberman lab (Durand et al., 
2016), in situ MboI primary + replicate) Source: Tobias Wiechmann, 2019 
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4 Aim of the thesis 
The development of stress-related psychiatric disorders involves the integration of 
genetic and environmental factors. How these factors are integrated on a molecular 
level to determine risk or resilience is far from being understood. The long-term 
integration of both factors is thought to be mediated by epigenetic adaptations. One 
molecular mechanism for a statistical GxE interaction has been described for the 
FKBP5 gene. In order to further investigate how genetic variants and environmental 
impacts are integrated at a molecular level to regulate FKBP5 gene expression, this 
thesis encompassed the following objectives: 
Objective 1: Develop a method to accurately measure DNA methylation levels 
within key regulatory sites of the FKBP5 gene in large cohorts of patients  
This objective was addressed by the development of highly accurate methylation 
measurements via targeted bisulfite sequencing (HAM-TBS) (Paper 1, chapter 5.1). 
The establishment, validation and key features of this method are discussed in 
Section 6.1. 
Objective 2: Investigate how environmental signals can relate to FKBP5 DNA 
methylation levels 
This objective was addressed by studying dynamic methylation changes in preterm 
infants (Paper II, chapter 5.2). The new possibilities of HAM-TBS have been used to 
better understand the underlying dynamics of GC-induced DNAm changes in FKBP5 
in healthy individuals upon a DEX challenge (Paper III, chapter 5.3). The implications 
from Paper II & Paper III are discussed in chapter 6.2. 
Objective 3: Investigate, how a 3.3 kb large INDEL (esv3608688) located in 
intron 1 can modulate GR-dependent gene expression with focus on 
alterations on the 3D chromatin structure and DNA methylation levels at 
functional sites of the FKBP5 gene. 
This objective was addressed by studying the effects of the INDEL allele onto FKBP5 
gene expression utilizing various quantitative PCR (qPCR) assays, onto FKBP5 
chromatin structure by application of a 4C approach and FKBP5 DNAm levels using 
HAM-TBS in lymphoblastoid cell lines (LCLs) (Manuscript I, chapter 5.4). The 
findings and the derived model of how the INDEL allele potentially regulates GC-
induced gene expression changes are discussed in chapter 6.3. 
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5.1 Paper I - HAM-TBS: high-accuracy methylation 
measurements via targeted bisulfite sequencing  
Roeh, S.*, T. Wiechmann*, S. Sauer, M. Kodel, E. B. Binder and N. Provencal 
(2018)  (* shared first authors) 
 
Originally published in: 
Epigenetics Chromatin. 2018 Jul 4;11(1):39. doi: 10.1186/s13072-018-0209-x. 
PMID: 29973294 
 
Additional supplementary material: 
Additional supplementary figures and tables are freely available for download at the 
publisher’s website (https://doi.org/10.1186/s13072-018-0209-x). 
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METHODOLOGY
HAM-TBS: high-accuracy methylation 
measurements via targeted bisulfite sequencing
Simone Roeh1†, Tobias Wiechmann1†, Susann Sauer1, Maik Ködel1, Elisabeth B. Binder1,2 
and Nadine Provençal1,3,4*
Abstract 
Background: The ability to accurately and efficiently measure DNA methylation is critical to advance the under-
standing of this epigenetic mechanism and its contribution to common diseases. Here, we present a highly accurate 
method to measure methylation using bisulfite sequencing (termed HAM-TBS). This novel method is able to assess 
DNA methylation in multiple samples with high accuracy in a cost-effective manner. We developed this assay for the 
FKBP5 locus, an important gene in the regulation of the stress system and previously linked to stress-related disorders, 
but the method is applicable to any locus of interest.
Results: HAM-TBS enables multiplexed analyses of up to 96 samples and regions spanning 10 kb using the Illumina 
MiSeq. It incorporates a triplicate bisulfite conversion step, pooled target enrichment via PCR, PCR-free library prepa-
ration and a minimum coverage of 1000×. TBS was able to resolve DNA methylation levels with a mean accuracy of 
0.72%. Using this method, we designed and validated a targeted panel to specifically assess regulatory regions within 
the FKBP5 locus that are not covered in commercially available DNA methylation arrays.
Conclusions: HAM-TBS represents a highly accurate, medium-throughput sequencing approach for robust detection 
of DNA methylation changes in specific target regions.
Keywords: Targeted bisulfite sequencing, DNA methylation, Next-generation sequencing, 5-methylcytosine, FKBP5
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
DNA methylation is the covalent addition of a methyl 
group at the 5-carbon ring of cytosine, resulting in 
5-methylcytosine (5mC). In the mammalian genome, 
this occurs predominantly in the context of CpG dinu-
cleotides. It is one of several epigenetic marks influenc-
ing gene expression and serving multiple other purposes 
such as genomic imprinting, X chromosome inactivation 
and maintenance of genomic stability [1, 2]. Aberrant 
regulation of the establishment, maintenance, erasure 
or recognition of DNA methylation has been associ-
ated with a range of disease phenotypes [3, 4]. In addi-
tion, lasting effects of environmental risk factors may be 
reflected by changes in DNA methylation [5]. The need 
to measure DNA methylation in large human cohorts in 
a cost-effective manner is therefore of increasing interest 
for research in epidemiology and medicine [6].
Assessing DNA modifications with high accuracy and 
sensitivity in candidate loci would increase the power 
to detect and replicate such effects as well as to perform 
time course experiments in large numbers of samples to 
understand the stability of the environmentally induced 
changes during development. In addition, changes 
related to specific environmental exposure may only be 
present in specific cell types, although most studies rely 
on more complex tissues such as postmortem brain or 
blood samples. Assessing these effects in mixed tissues 
requires high accuracy in order to detect small changes 
emerging from a small number of cells. DNA bisulfite 
treatment followed by next-generation sequencing ena-
bled the quantification of DNA methylation marks at 
single-base resolution. However, genome-wide bisulfite 
sequencing, although the best approach to identify DNA 
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modifications, is still too cost intensive to be applied to 
large human cohorts at the coverage needed (> 60×) to 
detect differentially methylated sites [6]. Another set of 
accurate and cost-efficient measurement methods for 
DNA methylation at single CpG level are Illumina DNA 
methylation arrays. However, the ones currently available 
lack coverage in key enhancer regions that are important 
for environmentally driven changes and have a relatively 
small number of probes (~ 10–13) covering each site. 
Targeted bisulfite sequencing (TBS) offers a candidate 
approach to perform such studies with high resolution 
by increasing depth of read coverage per CpG to detect 
small changes in DNA methylation in a cost-efficient 
manner. Recently, few applications of TBS have been 
developed with differences in accuracy, throughput and 
library preparation [7–10]. Our TBS approach focuses on 
the FKBP5 gene, which encodes the FK506-binding pro-
tein (FKBP51), a co-chaperone tightly involved in stress 
regulation. Genetic and epigenetic factors have repeat-
edly been shown to increase the activity of this gene and 
associated with increased stress-reactivity and psychi-
atric disorders [11]. We have previously reported allele-
specific demethylation of CpG sites located in intronic 
enhancer regions of FKBP5 specific to posttraumatic 
stress disorder (PTSD) in patients who had experienced 
child abuse [12]. These gene × environment interac-
tions (GxE) may be mediated by differential susceptibil-
ity to adversity-induced changes in DNA methylation in 
specific enhancers. Current methods do not cover the 
relevant enhancer regions of FKBP5 affected by stress 
exposure. A highly accurate, cost- and time-efficient 
method to investigate FKBP5 DNA methylation in a large 
number of samples is thus critical to gain more insight 
into how DNA methylation changes may mediate these 
GxE. In this manuscript, we present a cost-effective, high-
accuracy methylation measurement TBS (HAM-TBS) 
method to assess the regulatory regions of the FKBP5 
locus. Incorporating a triplicate bisulfite conversion step, 
PCR-free library preparation and rigorous quality control 
(validation of PCR target sites, > 95% bisulfite conver-
sion efficiency and 1000× coverage minimum) ensures 
that our method is extremely robust (Fig.  1). Medium 
throughput and handling accuracy of up to 96 samples 
spanning approximately 10 kb is facilitated by embedding 
the Hamilton pipetting robot and TapeStation with the 
Illumina MiSeq sequencer.
Results
QC, validation and optimization of the HAM-TBS method
TBS is based on bisulfite conversion coupled with tar-
geted enrichment via PCR, library preparation for 
sequencing and subsequent quantification of methyla-
tion levels. All steps are necessary and may influence 
the outcome by introducing bias to the assessment of 
methylation levels or by insufficient quality control of 
the data. The standard approach to minimize potential 
biases before sequencing is to produce replicates and 
assess the mean methylation levels during the analysis. 
In order to design a highly accurate yet cost-effective 
approach that is amenable to multiplexing, we assess at 
which step (bisulfite conversion or amplification) and to 
what extent technical variability would be introduced, 
as well as which quality control steps need to be per-
formed on the sequencing data to ensure a robust anal-
ysis. To this end, we assessed the methylation level of 0, 
25, 50, 75, 100% in vitro methylated bacterial artificial 
chromosome (BAC) control DNA for 3 different combi-
nations of pooling strategies during the bisulfite treat-
ment and PCR amplification (Fig. 2). Condition 1 (C1) 
assessed the methylation levels of control DNA using 
triplicate bisulfite treatments and PCR amplification for 
each replicate. C1 was considered the standard refer-
ence condition since each step was performed in tripli-
cates. In condition 2 (C2), triplicate bisulfite treatments 
were pooled to perform one PCR amplification reduc-
ing the costs by approximately 64%. Finally, in condi-
tion 3 (C3) one bisulfite treatment of the control DNAs 
was performed followed by 3 separate PCR amplifica-
tions to assess the extent of the target enrichment bias. 
A smaller panel of 11 different PCRs (Fig. 3) within the 
FKBP5 locus (see table in Additional file  1) served as 
basis for this analysis. Before comparing the three con-
ditions, the collected sequencing data were subjected 
to three quality control steps in order to ensure accu-
rate assessment of minimal methylation levels as well as 
small changes between samples.
Bisulfite conversion in triplicates
Pooling of bisulfite converted triplicates
Target enrichment (PCR)
reduces costs by ca. 64%
validated PCR panel to exclude 
Pooling of amplicons by Hamilton 
facilitates higher loading factor
eliminates handling error
captures variance of bisulfite treatment
HAM-TBS
w
orkflow
Fig. 1 Workflow of the HAM-TBS method, depicting important 
processing steps and their advantages
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1. Bisulfite conversion rate > 95%. We assessed the 
bisulfite conversion rate per sample and per amplicon 
and excluded rates lower than 95% from the analysis.
2. Removal of PCR artefacts During the target ampli-
fication, the PCR occasionally introduces artefacts 
presenting non-existent CpG sequences in the tar-
get region. They present at very low coverage and 
extreme levels of methylation (~ 0 or ~ 100%). In 
order to not exclude potential SNPs giving rise to 
CpGs, we removed artefacts on this basis rather than 
limiting the analysis to known CpGs according to the 
reference genome.
3. Minimum coverage of 1000 ×Higher sequencing 
depth and coverage of the CpGs yields higher accu-
racy of the methylation quantification. In order 
to determine the right balance between sequenc-
ing depth and thereby cost and sufficient accuracy, 
we took random subsamples of varying sequenc-
ing depth of an in silico created library represent-
ing methylation levels from 0 to 100% and assessed 
the standard deviation for each level of methylation 
with respect to coverage (Fig. 4a). To find a meaning-
ful cutoff for coverage, we considered the trade-off 
between sum of the average standard deviation per 
amplicon (cost) present in various levels of coverage 
(Fig. 4b). In accordance with previous findings [7], we 
identified 1000× coverage as a useful cutoff for our 
analysis, as the gain in accuracy with increasing cov-
erage above this threshold is low and 1000× is rea-
sonable to achieve for a larger locus, e.g., 9 kb in the 
FKBP5 panel.
All PCRs for our validation experiment showed 
bisulfite conversion levels > 99%. After QC, a total of 40 
CpG spread across 7 amplicons remained in our analysis 
(1 PCR failed due to coverage < 1000×, 1 showed nonlin-
ear amplification and coverage < 1000×, 2 showed non-
linear amplification). Methylation levels were very similar 
between all 3 conditions with an average error of < 1% 
when comparing absolute methylation levels of C2 and 
C3 versus C1 (Fig.  5b). We calculated the R2 values for 
each assessed CpG across the titration levels and used 
the mean per amplicon to compare the 3 conditions. R2 
is a measure for assessing linearity of amplification of 
the methylation signal, which is crucial when quantify-
ing methylation changes in, e.g., cohort studies. Again, all 
conditions showed very high mean R2 values above 0.99 
(Fig.  5a). This confirms that all conditions are suitable 
for high-accuracy methylation detection. The introduced 
biases in our workflow, based on the control DNA, are 
minimal and enable very accurate methylation quantifi-
cation even without including triplicates for the bisulfite 
conversion or target amplification. However, opposed to 
the target amplification, we cannot exclude slightly ele-
vated variance of the bisulfite conversion on non-in vitro 
methylated DNA from, e.g., patients. Therefore, we chose 
to use C2 for our HAM-TBS method. While it still main-
tains a triplicate bisulfite conversion step, it is the most 
cost-effective of the tested conditions, an important fac-
tor when processing many samples from cohort studies.
Comparison of the technical accuracy of pyrosequencing 
to TBS
Next, we aimed to compare TBS to pyrosequencing, the 
reference method used for targeted DNA methylation 
analysis. We assessed the methylation levels of 5 CpGs 
within PCR_5 and PCR_11 measured by pyrosequenc-
ing as well as using HAM-TBS with the C1 protocol. 
The methylation analysis using pyrosequencing showed 
a high mean standard deviation of 4.68% with a maxi-
mum  SD of 14.56%. The analysis using next-generation 
sequencing with C1 showed a much lower mean stand-
ard deviation of 0.72% with a maximum SD of 1.83%. This 
demonstrates a significantly lower technical variation 
and therefore higher accuracy when assessing methyla-
tion levels using a TBS approach.
Development of an extensive HAM-TBS FKBP5 panel 
covering relevant regulatory sites
FKBP5 is an important gene in the field of psychiatry. The 
gene is larger than 100  kb rendering the assessment of 
the full locus including the adjacent up- and downstream 
C1 C2 C3
PCR-free library 
bisulfite treatment
C U
PCR
genomic DNA 
Fig. 2 Setup of the TBS validation approach with the control 
conditions C1, C2 and C3. C1 is the reference condition with 
replicates in the bisulfite treatment and target enrichment step. 
C2 and C3 are more cost-effective versions dropping the replicate 
bisulfite treatment or target enrichment, respectively
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regions unfeasible and too cost intensive for TBS meth-
ods. We thus restricted our analysis to functionally 
relevant sites of interest to ensure compatibility with tar-
geted measurement methods and enable the assessment 
in large cohorts. To this end, we designed and validated 
a comprehensive amplicon panel (Fig.  6) including the 
TSS, TAD boundaries, intergenic and proximal enhanc-
ers as well as GR and CTCF binding sites (see methods 
for further details). The resulting HAM-TBS FKBP5 
panel is composed of 29 amplicons passing our QC’s 
threshold (described above) and covering 315 CpGs 
across the locus. The sequencing data showed sufficient 
bisulfite conversion for all amplicons when performed 
on control DNA using C2. In total, 27 of the amplicons 
included in the panel presented good linearity (see fig-
ure in Additional file 2) across the assessed methylation 
levels. Two amplicons located near the TSS showed a 
mild PCR bias, where methylation levels were lower than 
expected for the 50% and 75% controls (PCR_7, PCR_9). 
These amplicons have a very high CpG content of > 25%; 
hence, CpGs in the primer could not be avoided. It has 
been previously shown that methylation levels in this 
region are very low (< 5%) across tissues [12], so that 
any bias at higher methylation levels would not impair 
accurate quantification of this region. We thus incorpo-
rated sites located in this region in the panel, but they 
should be used with caution if higher methylation levels 
are observed. PCR_26 of the HAM-TBS FKBP5 panel 
is located in the H19 locus [13] which is an imprinted 
gene and serves as an internal positive control with an 
expected methylation level ~ 50%.
Application and costs
The HAM-TBS method can be multiplexed up to 96 
samples in a medium-throughput manner. To demon-
strate the applicability of our approach, quality control 
statistics of data derived from an experiment contain-
ing 95 blood samples from patients and the full FKBP5 
PCR_45 PCR_47 PCR_5
PCR_3 PCR_41 PCR_42 PCR_43
PCR_1 PCR_11 PCR_2 PCR_24
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Fig. 3 Methylation quantification of the control DNA used to evaluate the technical variability. Linear regression line (purple), Loess fit line (green). 
PCR_3 was excluded due to low coverage, PCR_47 was excluded due to low coverage and nonlinear amplification, and PCR_43 and PCR_45 were 
excluded due to nonlinear amplification
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panel of 29 amplicons are described here. After reads 
mapping and methylation calling, we identified PCR 
artefacts comprising ~ 1% of the methylation sites and 
removed them from the data, and 9 samples in 1 PCR 
showed insufficient bisulfite conversion rates (< 95%) 
and were also removed. Two loci were identified as 
SNPs giving rise to a CpG sites in patients. In total, 
91% of sample x amplicon data passed our filtering cri-
teria. 27 amplicons passed QC with sufficient coverage 
and quality in > 75% of samples, while two amplicons 
were dropped due to < 1000× coverage (Additional 
file  3A, B). The control amplicon spanning the H19 
imprinted locus for which methylation level is known 
to be ~ 50% [14] shows the expected methylation profile 
in all samples (Additional file 3C). HAM-TBS approach 
allowed the quantification of 276 methylation sites for 
95 samples in one single MiSeq run.
An assessment of the relative costs for each of the main 
reagents for this experiment containing 96 samples (95 
patients and unmethylated control) with increasing num-
ber of amplicons assessed is depicted in Additional file 4. 
The quantifications using TapeStation and the PCR-free 
library preparation are the two most cost-intensive steps. 
The proportion of costs for the amplicon quantification 
using the TapeStation increases with the higher amount 
of amplicons investigated, while relative costs for the 
library preparation and sequencing chemistry decrease 
with the inclusion of more amplicons.
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Discussion
We developed a targeted medium-throughput approach 
for measuring DNA methylation levels in multiple sam-
ples in parallel. This method enables cost-efficient high-
resolution methylation measurements of target loci in 
cohorts of patients and probands at the FKBP5 gene, a 
locus with large interest in the psychiatric and psycholog-
ical community [11]. This cost-efficient, accurate method 
to determine FKBP5 methylation levels would thus serve 
a large number of researchers. Our method is positioned 
between whole genome bisulfite sequencing and tar-
geted approaches as pyrosequencing. The first is expen-
sive and yields lower coverage and accuracy of single 
CpGs; the latter only allows to assess very small regions 
at a time and can generate significant variance between 
replicates. HAM-TBS enables the analysis of a targeted 
but larger region (~ 10  kb) at high resolution and low 
costs. DNA methylation studies in large cohorts, inves-
tigating the impact of environment or association with 
disease status in mixed tissues, necessitate high accuracy 
at single-site resolution. In fact, TBS was able to resolve 
methylation levels with a mean accuracy of 0.72%. A high 
level of accuracy was maintained in more cost-efficient 
approaches using only one PCR amplification round. 
By pooling triplicate bisulfite treatments prior to PCR 
amplification, we can account for variance introduced by 
the bisulfite treatment but also reduce costs and hands-
on time during the target amplification.
The accuracy of the method benefits from a PCR-free 
library preparation and rigorous quality control (prior 
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C1. x-axis: target methylation levels during in vitro methylation
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Fig. 6 Genome browser shot (hg19) illustrating the HAM-TBS FKBP5 panel and important locus-specific data. CTCF-ChIA-PET: track indicating 
the locations of CTCF factor-mediated chromatin interactions determined by Chromatin Interaction Analysis with Paired-End Tag (ChIA-PET) data 
(GM12878 [24]). CTCF ChIP-seq and GR Chip-seq: regions of transcription factor binding derived from chromatin immunoprecipitation (ChIP) 
experiments in multiple cell lines from the ENCODE project; HAM-TBS FKBP5 panel: locations of the amplicons contained in this panel
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evaluation of linear PCR amplification of the target site, 
bisulfite conversion efficiency > 95% and read cover-
age minimum of 1000×). Nonetheless, a proper assess-
ment of possible amplification biases due to the choice 
of amplicon location in the design step is critical. Some 
loci can show nonlinear amplification curves, which 
renders them inappropriate for methylation quantifica-
tion. Adjustment of primer design and PCR conditions 
may help solve this issue, but for some loci optimiza-
tion may not be possible. For instance, in CpG islands 
with high CpG density, we observed that amplification 
curves were not linear, revealing a bias which became 
more pronounced as the level of methylation increased. 
Differential methylation results from these sites should 
be interpreted with caution and perhaps require addi-
tional replication. Besides validating each ampli-
con prior to usage, including controls such as in  vitro 
unmethylated DNA, water and endogenous hemimeth-
ylated region, the H19 locus, during each HAM-TBS 
experiment is important and enables quality checks for 
each step of the protocol.
Additionally, reaching 1000× coverage is an impor-
tant step to provide high resolution on methylation 
changes [8]. However, accurate quantification and pool-
ing of many amplicons across multiple samples while 
reaching sufficient coverage of all regions has limita-
tions. In theory, even though the MiSeq can handle a 
much higher loading factor (amplicons x samples) of 
almost 20,000 (disregarding uneven pooling of libraries, 
filtering of reads due to low quality or high amounts of 
PhiX), a maximum of 2500–3000 has proven to be feasi-
ble with minimal dropout rates. Assuming multiplexing 
of 96 samples and 25 amplicons at an average length of 
400 bp, a region of approximately 10 kb can be comfort-
ably covered with this approach. Notably, we streamlined 
the method to handle loading factors > 2000 by imple-
mentation of Agilent’s TapeStation and a pipetting robot 
for quantification and pooling of amplicons. Besides the 
throughput, this improves the robustness of the work-
flow. Our approach is designed to match the specifica-
tions of the Illumina MiSeq with its ability to run for 600 
cycles resulting in 300  bp-long paired-end reads. This 
enables full-length coverage of amplicons up to a length 
of 600 bp. While our approach can be applied to differ-
ent sequencers, such as the Illumina HiSeq for exam-
ple, it would be necessary to design shorter amplicons 
due to the current limits of the sequencing chemistry. 
Using another sequencer, it is important to mention the 
index hopping phenomenon on the Illumina platforms 
[15]. It is less present on the MiSeq compared to other 
machines with pattern flow cells as our data show con-
sistent levels of methylation close to 0% across all in vitro 
unmethylated control samples indicating no issue with 
this specific bias. Nonetheless, it should be kept in mind 
that approaches like unique dual indexes when available 
or Illumina’s Free Adapter Blocking Reagent are recom-
mendable and gain importance, especially when using a 
different Illumina sequencer.
In the past years, only few TBS methods have been 
developed [8–10] with different methodological foci. 
Thus far, Bernstein et  al. [10] allows a panel of 48 indi-
ces, while the approach by Chen et al. [9] could allow for 
a multiplexing rate of 1536 samples due to custom-made 
barcodes, but in practice only 478 have been used to 
date. In the latter method, the high multiplexing capacity 
comes at the cost of an additional PCR step potentially 
introducing additional bias. Moreover, increasing the 
number of samples needs to be weighed against the size 
of the target region in order to ensure sufficient cover-
age. We identified 1000× coverage as an optimal cutoff in 
terms of accuracy and cost in agreement with a publica-
tion by Masser et al. [8]. In the above-described study by 
Chen et al. [9], 100× was used as minimum cutoff. Based 
on our in silico analysis (Fig. 4a), this would lead to less 
accurate quantification of methylation levels. Besides the 
number of samples that can be processed, the size of the 
region of interest is also an important factor to be con-
sidered. The method by Masser et al. [8] has been applied 
to 2 amplicons (233 and 320 bp), while Chen et al. enable 
the assessment of larger loci around 10 kb—comparable 
to our HAM-TBS approach. Lastly, amplification-based 
library preparation methods have been adapted by most 
TBS approaches. At this point, HAM-TBS utilizes a PCR-
free library preparation to avoid adding amplification 
biases.
Finally, using the optimized HAM-TBS workflow, we 
designed a panel comprising 29 amplicons to accurately 
assess methylation within the FKBP5 locus using HAM-
TBS. This panel covers ~ 9  kb and targets important 
regulatory regions of the FKBP5 gene including the TSS, 
intergenic and proximal enhancers and TAD boundaries 
including CTCF binding sites. The HAM-TBS method 
and the FKBP5 panel present valuable tools for epigenetic 
studies in which a highly accurate assessment of meth-
ylation levels is critical such as GxE studies in psychiatric 
research. It allows cost-efficient quantification of methyl-
ation in larger cohorts with optimized hands-on time due 
to automatization.
Conclusion
The presented method HAM-TBS offers a robust and 
low-cost method for researchers interested in DNA 
methylation measurements of specific target regions. In 
addition, we supply a validated panel of 29 amplicons to 
assess methylation levels of important regulatory regions 
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in the FKBP5 locus, a gene of great interest in the field of 
psychiatry.
Methods
Generation of in vitro methylated control DNA
All primers designed for bisulfite PCR were first tested 
on in vitro methylated DNA to assess amplification effi-
ciency and bias. For PCRs within the FKBP5 gene, an 
in  vitro methylated BAC (RP11-282I23, BACPAC) was 
used to generate control DNA. For PCRs outside the 
FKBP5 locus (PCR_26, PCR_34, PCR_35), genomic DNA 
extracted from whole blood was amplified using the 
REPLI-g Mini Kit (QIAGEN GmbH, Hilden, Germany) to 
generate unmethylated DNA. 100% methylated DNA was 
achieved using in  vitro methylation with M.SssI meth-
yltransferase. After a first incubation (3  µg DNA, 0.5  µl 
SAM (32 mM), 1 µl M.SssI (20 U/µl, 40 µl NEB buffer 2 
[10×], diluted with ddH2O up to 400 µl) of 4 h at 37C, 
1 µl of M.SssI (20 U/µl) and 1 µl of SAM (32 mM) were 
added, and a second 4-h incubation was performed. Sub-
sequently, the reaction was purified using the nucleotide 
removal kit (QIAGEN GmbH, Hilden, Germany). In vitro 
methylation was repeated with the eluted DNA for a sec-
ond time. 25, 50 and 75% methylated control DNA was 
obtained by mixing 0 and 100% DNAs. In vitro methyla-
tion of control DNA was checked via pyrosequencing.
Bisulfite treatment of DNA
We used the EZ DNA Methylation Kit (Zymo Research, 
Irvine, CA) in column and plate format depending on 
the amount of DNA and throughput needed. Between 
200 and 500  ng was used as input DNA and processed 
according to the manufacturer’s instructions. DNA was 
eluted twice in 10 µl elution buffer which recovered over 
90% of the input DNA after bisulfite conversion when 
using the column format. In order to quantify bisulfite 
treated DNA, we use a spectrophotometer with RNA 
quantification settings.
Target enrichment and amplicon pooling
The amplification of target locations from converted 
DNA (20  ng per amplicon) was achieved using the 
TaKaRa EpiTaq HS Polymerase (Clontech, Mountain 
View, CA; final concentration: 0.025 U/l), bisulfite-spe-
cific primers (final concentration of each primer: 0.4 M) 
and a touchdown cycling protocol with 49 cycles [for 
more details (see table in Additional file  5 and section 
HAM-TBS FKBP5 panel). The amplicons of all PCR reac-
tions were quantified using the Agilent 2200 TapeStation 
(Agilent Technologies, Waldbronn, Germany] and equi-
molar pooled with the Hamilton pipetting robot. After 
speed-vacuum and resuspension in 50  µl, a double-size 
selection was applied using Agencourt AMPure XP beads 
(Beckman Coulter GmbH, Krefeld, Germany) to remove 
excess of primers and genomic DNA.
Control samples
For every TBS run, we included three different controls. 
First, up to three water controls in order to monitor 
cross-contamination with DNA and detect if the plate 
was accidentally rotated. Second, an unmethylated con-
trol DNA as a positive control and to detect failed steps 
throughout the workflow. And third, the H19 locus which 
is an imprinted region and presents with methylation 
levels ~ 50% as a positive control for bisulfite conversion 
in genomic DNA and detect outliers in patient samples. 
An amplicon located at this locus is incorporated in the 
FKBP5 panel.
Library preparation and sequencing
For library generation, Illumina TruSeq DNA PCR-Free 
HT Library Prep Kit (Illumina, San Diego, CA) was used 
according to the manufacturer’s standard protocol and 
obtained high-quality libraries using 500  ng of start-
ing material (during optimization, input amounts as low 
as 100 ng were tested and showed no loss of quality on 
the QC level). Qubit 1.0 (Thermo Fisher Scientific Inc., 
Schwerte, Germany) was used for quantification, Agi-
lent’s 2100 Bioanalyzer (Agilent Technologies, Wald-
bronn, Germany) for quality assessment and Kapa 
HIFI Library quantification kit (Kapa Biosystems Inc., 
Wilmington, MA) for final quantification before pool-
ing. Libraries were pooled equimolarly. Sequencing of 
the libraries was performed on an Illumina MiSeq using 
Reagent Kit v3 (Illumina, San Diego, CA; 600 cycles) in 
paired-end mode, with 30% PhiX added.
Sequencing data processing
First, read quality was verified using FastQC [16]. Adapter 
sequences were trimmed using cutadapt v.1.9.1 [17]. For 
alignment to a restricted reference of hg19 based on the 
PCR locations, Bismark v.0.15.0 [18] was used. Due to 
the 600-cycle sequencing chemistry, PCRs shorter than 
600  bp produce overlapping paired-end reads. Using an 
in-house developed Perl script, we trimmed low-quality 
overlapping ends. Quantification of methylation levels in 
CpG and CHH context was performed using the R pack-
age methylKit [19] with a minimum quality score of 20. 
The methylation calls were subjected to 3 quality control 
steps. First, we considered CHH levels for each sample 
and excluded samples if the conversion was less than 95% 
efficient. Second, we filtered PCR artefacts introduced 
by PCR amplification errors giving rise to CpG sites in 
some reads. As we do not restrict the analysis to known 
CpG sites, every read indicating the presence of a CpG 
will be considered and the information extracted. These 
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artefacts mostly present at very low levels of coverage 
and 0 or 100% methylation. Lastly, according to our cov-
erage cutoff, we excluded CpG sites supported by less 
than 1000 reads. Subsequent analysis comparing meth-
ylation levels from the conditions C1, C2 and C3 as well 
as data from pyrosequencing was performed in R.
Coverage considerations
When performing a sequencing experiment, one will 
usually sequence part of the generated library and quan-
tify the methylation levels on this basis rather than 
sequence the whole library to see the true level within. 
Therefore, each sequencing experiment corresponds to 
drawing a random subset of a certain size (sequencing 
depth) of the whole library and can be viewed as a sub-
sampling problem. Depending on the sequencing depth, 
this will yield a different level of accuracy of the meth-
ylation levels. We created a dataset simulating CpGs 
methylated at levels from 0 to 100% supported by 100,000 
“fragments” each. Therefore, e.g., for 10% methylation 
level, a set 10,000 Cs and 90,000 Ts was created. Accord-
ingly, sets for 0–100% methylation were created. Using a 
bootstrapping approach, we drew 1000 random subsets 
of varying sequencing coverage (100, 200, 400, …, 2000, 
3000, 4000, 5000) from each set representing a certain 
level of methylation and the standard deviation (SD) was 
calculated. As a proxy for the increase in accuracy ver-
sus increase in sequencing depth (costs), the combined 
SD was divided by the sequencing depth. Of note, this 
is in concordance with results from the same analysis on 
highly covered amplicon data from our laboratory (data 
not shown).
Pyrosequencing
Methylation analysis by pyrosequencing of 5 CpGs cov-
ered within PCR_5 (CpG 35607969, CpG 35608022) and 
PCR_11 (CpG 35690280, CpG 35690318, CpG 35690365) 
was performed in triplicates on BAC control DNA. 
Bisulfite conversion of in vitro methylated control DNA 
was applied as described above. Target enrichment by 
PCR was achieved with a biotinylated reverse primer but 
otherwise performed as described above. Pre-treatment 
of PCR amplicons was facilitated with the PyroMark Q96 
Vacuum Workstation (QIAGEN GmbH, Hilden, Ger-
many). Sequencing of FKBP5 CpGs was performed on a 
PyroMark Q96 ID system using PyroMark Gold Q96 rea-
gents (QIAGEN GmbH, Hilden, Germany) and sequenc-
ing primers according to Klengel et al. [12]: P4 S1 (TTT 
GGA GTA GTA GGT TAA A) GRE3 S1 MPI (GGG AAT 
TAT GAG GTTG). The PyroMark Q96 ID Software 2.5 
(QIAGEN GmbH, Hilden, Germany) was used for data 
analyses.
HAM-TBS FKBP5 panel
We designed 29 primer pairs (see table in Additional 
file  5) using BiSearch [20, 21] targeting the FKBP5 
locus. Initially, 32 PCRs were included, but 3 PCRs 
were not selected for the panel due to QC failure. The 
excluded amplicons showed nonlinear amplification 
due to an elevated GC content in the region. Positions 
of amplicons covering glucocorticoid response ele-
ments (GREs) were selected from Klengel et  al. [12] 
and the GR ChIP-Seq from the ENCODE project [22]. 
Amplicons covering CTCF binding sites were selected 
using HI-C peaks [23], CTCF-ChIA-Pet interac-
tions from a lymphoblastoid cell line (GM12878, Tang 
et  al. [24]) and CTCF ChIP-Seq information from the 
ENCODE project [22]. Lastly, amplicons located near 
the TSS were included in the panel. Only primers 
without CpGs in their sequence were chosen, with the 
exception of 2 amplicons close to the TSS where this 
could not be avoided due to the high CpG content of 
the region. The selected amplicons ranged from 200 to 
450 bp in length.
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Dynamic Changes in DNA 
Methylation Occur during the 
First Year of Life in Preterm Infants
Chinthika Piyasena1,2, Jessy Cartier1, Nadine Provençal3, Tobias Wiechmann3, Batbayar 
Khulan1, Raju Sunderesan2, Gopi Menon2, Jonathan R. Seckl1, Rebecca M. Reynolds1, 
Elisabeth B. Binder3 and Amanda J. Drake1*
1 British Heart Foundation Centre for Cardiovascular Science, The Queen’s Medical Research Institute, University of 
Edinburgh, Edinburgh, UK, 2 Neonatal Unit, Simpson Centre for Reproductive Health, Royal Infirmary of Edinburgh, 
Edinburgh, UK, 3 Department of Translational Research in Psychiatry, Max-Planck Institute of Psychiatry, Munich, Germany
Background: Preterm birth associates with a substantially increased risk of later 
cardiovascular disease and neurodevelopmental disorders. Understanding underlying 
mechanisms will facilitate the development of screening and intervention strategies to 
reduce disease risk. Changes in DNA methylation have been proposed as one mecha-
nism linking the early environment with later disease risk. We tested the hypothesis that 
preterm birth associates with altered DNA methylation in genes encoding insulin-like 
growth factor 2 (IGF2) and FK506-binding protein 5 (FKBP5), which appear particularly 
vulnerable to early life adversity.
Methods: Fifty preterm infants were seen and assessed at birth, term equivalent age, 
3 months and 1-year corrected ages; 40 term infants were seen at birth, 3 months and 
1 year. Saliva was collected for DNA extraction at birth, term, and 1 year. Pyrosequencing 
of bisulfite-converted DNA was performed to measure DNA methylation at specific CpG 
sites within the IGF2 and FKBP5 loci.
Results: Weight and head circumference was reduced in preterm infants at all time 
points. Preterm infants had a higher percentage body fat at term-corrected age, but 
this difference was not persistent. DNA methylation at the differentially methylated 
region (DMR) of IGF2 (IGF2DMR2) and FKBP5 was lower in preterm infants at birth- and 
term-corrected age compared to term infants at birth. IGF2DMR2 and FKBP5 methyl-
ation was related to birthweight SD score in preterm infants. Among preterm infants, 
social deprivation was an independent contributor toward reducing DNA methylation 
at IGF2DMR2 at birth- and term-corrected age and maternal smoking was associated 
with reduced DNA methylation at FKBP5 at birth. There were no persistent differences in 
DNA methylation at 1 year of age.
Conclusion: Changes in DNA methylation were identified at key regions of IGF2/H19 
and FKBP5 in preterm infants in early life. Potential contributing factors include maternal 
smoking and social deprivation. However, these changes did not persist at 1 year of 
age and further longitudinal studies are required to determine any associations between 
altered DNA methylation in the perinatal period of individuals born preterm and their 
long-term health.
Keywords: prematurity, DNA methylation, IGF2, FKBP5, glucocorticoids
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INTRODUCTION
Epidemiological evidence linking low birthweight with an 
increased risk of cardiovascular disease as well as developmental 
neuropsychiatric disorders (1) has led to the concept of “early life 
programming.” This proposes that exposure to adverse conditions 
during critical stages of early development results in a change in 
the offspring structural and functional phenotype (2). Preterm 
birth acts as a profound challenge in early life. There is now 
substantial evidence that prematurity associates with risk factors 
for cardiovascular disease in adulthood, including hypertension 
and insulin resistance (3–5). Furthermore, preterm birth is 
closely associated with neurodevelopmental disorders including 
cognitive impairment and autism spectrum disorder (6). This 
has important implications for public health, since worldwide, 
15 million infants are born preterm every year, and survival rates 
have increased markedly over recent years (7).
Factors acting during intrauterine development, which may be 
important in mediating programing effects in infants born small 
at term, include undernutrition and glucocorticoid overexposure. 
These may be of particular importance in infants born preterm. 
In addition, preterm infants are vulnerable to these factors acting 
in early postnatal life (4). Following birth, many preterm infants 
develop a cumulative protein and energy deficit and exhibit early 
postnatal growth failure (8). Preterm infants are additionally 
exposed to repeated stressful and often painful procedures dur-
ing a period of rapid brain maturation, and several studies have 
shown an impact of these procedures on neurodevelopment and 
hypothalamic–pituitary–adrenal (HPA) axis activity (9, 10).
Understanding the mechanisms by which prematurity associ-
ates with long-term effects on health would facilitate the develop-
ment of effective screening and intervention strategies. Changes 
in DNA methylation have been proposed as one mechanism link-
ing early life events and later disease risk (11), and genome-wide 
profiling has revealed DNA methylation differences between 
preterm and term infants in early life (12–14). Exposure to an 
adverse environment in early life has repeatedly been associated 
with altered DNA methylation at a gene of particular importance 
for fetal growth: the imprinted gene insulin-like growth fac-
tor 2 (IGF2). IGF2 is a key growth factor, particularly in early 
development. IGF2 expression is controlled by DNA methylation 
at a number of differentially methylated regions (DMRs) (15) 
and altered IGF2 DNA methylation has been reported following 
exposure to altered maternal nutrition including severe famine 
(16, 17).
The early life environment can also impact on the normal 
functioning of the HPA axis, with implications for neurodevelop-
ment. Exposure to an adverse environment pre- or postnatally 
has been associated with altered DNA methylation at a number 
of genes important in determining HPA axis function, including 
the glucocorticoid receptor (GR) and 11beta-hydroxysteroid 
dehydrogenase type 2 (11β-HSD2). Differences in DNA meth-
ylation at GR and 11β-HSD2 in placenta have been reported in 
association with infant behavioral development (18); however, 
we have previously reported that DNA methylation at GR and 
11β-HSD2 is extremely low in individuals exposed to an adverse 
early life environment and is, therefore, unlikely to impact on 
gene expression (17). FK506-binding protein 5 (FKBP5) encodes 
a co-chaperone of GR and is induced following stress exposure 
through GR binding to specific genomic response elements; 
in turn, FKBP5 protein binds to the GR complex, reducing its 
affinity for cortisol and decreasing nuclear translocation (19). 
Thus, it is an important component of the stress response. A 
functional polymorphism in FKBP5 intron 2 alters mRNA and 
protein induction following GR activation (20), such that the 
allele associated with stronger FKBP5 mRNA induction associ-
ates with GR resistance and an increased risk of a number of 
psychiatric disorders following childhood trauma (20). Exposure 
to childhood trauma leads to allele-specific epigenetic changes, 
with a GR-binding-induced decrease in DNA methylation within 
a functional glucocorticoid response element in intron 7, specifi-
cally, in carriers of the risk allele (20). Further, DNA methylation 
of FKBP5 in placenta associates with infant arousal scores (21).
In this study, we tested the hypothesis that preterm birth, 
a profound stressor in early life, associates with altered DNA 
methylation at the candidate loci IGF2 and FKBP5, which may 
be particularly vulnerable to early life adversity, and examined 
whether any changes were persistent over the first year of life.
MATERIALS AND METHODS
Cohort
Fifty preterm (<32 weeks gestation) and 40 term (37–42 weeks 
gestation) infants were recruited within the first week of life 
from the Simpson Center for Reproductive Health, Edinburgh, 
UK, with informed written parental consent. Ethical approval 
was obtained from the South East Scotland Research Ethics 
Committee (Reference 11/AL/0329). NHS management 
approval was obtained (Lothian R&D Project number 2011/R/
NE/03). Perinatal samples were collected under the Edinburgh 
Reproductive Tissue BioBank (ERTBB) (West of Scotland 
Research Ethics Service Reference 09/S0704/3). All parents 
gave written informed consent and all studies were performed 
in accordance with the declaration of Helsinki. Infant samples 
were collected under the framework of the ERTBB follow-
ing an amendment to ethical approval (Reference AM07/1). 
Demographic details were obtained during clinic visits and 
from hospital records. All of the preterm infants were admit-
ted to the neonatal unit; of these, six infants died. In three of 
these infants, saliva for buccal cells was not collected after birth 
due to clinical instability and DNA was of poor quality in a 
fourth infant. Five of the term infants were also admitted to the 
neonatal unit for a short period (respiratory distress syndrome, 
weight loss, and hemolysis from Rhesus isoimmunization) but 
none required follow-up. Preterm infants were seen at birth, 
at term-corrected age, and at 3  months and 1-year corrected 
ages; term infants were seen at birth, 3 months, and 1 year. All 
visits occurred in the afternoon, supervised by one researcher 
(Chinthika Piyasena).
Growth and Body Composition
Weight, length, and occipitofrontal head circumference (OFC) 
was measured by one trained researcher. Percentage body fat mass 
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was measured by air displacement plethysmography in preterm 
infants at term-corrected age and 3 months corrected age, and 
in term infants at birth and 3 months using the PEAPOD Body 
Composition System (COSMED, Chicago, IL, USA). Skin fold 
thickness (subscapular and triceps) was measured at 1 year by the 
same trained researcher. Term infants were measured at a median 
of 2 days (range 0–8) after birth, at 3 months (13.3 weeks; range 
10.4–16.9), and 1  year (52.3  weeks; range 48.1–57.4). Preterm 
infants were measured at term-corrected age at a median of 40 
(range 35 + 0 to 44 + 1)-corrected weeks, at 3 months corrected 
(13.4 weeks; range 10.3–18.3) and 1 year corrected (53.9 weeks; 
range 52.1–68.7).
Analysis of DNA Methylation
Saliva was collected using the Oragene DNA (OG-250) kits 
and saliva sponges CS-1 and extracted using prepIT-2LP (DNA 
Genotek, Ottawa, ON, Canada). DNA was quantified using the 
Qubit 2.0 Fluorometer (Life Technologies, Paisley, UK). Five 
hundred nanograms of DNA were bisulfite converted using the 
EZ DNA Methylation Gold Kit (Zymo Research Corporation, 
CA, USA). Pyrosequencing was performed to analyze DNA 
methylation for DMRs controlling IGF2 expression: IGF2 DMR2 
(IGF2DMR2, n = 9 CpGs) and the H19 imprinting control region 
(H19ICR, n  =  8 CpGs) as previously described (22). Primers 
were purchased from Invitrogen (Life Technologies, Paisley, 
UK). DNA was amplified using the AmpliTaq Gold 360 kit 
(Applied Biosystems, Warrington, UK) and pyrosequencing per-
formed using PyroMark Q24Gold reagents on a PyroMark Q24 
Pyrosequencer (Qiagen, Crawley, UK). Data were analyzed using 
PyroMark Q24 1.0.10. Percentage DNA methylation is expressed 
as the average across all CpGs in each of the two loci in IGF2.
Methylation analysis of three CpGs in FKBP5 intron 7, two 
of which are located in consensus GRE motif (CpG 2 and 3), 
was performed in triplicates using a protocol adapted from 
Klengel et  al. (20). One hundred twenty nanograms genomic 
DNA was bisulfite converted using the EZ DNA Methylation 
Kit (Zymo Research Corporation, CA, USA). Bisulfite converted 
DNA was amplified in a 50 µl reaction mix (4–10 µl DNA; each 
bisulfite specific Primer with a final concentration of 0.2  µM, 
FKBP5int7_P1_F: GTTGTTTTTGGAATTTAAGGTAATTG, 
and FKBP5int7_P1_R_biot: biotin-TCTCTTACCTCCAACAC-
TACTACTAAAA) using the Kapa HIFI Uracil  +  Hot start 
Ready Mix (Kapa Biosystems Inc., Wilmington, DE, USA). 
Cycling conditions of the touchdown PCR were 98°C for 
5 min, 2× (98°C – 40 s, 62°C – 30 s, 72°C – 60 s), 5× (98°C – 
40  s, 60°C – 30  s, 72°C – 60  s), 8× (98°C – 40  s, 58°C – 30  s, 
72°C – 60 s), 34× (98°C – 40 s, 56°C – 30 s, 72°C – 60 s), 72°C 
for 1 min and cooling to 4°C. Pyrosequencing of FKBP5 CpGs 
was performed on a PyroMark Q96 ID system (QIAGEN 
GmbH, Hilden) using PyroMark Q96Gold reagents with the 
following sequencing primer: FKBP5int7_P1_S2: 5′-GTT 
GATATATAGGAATAAAATAAGA-3′ for CpG1 and CpG2 and 
FKBP5int7_P1_S3: 5′-TGGAGTTATAGTGTAGGTTTT-3′ for 
CpG3. PyroMark Q96 ID Software 2.5 (QIAGEN GmbH, Hilden) 
was used to calculate percentage methylation.
The legends for Figures 1 and 2 state the number of values/
measurements analyzed, excluding samples, which were discarded 
because of insufficient DNA and/or poor pyrosequencing qual-
ity. Additionally, we were unable to collect saliva from several 
babies for various reasons, although these babies still underwent 
anthropometry.
FKBP5 SNP Genotyping
FKBP5 rs1360780 genotyping was performed on a Roche 
LightCycler 480 System using a TaqMan SNP Genotyping Assay 
(Applied Biosystems). Thermal cycling conditions were 95°C for 
10 min, 45× (95°C – 15 s, 60°C – 1 min, 50°C – 30 s). Genotypes 
were called using endpoint genotyping LightCycler 480 Software 
version 1.5. Genotypes were in Hardy–Weinberg equilibrium 
(p  =  0.17). Participants were divided into protective–genotype 
(CC) and risk-allele carriers (CT or TT).
Covariates
Covariates that could confound the association or be in the 
causal pathway were added into the model in a hierarchical 
manner: maternal smoking, male gender, and social depriva-
tion for FKBP5 and IGF2/H19. Additionally, breast milk at 
3  months for IGF2/H19 at 1  year and risk-allele carriage for 
FKBP5 at all time points. Social deprivation was coded as 
deprivation category (DEPCAT) scores based on the mother’s 
postcode at booking and obtained from the “Carstairs scores 
for Scottish postcode sectors from the 2001 Census.” In this 
system, scoring is based on the material affluence/deprivation 
of the area in which a person lives. Postcode sectors are allo-
cated a DEPCAT score, derived from four sets of information: 
overcrowding, male unemployment, car ownership, and the 
proportion of people in households in social class 4 or 5 and 
scores range from 1 to 7 where 7 indicates the worst social 
deprivation. Maternal smoking was categorized as current 
smoker, never smoked, former (stopped pre-pregnancy), or 
former (stopped during pregnancy). Breast milk at 3 months 
indicates whether or not the infant was receiving any breast 
milk at 3 months corrected age.
Statistics
Weight, length, OFC, skin fold thickness, and weight gain were 
adjusted for age and gender by converting to SD scores (SDS) 
(z-scores) using LMSgrowth, a Microsoft Excel Add-in to access 
growth references that define the UK-WHO growth charts (23). 
Demographic, clinical characteristics, and risk-allele carriage 
between preterm and term infants were compared using inde-
pendent samples t-testing and chi-square analyses, as appropri-
ate. Multivariate linear regression was used to assess variation in 
body composition and to test the hypothesis that preterm birth 
is associated with altered DNA methylation. Outcome variables 
were percentage DNA methylation at birth, term-corrected age, 
and 1  year. Unstandardized regression (β) coefficients from 
these models indicate the change in percentage methylation 
associated with prematurity and a one-unit change in the other 
predictors. Paired samples t-testing was used where appropriate. 
One-way ANOVA with Dunnett’s post  hoc t testing was used 
to test the effect of maternal smoking on DNA methylation at 
FKBP5. Statistical significance for all analyses was set at p < 0.05 
(two-tailed).
FIGURE 1 | Growth of term and preterm infants over the first year: box and whisker plots: Tukey with line at median (+ indicates mean). (A) Weight, 
OFC, and length at birth- and term-corrected age. Term infants: n = 40, preterm infants: n = 43. (B) Weight, OFC, and length at 3 months/3 months-corrected age. 
Term infants n = 35, preterm infants n = 35. (C) Weight, OFC, and length at 1 year/1-year corrected. Term infants n = 35, preterm infants n = 42. (D) % fat mass in 
preterm and term infants at birth- and term-corrected age and 3 months of age. Term infants: n = 32 at birth and 30 at 3 months, preterm infants: n = 21 at 
term-corrected age and 32 at 3 months corrected. (E) Skinfold thickness in term and preterm infants at 1 year/1-year corrected. Term infants n = 32, preterm 
infants, n = 31 (n denotes the number of measurements obtained). *p < 0.05, **p < 0.001.
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RESULTS
Preterm and Term Infant Demographics
Characteristics of the cohort are shown in Table 1. Birth weight 
SDS was lower in preterm infants p < 0.001, and there were more 
males in the preterm group, p = 0.006. There was no significant 
difference between the frequency of FKBP5 risk-allele carriage 
between the groups (p = 0.43). Maternal age, body mass index 
(BMI), DEPCAT scores, folic acid in first trimester, and maternal 
smoking were different between the two groups.
Growth and Body Composition
Weight and OFC was reduced in preterm infants at all time points 
compared to term infants (Figures 1A–C). Preterm infants were 
shorter than term infants at term-corrected age and 3 months cor-
rected age, but not at 1-year corrected (Figures 1A–C). Preterm 
infants had a higher percentage body fat at term-corrected age 
when compared with term infants at birth (Figure  1D) (mean 
difference 5.5%, 95% CI [8.0, 3.0], p < 0.001) and this remained 
significant following adjustment for gender (β = 5.7, 95% CI [3.1, 
8.3], p < 0.001). The difference in percentage body fat did not 
persist at 3 months/3 months corrected, including when adjusted 
for gender and breast milk intake (β = −0.3, 95% CI [−2.8, 2.2], 
p = 0.82) (Figure 1D). At 1-year corrected, preterm infants had 
lower triceps skin fold thickness SDS than term infants, adjusted 
for breast milk exposure at 3 months (β = −0.4, 95% CI [−1.3, 
−0.3], p = 0.008), but there were no differences in subscapular 
skin fold thickness (Figure 1E).
Prematurity and DNA Methylation
Mean DNA methylation at IGF2DMR2 was lower in preterm 
infants at birth compared to term infants at birth and this 
remained significant in adjusted analyses (β  =  −11.2, 95% CI 
[−15.2, −7.3], p < 0.001) (Figure 2B). There was no difference 
in mean DNA methylation at the H19ICR between preterm and 
term infants at birth after adjusted analysis (β = −1.3, 95% CI 
[−3.8, 1.2], p =  0.3) (Figure  2A). In preterm infants at term-
corrected age, DNA methylation was reduced at IGF2DMR2 and 
H19ICR compared to infants born at term, and this remained 
significant in adjusted analyses (β  =  −2.8, 95% CI [−5.0, 
−0.6], p = 0.01 and β = −2.3, 95% CI [−4.6, −0.1], p = 0.049, 
respectively) (Figures  2A,B). However, the significance was 
attenuated when social deprivation was added into the model 
for IGF2DMR2 (β = −2.1, 95% CI [−4.3, 0.05], p = 0.055). At 
1 year of age, there was no difference in mean DNA methyla-
tion in adjusted analyses at either IGF2DMR2 (β = −0.3, 95% 
FIGURE 2 | Percentage DNA methylation at IGF2/H19 and FKBP5: box and whisker plots: Tukey with line at median (+indicates mean). (A) % DNA 
methylation at H19ICR: term infants: n = 28 at birth and 31 at 1 year. Preterm infants: n = 23 at birth, 31 at term corrected, and 32 at 1-year corrected. (B) % DNA 
methylation at IGF2DMR2: term infants: n = 25 at birth and 23 at 1 year. Preterm infants: n = 22 at birth, 32 at term corrected, and 28 at 1-year corrected. (C) DNA 
methylation at FKBP5 CpG1: term infants: n = 32 at birth and 31 at 1 year. Preterm infants: n = 27 at birth, 37 at term-corrected age, and 32 at 1-year corrected. 
(D) DNA methylation at FKBP5 CpG2: term infants: n = 28 at birth and 30 at 1 year. Preterm infants: n = 25 at birth, 33 at term-corrected age, and 32 at 1-year 
corrected. (E) DNA methylation at FKBP5 CpG3: term infants: n = 30 at birth and 30 at 1 year. Preterm infants: n = 27 at birth, 36 at term-corrected age, and 36 at 
1-year corrected (n denotes the number of measurements obtained). *p < 0.05, **p < 0.001.
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CI [−4.0, 3.3], p = 0.86) or H19ICR (β = 0.8, 95% CI [−1.5, 3.0], 
p = 0.49) (Figures 2A,B).
The presence of the FKBP5 risk allele was associated with 
higher DNA methylation at FKBP5 CpG3 at birth (β = 4.0, 95% 
CI [0.3, 7.6], p = 0.03) and term-corrected age (β = 2.5, 95% CI 
[0.4, 4.5], p = 0.02) across all infants. DNA methylation at CpG1, 
CpG2, and CpG3 was lower in preterm infants at birth and at 
term-corrected age when compared to term infants at birth, 
including after adjusted analysis (Table 2). There was an increase 
in DNA methylation at all three CpGs in both groups during the 
first year (Figures  2C–E) and, by 1  year of age, there were no 
persistent differences in mean methylation at any CpG between 
preterm and term infants (Table  2). The presence/absence of 
the FKBP5 risk allele as a covariate did not alter the findings at 
1 year and there was no moderation of the relationship between 
prematurity and DNA methylation by the presence of the risk 
allele at any time.
Body Composition and DNA Methylation
IGF2DMR2 methylation was highly significantly related to birth-
weight SDS in preterm (R = 0.7, p < 0.001), but not term infants. 
DNA methylation across FKBP5 was also positively associated 
with birthweight SDS (β = 0.3, 95% CI [0.3, 5.4], p = 0.03) when 
adjusted for prematurity, but only in the preterm infants when 
analyzed separately (R = 0.4, p = 0.04). There were no other sig-
nificant relationships between DNA methylation at IGF2DMR2, 
TABLE 1 | Characteristics of the study participants.
Term Preterm p-Value
Infant characteristics
Gestation at birth, weeks 40.2 ± 1.1 28.5 ± 2.1 <0.001
Birth weight, g 3,649 ± 517 1,136 ± 350 <0.001
Birth weight SDS 0.44 ± 1.0 −0.44 ± 0.9 <0.001
Male, n (%) 15 (38) 35 (70) 0.006
Death, n (%) 0 6 (12)
Bronchopulmonary dysplasia, n (%) 0 14 (31)
Laser for retinopathy of prematurity, n (%) 0 5 (11)
Necrotizing enterocolitis, n (%) 0 6 (13.3)
Intraventricular hemorrhage, n (%) 0 3 (6)
Periventricular leucomalacia, n (%) 0 2 (4.2)
Late onset sepsis, n (%) 0 17 (37)
TPN duration, days 0 17.8 ± 21.8
Any breast milk at 3 months, n (%) 28 (75.7) 9 (22.5) <0.001
FKBP5 risk allele carriage, n (%) 21 (52.5) 28 (60.9) 0.43
Maternal characteristics
Age, years 35.2 ± 4.6 31.3 ± 6.2 0.001
Body mass index at booking, kg/m2 24.3 ± 3.1 27.2 ± 6.9 0.016
High DEPCAT score, n (%) 11 (27.5) 27 (61.4) 0.002
Caucasian ethnicity, n (%) 40 (100) 41 (93.8) 0.09
Smoking, n (%)
Current 0 10 (22.7)
Former – stopped during pregnancy 2 (5) 4 (9.1) 0.5
Former – stopped pre-pregnancy 12 (30) 11 (25) 0.61
Never 26 (65) 18 (40.9) 0.03
Primiparity, n (%) 21 (52.5) 29 (65.9) 0.69
Folic acid during first trimester, n (%) 40 (100) 38 (86.3) <0.001
Assisted reproduction, n (%) 0 6 (13.6)
Multiple pregnancy, n (%) 0 9 (20.4)
Hypertension or preeclampsia, n (%) 0 10 (22.7)
Diabetes during pregnancy, n (%) 0 3 (6.8)
Antenatal steroids, n (%)
None 40 (100) 3 (6.8) <0.001
Incomplete course – 11 (25)
Complete course – 30 (68.2)
Antenatal magnesium sulfate, n (%) 0 10 (22.7)
Cesarean section, n (%) 28 (70) 23 (52.2) 0.1
Labor, n (%) 18 (37.5) 27 (61.4) 0.13
Age of partner 35.3 ± 5.2 33.1 ± 6.9 0.1
Plus–minus values are means ± SD. n = 40 full term and 50 preterm infants. n = 44 
for mothers of preterm infants. Bronchopulmonary dysplasia (BPD) is defined as need 
for respiratory support and/or supplemental oxygen at 36 weeks’ postmenstrual age 
to maintain oxygen saturations of 90% or more. A diagnosis of necrotizing enterocolitis 
was applied when cases achieved Bell stage 2 or greater. Intraventricular hemorrhage 
is defined as only grades III or IV events. The definition of late onset sepsis is taken 
from the Vermont Oxford Network Manual of Operations, release 16.3. Five preterm 
infants died before 36 weeks’ postmenstrual age (mean 24.9 weeks’ gestational age at 
birth, mean 692 g birthweight). A further preterm infant died at term-corrected age from 
severe BPD (26-weeks’ gestation at birth weighing 1,000 g). In three of these infants, 
saliva for buccal cells was not collected after birth due to clinical instability and DNA 
was of poor quality in a fourth infant. Three term infants and six preterm infants were 
not seen at 3 months. High DEPCAT was regarded as scores 4–7.
SDS, SD score; DEPCAT, deprivation category.
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H19ICR, or FKBP5 and weight or measures of body composition 
in either preterm or term infants at any other time point (Table 3).
Social Deprivation, Maternal Smoking, and 
DNA Methylation
Social deprivation was an independent contributor toward reduc-
ing DNA methylation at IGF2DMR2 in preterm infants at birth 
(β = −1.6, 95% CI [−2.8, −0.3], p = 0.02) and at term-corrected 
age (β = −0.9, 95% CI [−1.5, −0.2], p = 0.02) although this did 
not persist at 1-year corrected age (p = 0.07). Social deprivation 
was also independently associated with a reduction in DNA 
methylation at FKBP5 CpG2 in preterm infants at term-corrected 
age (β = −1.5, 95% CI [−2.9, −0.02], p = 0.047). Finally, maternal 
smoking was independently associated with a marked reduc-
tion in DNA methylation in preterm infants at FKBP5 CpG1 
(β = −2.6, 95% CI [−4.4, −0.7], p = 0.008) and CpG2 (β = −2.1, 
95% CI [−4.1, −0.03], p  =  0.047) at birth, compared to term 
infants. Additionally, maternal smoking was associated with a 
reduction in DNA methylation at birth in both groups at these 
loci (Table 4).
DISCUSSION
Preterm infants demonstrated a growth trajectory comparable to 
that reported in previous studies, such that they were lighter than 
term infants during the first year of life (24, 25). Although pre-
term infants had increased percentage fat mass at term-corrected 
age, there was no persisting difference at 3  months. Previous 
studies have reported increased and/or altered fat distribution 
in preterm infants at term-corrected age (26–28), with some 
reporting that these differences had resolved by 3 months (28). 
Despite this apparent resolution of excess adiposity in early life, 
preterm infants do show abnormalities of body composition in 
young adulthood, with higher adiposity, ectopic lipid deposition, 
and increased intra-abdominal fat (29).
DNA methylation at IGF2DMR2 and FKBP5 intron 7 was 
markedly lower in preterm infants at birth in comparison to 
term-born infants, and this was still the case at term-corrected 
age. Although we did not test the functional consequences of 
these alterations in DNA methylation, reduced IGF2DMR2 DNA 
methylation would be predicted to reduce IGF2 expression with 
potential implications for early growth. Reduced methylation 
of FKBP5 intron 7 CpGs is associated with higher induction 
of FKBP5 by GR activation, leading to increased GR resistance 
(20); however, whether this might play a role in the HPA axis 
dysregulation seen in preterm infants (9) is unclear. Social dep-
rivation was an independent predictor of reduced methylation at 
IGF2DMR2 at birth and term-corrected age. Inter-related factors 
such as smoking that accompany socioeconomic deprivation can 
impact on DNA methylation in adults (30), including at FKBP5 
(31). Recent studies in children and adults exposed to cigarette 
smoke in utero have reported alterations in global and site-specific 
DNA methylation (32–35), and our results showing that maternal 
smoking was independently associated with a marked reduction 
in DNA methylation at FKBP5 at birth suggest that this extends 
to effects on FKBP5.
There were no persistent differences in DNA methylation 
at 1 year of age at the DMRs of IGF2 and at FKBP5. Our data 
support an epigenome-wide association study (EWAS), which 
demonstrated that although there were many differences in 
DNA methylation between preterm and term babies at birth, 
these had largely resolved by 18  years of age. However, DNA 
methylation differences did persist at a subset of CpGs (12). This 
TABLE 4 | DNA methylation at FKBP5 according to maternal smoking status.
Smoking status CpG1 CpG2 CpG3
Mean SEM p-Value Mean SEM p-Value Mean SEM p-Value
Birth (term and preterm infants)
Never 73.6 1.1 59.9 1.2 20.2 1.0
Former stopped pre-pregnancy 66.1 2.4 0.007 56.4 2.7 0.49 21.4 2.3 0.91
Former stopped during pregnancy 68.8 3.0 0.47 57.0 5.3 0.90 20.8 3.4 1.00
Current 57.1 4.7 0.001 42.5 3.9 0.002 16.9 2.3 0.71
Term age (preterm infants)
Never 62.9 1.4 53.1 1.6 20.4 1.0
Former stopped pre-pregnancy 65.9 1.7 0.51 54.1 1.6 0.96 20.6 1.7 1.00
Former stopped during pregnancy 62.2 5.4 1.00 55.1 1.4 0.95 19.2 1.9 0.97
Current 61.6 2.0 0.95 50.6 2.1 0.71 18.1 1.0 0.66
1 year (term and preterm infants)
Never 80.6 0.5 72.6 0.8 37.8 0.8
Former stopped pre-pregnancy 81.4 1.1 0.82 72.1 0.9 0.97 37.2 1.5 0.97
Former stopped during pregnancy 83.6 1.4 0.23 72.5 1.6 1.00 36.4 2.6 0.91
Current 80.5 1.9 1.00 72.5 1.6 1.00 40.0 3.1 0.79
Smoking status is recorded as never (regarded as the control group for one-way ANOVA and Dunnett’s post hoc t testing), former smokers who stopped before pregnancy, former 
smokers who stopped during pregnancy, and current (smokers who continued throughout pregnancy).
TABLE 3 | Correlations between percentage DNA methylation at IGF2DMR2, H19ICR, and FKBP5 with weight SDS and percentage body fat.
IGF2DMR H19ICR FKBP5 CpG1 FKBP5 CpG2 FKBP5 CpG3 Intron average
R p R p R p R p R p R p
% DNA methylation vs. weight SDS
Term infants at birth vs. birthweight SDS 0 0.98 −0.2 0.44 0 0.83 0.2 0.43 −0.2 0.22 0.2 0.37
Preterm infants at birth vs. birthweight SDS 0.7 <0.001 0.2 0.41 0.6 <0.001 0.5 0.01 0.4 0.04 0.4 0.04
Preterm infants at term age vs. weight SDS 0 0.96 0.2 0.37 0.2 0.34 −0.3 0.16 −0.1 0.53 0.1 0.73
Term infants at 1 year vs. weight SDS −0.1 0.72 0.2 0.28 0 0.89 0.4 0.05 0.4 0.06 0.1 0.79
Preterm infants at 1 year corrected vs. weight SDS −0.06 0.75 0.27 0.14 −0.2 0.29 −0.1 0.51 −0.2 0.22 0 0.86
% DNA methylation vs. % body fat
Term infants at birth vs. % fat 0 0.94 −0.2 0.29 0 0.9 0 0.98 −0.2 0.4 0.2 0.27
Preterm infants at term age vs. % fat −0.2 0.51 −0.2 0.62 0.3 0.17 0.2 0.47 0.2 0.48 −0.1 0.81
TABLE 2 | DNA methylation at FKBP5 in preterm and term infants.
A CpG1 CpG2 CpG3
β p β p β p
Preterm infants at birth vs. term infants at birth  −12.1 [−15.6, −8.8] <0.001 −12.9 [−16.9, −9.0] <0.001 −5.2 [−9.3, −1.2] 0.01
Preterm infants at term-corrected age vs. term infants at birth −11.7 [−14.6, −8.7] <0.001 −7 [−11.5, −2.5] 0.003 −3 [−5.3, −0.7] 0.01
Preterm infants at 1-year corrected vs. term infants at 1 year −1.9 [−4.0, 0.2] 0.07 −2 [−4.4, 0.4] 0.1 3.1 [0.8, 6.0] 0.05
β values represent unstandardized regression coefficients adjusting for male gender, maternal smoking, social deprivation score, and risk-allele carriage. Values in square brackets 
represent 95% confidence intervals.
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EWAS did not identify changes at IGF2 or FKBP5, which may 
reflect that it was small (n = 12 per group) and studied DNA 
methylation changes in blood spots, rather than buccal DNA. 
Our findings are also in agreement with longitudinal EWASs, 
which show that DNA methylation undergoes developmental 
changes during childhood (36). Notably, for FKBP5, DNA 
methylation increased between birth and 1  year in both term 
and preterm infants, and DNA methylation at CpG3 was still 
significantly lower at 1  year of age in comparison to levels 
described in adulthood (20), suggesting that there are ongoing 
changes in DNA methylation at this locus through childhood. 
Since studies clearly show that DNA methylation changes 
through infancy and childhood, it may be that the lower levels of 
DNA methylation in preterm infants at birth is a normal finding 
for infants at this gestation. For obvious reasons, we are unable 
to compare DNA methylation in saliva in infants of comparable 
gestation, who remained in utero. There were some persistent 
differences between term infants and preterm infants at term-
corrected age, and we suggest that this may reflect differences 
between the intrauterine maturation in term-born infants and 
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factors acting during the extra-uterine period to which preterm 
infants are exposed.
Alternative/additional explanations for the differences in 
DNA methylation between preterm and term infants in very 
early life could include the altered nutritional state of infants 
born preterm (37, 38); and/or glucocorticoid overexposure, 
since preterm infants experience both in utero exposure to syn-
thetic glucocorticoids and significant early postnatal “stress.” 
In vivo and in  vitro studies have shown that glucocorticoid 
exposure leads to stable DNA demethylation at these specific 
sites within the FKBP5 locus (20, 39), and several studies have 
now shown that exposure to trauma during childhood associ-
ates with allele-specific demethylation at FKBP5 in adulthood 
(20, 40). Although childhood abuse impacts on DNA methyla-
tion in carriers of the risk allele (20), we found no additional 
effects of the presence or absence of the risk allele. This is 
in agreement with a lack of effect of the risk allele on DNA 
methylation patterns following severe parental trauma (40), 
supporting the concept that these effects are specific to the 
timing of exposure (20), and it may be that the stresses around 
preterm birth occur outside this “vulnerable” period. Finally, 
it is also possible that differences in cell subtype populations in 
the saliva from preterm and term infants may impact on DNA 
methylation (41).
In summary, we found changes in DNA methylation at key 
regions of IGF2/H19 and FKBP5 in this cohort of preterm 
infants who did not achieve the reference for either growth 
or body composition by the time they reached 1 year of age. 
Further, we identified a number of contributing factors includ-
ing maternal smoking and social deprivation. We found no per-
sisting differences at 1 year of age. Whether further differences 
will emerge over longer follow-up is unknown; alterations in 
DNA methylation at key DMRs controlling the expression of 
IGF2 have been reported in adults exposed to altered nutrition 
or prematurity (16, 17, 42); however, these were not longitudi-
nal studies, so that any differences may have arisen postnatally. 
Additionally, these studies may have been complicated by the 
phenomenon of reverse causation, where the development 
of disease leads to changes in DNA methylation rather than 
vice  versa (41). Further longitudinal studies are required to 
understand any potential long-term effects of early differences 
in DNA methylation in the perinatal period on the health of 
individuals born preterm.
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Identification of dynamic glucocorticoid-
induced methylation changes at the FKBP5
locus
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Abstract
Background: Epigenetic mechanisms may play a major role in the biological embedding of early-life stress (ELS).
One proposed mechanism is that glucocorticoid (GC) release following ELS exposure induces long-lasting
alterations in DNA methylation (DNAm) of important regulatory genes of the stress response. Here, we investigate
the dynamics of GC-dependent methylation changes in key regulatory regions of the FKBP5 locus in which ELS-
associated DNAm changes have been reported.
Results: We repeatedly measured DNAm in human peripheral blood samples from 2 independent cohorts exposed
to the GC agonist dexamethasone (DEX) using a targeted bisulfite sequencing approach, complemented by data
from Illumina 450K arrays. We detected differentially methylated CpGs in enhancers co-localizing with GC receptor
binding sites after acute DEX treatment (1 h, 3 h, 6 h), which returned to baseline levels within 23 h. These changes
withstood correction for immune cell count differences. While we observed main effects of sex, age, body mass
index, smoking, and depression symptoms on FKBP5 methylation levels, only the functional FKBP5 SNP (rs1360780)
moderated the dynamic changes following DEX. This genotype effect was observed in both cohorts and included
sites previously shown to be associated with ELS.
Conclusion: Our study highlights that DNAm levels within regulatory regions of the FKBP5 locus show dynamic
changes following a GC challenge and suggest that factors influencing the dynamics of this regulation may
contribute to the previously reported alterations in DNAm associated with current and past ELS exposure.
Keywords: DNA methylation, FKBP5, Glucocorticoid receptor, Early-life stress, Targeted bisulfite sequencing,
Dexamethasone
Background
Epidemiological studies indicate a combined contribu-
tion of genetic and environmental factors in the risk for
psychiatric diseases, which converge to alter gene regula-
tion and consequently cell function [1]. Evidence sug-
gests that epigenetic mechanisms play a major role in
embedding environmental risk, including early-life ad-
versity, but our understanding of the underlying mecha-
nisms is limited. Epigenetic mechanisms encompass
post-translational modifications of histone proteins and
chemical modifications of single nucleotides (most com-
monly in the form of methylation at cytosine guanine di-
nucleotides (CpGs)), which alter chromatin structure, and
thus accessibility of the DNA to transcriptional regulators.
Even DNA methylation (DNAm), a stable chemical
modification, undergoes highly dynamic regulation in
post-mitotic cells. This property makes DNAm a suitable
molecular mechanism to encode the impact of environ-
mental cues in post-mitotic tissue [2, 3]. A mechanism
that likely contributes to such dynamic, environmentally
triggered DNAm changes is transcription factor-mediated
DNA demethylation [4]. One example is local demethyla-
tion of glucocorticoid response elements (GREs) following
activation of the glucocorticoid receptor (GR), a nuclear
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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transcription factor [5]. The GR is activated by the gluco-
corticoid (GC) cortisol, a major mediator of the stress
response.
Stress, especially in the form of early adverse life
trauma, is a major environmental risk factor for psychi-
atric disorders [1, 6, 7]. Excessive GC release after stress
exposure may induce long-lasting DNAm changes,
thereby contributing to the biological embedding of risk
trajectories. The mechanism of GR-induced local de-
methylation is not fully understood, but activation of
DNA repair machinery is implicated. Demethylation of
GREs facilitates the transcriptional effects of the GR on
the target gene [8, 9].
FKBP5 is a stress-responsive gene and co-chaperone
protein of GR. Increased activation of this gene by gen-
etic or epigenetic factors has been repeatedly associated
with increased stress-sensitivity and risk for psychiatric
disorders in both animal and human studies (see [10, 11]
for review). We have previously reported on GR-sensi-
tive CpGs in GREs of the FKBP5 locus. These are lo-
cated in a functional GRE in intron 7 of the gene.
Chromatin conformation capture experiments confirmed
an interaction of this intronic enhancer with the tran-
scription start site (TSS) of FKBP5. Reporter gene assays
also demonstrated that higher DNAm of this enhancer
region was associated with lower transcriptional activa-
tion of FKBP5 by GCs [12]. Relative reduction of DNAm
in this region has been reported both in peripheral blood
and buccal cells of adults as well as children exposed to
childhood trauma and in a hippocampal neuronal pro-
genitor cell (HPC) line following exposure to GCs [12–
16]. Changes in DNAm following exposure to child
abuse seemed to be accentuated in individuals carrying
the minor allele of a functional genetic variant in this
locus (rs1360780). This variant, located in close proxim-
ity to a GRE in intron 2, alters the 3D conformation of
the locus. The minor allele generates a TATA-box bind-
ing site which allows binding of this intron enhancer to
the transcription start site. This is also associated with
higher FKBP5 induction following GR activation. We
and others have shown that increased FKBP5 leads to re-
duced GR sensitivity and impaired negative feedback
regulation of the stress hormone axis [17, 18]. In fact,
minor allele carriers have repeatedly been shown to have
prolonged cortisol release following stress exposure [11].
Finally, this functional allele has consistently been shown
to increase risk for a range of psychiatric disorders with
exposure to early adversity [11, 19–21], suggesting that
gene x environment interactions at the level of epigen-
etic regulation may contribute to disease risk.
These studies suggest that the CpGs associated with
early trauma exposure may also be responsive to GCs
and that increased GR activation with trauma may lead
to DNAm changes of the sites. However, direct evidence
for this is so far missing. Furthermore, due to the limita-
tion of the previously used pyrosequencing-based
DNAm assessment of these enhancers, only a small
number of CpGs had been investigated. Transcriptional
regulatory sites of FKBP5 are distributed throughout the
locus and include several upstream, downstream, and in-
tronic enhancer regions with GREs [22] as well as
CCCTC-binding factor (CTCF) sites in addition to the
TSS. CTCF creates boundaries between topologically as-
sociating domains (TADs) in chromosomes, and within
these domains, CTCF facilitates interactions between
transcription regulatory sequences [23, 24]. The extent
of GR-associated DNAm changes in different categories
of regulatory elements within the FKBP5 locus has not
yet been explored.
Here, we investigate the changes of DNAm following
exposure to the selective GR agonist dexamethasone
(DEX) in peripheral blood cells over 24 h and in relation
to rs1360780 genotype, in two independent cohorts.
DNAm levels were assessed using a high-accuracy
methylation measurements via targeted bisulfite sequen-
cing (HAM-TBS) approach [25], which extensively
covers CpG sites located in the different categories of
regulatory elements in the FKBP5 locus. The changes
are also compared to data generated by the widely used
Illumina methylation arrays.
Results
DEX-induced dynamic changes at the FKBP5 locus in
human peripheral blood (study 1)
In order to test if GR activation is associated with
changes in DNAm in vivo, we first analyzed serial blood
samples from 19 subjects exposed to a single oral dose
(1.5 mg) of DEX (see Table 1 for demographic details).
DEX-induced changes in ACTH, cortisol, and FKBP5 mRNA
levels
Analysis of serum adrenocorticotropin (ACTH) and cor-
tisol levels showed the expected suppression following
Table 1 Description of study 1 and 2 subjects
Study 1 Study 2
Samples 19 89
Male 19 67
Female 0 22
rs1360780 genotype CC = 6; CT = 6; TT = 7 CC = 50; CT = 30; TT = 9
Time points of blood draw
after DEX
0 h, 1 h, 3 h, 6 h, 23 h 0 h, 3 h, 18–24 h
Age (mean ± SD) 25.4 ± 2.9 41.6 ± 14.0
BMI (mean ± SD) N/A 25.1 ± 3.8
Smoking score (mean ± SD) N/A − 0.6 ± 4.9
Major depressive disorder 0 59 (M = 38; F = 21)
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DEX administration with maximal effects observed at 3
and 6 h post-treatment. In addition, DEX induced a 4.2-
and 4.0-fold increase in FKBP5 mRNA levels after 3 and
6 h of treatment, respectively, and returned to baseline
level after 23 h (Fig. 1a).
DEX-induced transient DNAm changes—dynamics
DNAm was analyzed using our HAM-TBS technique
[25], where a total of 25 amplicons covering 228 CpGs
at 5 time points from baseline (0 h) to 1, 3, 6, and 23 h
following DEX administration passed QC. Three ampli-
cons located in the proximal enhancer did not pass QC
due to increased CHH methylation levels (PCR18) or
low coverage (PCR 28 and PCR29; < 1000 reads, Add-
itional file 6: Table S1). DNAm analysis across the loci at
baseline revealed low methylation at the TSS and higher
methylation within the gene body and 3′ and 5′ flanking
regions (Fig. 1b “% Methylation baseline” track).
Following an acute dose of DEX, 44 CpG sites showed
significant changes in DNAm over all time points
(FDR ≤ 0.05 and absolute delta methylation (Ti-base-
line) ≥ |1%|; Fig. 1b “Max. ∆ % methylation” track,
shaded regions; Additional file 7: Table S2). Significant
DEX-induced differential DNAm was seen as early as 1
h after treatment (n = 17 sites, mean absolute ∆ methyla-
tion = |2.4%|), and the largest effects were observed after
3 and 6 h (n = 40 sites, mean absolute ∆ methylation
= |4.4%| and |5.4%|, respectively) with a range from − 17
to + 0%. Seventy-four percent of the sites, however,
showed decreases in DNAm levels following DEX treat-
ment ranging from − 17 to − 1% compared to baseline.
For the majority of the sites, DNAm levels returned to
baseline after 23 h of treatment while only 8 sites
remained differentially methylated at FDR < 0.05 with a
small change compared to baseline (mean absolute ∆
methylation = |1.8%|).
DEX-induced transient DNAm changes—localization
DEX-induced differentially methylated CpG sites
(DMCs) were found in the proximal and intronic en-
hancers and co-localized with ENCODE GR binding
sites and those located at the chromatin interaction
blocks overlapped with ENCODE CTCF binding sites
(examples are shown in Fig. 1c). Within the 82 CpGs an-
alyzed surrounding the TSS, no DMCs were observed.
Out of the 129 CpGs located in GR binding sites, 36
(28%) showed DEX-induced changes whereas only 8
(10%) out of 83 sites located in CTCF binding sites
showed changes after DEX. Most of the DMCs located
in GR binding sites (n = 30) showed reduction of DNAm
following DEX (mean ∆ methylation − 3.8 ± 3.3%) with
the exception of 6 sites located in the proximal enhancer
(n = 4), intron 5 (n = 1) and intron 2 (n = 1) showing in-
creased DNAm (mean ∆ methylation + 2.9 ± 1.3%).
DMCs within CTCF binding sites located in TAD
boundaries and intron 3 showed increase in DNAm (n =
5 sites, mean ∆ methylation + 3.6 ± 3.3%) whereas those
located in the proximal enhancer showed decrease in
DNAm (n = 3 sites; mean ∆ methylation − 3.0 ± 1.1%).
Demethylated CpGs in the proximal enhancer overlap
with both GR and CTCF binding sites (see Fig. 1c).
To assess whether changes in DNAm might directly
affect binding of GR and CTCF to DNA, we mapped the
changes to their relative distance to GR and CTCF con-
sensus binding motifs. DNAm of CpG sites within these
motifs has previously shown to impair or decrease tran-
scription factor binding [27, 28]. We used predicted
DNA binding motif locations for GR and CTCF from
[29] (http://compbio.mit.edu/encode-motifs/). Selecting
CpGs within ± 50 bp of the consensus motif sequences
(n = 16 for GR and n = 9 for CTCF), we observed that
CpG sites directly in CTCF motifs consistently displayed
very low DNAm levels (0.57 ± 0.10%) whereas those in
NR3C1 motifs showed intermediate levels at baseline
with a high variation (39.98 ± 18.43%; Fig. 2a). For CTCF
motif regions, higher DNAm was observed at more dis-
tal sites at the edges of the motif. DEX-induced DMCs
were found directly in GR motifs (n = 4) whereas none
were observed within CTCF motif but at the edges of
this motif (n = 2, Fig. 2b).
Increases in FKBP5 mRNA levels occurred in parallel
with the decrease of DNAm for 10 DMCs located within
50 bp of GR binding motifs (Fig. 2c and Additional file 6:
Table S1).
Validation of DEX-induced DNAm changes in blood in an
independent sample (n = 89, study 2)
Using study 2, see Table 1 for demographic details, we
replicated the findings in an independent sample. Similar
to study 1 and has been reported previously [30], DEX
treatment induced a significant decrease in CORT and
ACTH levels as well as an increase in FKBP5 mRNA
levels (Fig. 3a).
Ten amplicons covering 50 CpG sites (including 25
with significant DEX effect in study 1) were selected. Of
these 50 sites, 21 showed significant changes (FDR ≤
0.05 and absolute ∆ methylation ≥ |1%|) in DNAm after
DEX treatment validating 19 sites from the first study
(Fig. 3b). Similar to the effects observed in the first
study, DNAm changes were seen after 3 h of treatment
(mean absolute ∆ methylation = |4.3%|), and for most
sites (n = 13), DNAm returned to baseline after 24 h.
Eight DMCs remained significant after 24 h of treatment
but showed a much smaller effect (mean absolute ∆
methylation = |1.8%|). As observed before, the majority
of sites (76%) show decrease in DNAm levels following
DEX treatment with a range from − 10 to − 1% com-
pared to baseline.
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Fig. 1 Dexamethasone (DEX)-induced transient changes in hormonal, FKBP5 mRNA and methylation levels in blood. a Serum adrenocorticotropin
(ACTH) and cortisol (CORT) levels as well as whole blood FKBP5 mRNA levels after an oral dose of DEX in 19 healthy male subjects are shown.
Peripheral blood was drawn just before administration of DEX (time = 0) as well as 1, 3, 6, and 23 h thereafter. The mean and SEM are presented for
each time point. Linear mixed models showed a significant effect across time for ACTH (p value = 1.26e−23), CORT (p value = 1.18e−24), and FKBP5
mRNA (p value < 2.2e−16) levels. p values of linear mixed models for each time point are indicated as follows: *≤ 0.05, **≤ 0.01, ***≤ 0.001. b Genome
browser shot illustrating FKBP5 regulatory elements and DEX-induced methylation changes across the locus (hg19/chr6:35487554-35718452). Genes,
genes located within the locus; CTCF-ChIA-PET, locations of CTCF factor-mediated chromatin interactions determined by Chromatin Interaction
Analysis with Paired-End Tag (ChIA-PET) data extracted from lymphoblastoid cell line (GM12878, [26]). Chromatin interactions are represented by PET
blocks connected with an horizontal line. CTCF-ChIP-seq and GR-Chip-seq, regions of transcription factor binding derived from chromatin
immunoprecipitation (ChIP) experiments in multiple cell lines from the ENCODE project; TBS amplicons, locations of targeted bisulfite sequencing (TBS)
amplicons; % methylation baseline, methylation levels across TBS amplicons at baseline; Max. ∆ % methylation, maximum methylation difference
(delta) between any time points after DEX treatment and baseline for each TBS amplicons. Color-shaded regions highlight the main regulatory
elements in the locus. c Example of CpG sites showing DEX-induced methylation changes. Boxplots represent the methylation levels per time point of
CpGs located in the intronic enhancers (top), proximal enhancer (bottom left), and topologically associating domain (TAD) boundaries (bottom right).
Methylations of individual CpG sites are shown except for the proximal enhancer plots where the mean methylation per amplicon is shown since this
region covers 94 CpG sites. X axes indicate the coordinate of each site or region represented. Shaded boxes indicate sites where significant DEX effects
were observed at FDR≤ 0.05 and absolute delta methylation (Ti-baseline)≥ 1% in at least one time point
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Inter-individual variability influencing DEX-induced
methylation changes
Changes in DNA methylation in peripheral blood may re-
flect changes in immune cell composition. In study 2, we
had data on blood cell counts (BCCs) as well as estimated
immunes cell types from the Illumina 450K array data.
BCCs changed over time followingDEX (see Additional file 1:
Figure S1A) and lymphocyte counts significantly correlated
with 9 DMCs (Additional file 8: Table S3). However, when
we corrected for lymphocyte counts in the models testing
DEX effects on DNAm across time, all 9 sites remained sig-
nificant (FDR ≤ 0.05, Additional file 8: Table S3). Since both
DNAm and lymphocytes change over time with DEX, we
next assessed how much of the variance in DNAm may still
be explained by differences in BCCs. Comparing the stan-
dardized coefficients of lymphocyte counts change to the
time changes in DNAm in a linear mixed model (LMM), we
observed a significantly larger absolute coefficient at the 3-h
time point (> 2.8 times larger) for all the associated sites for
the changes in DNAm vs. the changes in lymphocytes
(Additional file 8: Table S3 and Additional file 1: Figure S1B
showing the residuals of the null model correcting for
lymphocyte count). Using estimated cell types from the Illu-
mina 450K array data, we did not observe any effects of
DEX on differential cell proportions (see Additional file 1:
Figure S1C). Together, these analyses suggest that change in
immune cell counts with DEX are likely not a major con-
founder of our results. In addition to immune cell counts,
we also assessed the effects of other possible confounders
including sex, age, ethnicity, body mass index (BMI), smok-
ing, and depression symptoms. We observed significant
main effects of age (7 sites), sex (5 sites), smoking (6 sites),
BMI (8 sites), and major depressive disorder (MDD) (4 sites)
on methylation but no significant interactions with DEX
(Additional file 6: Table S1 and see Additional file 2: Figure
S2A–C for examples). For MDD associations with DNAm,
only men were included in the analysis (n = 67). We have
previously reported no change at baseline for FKBP5 mRNA
levels between MDD patients and controls in a sub-sample
of men from study 2 (29 cases and 31 controls, [30]). For
the larger sample used here to test associations with MDD
status in men (38 cases and 29 controls), there is also no
A
B
C
Fig. 2 Dexamethasone (DEX)-induced DNA methylation changes (DMCs) within glucocorticoid receptor (GR) and CTCF consensus binding motifs. a
Blood methylation levels at baseline across CpGs located within ± 50 bp of GR (left) and CTCF (right) consensus binding motifs. Line plots represent
mean and SEM for each CpGs within the region. b Histogram representing counts of CpGs located within 50 bp of motifs (n = 16 for GR (left) and n =
9 for CTCF (right)) where DEX-induced DMC counts are shown in black. c Fold change FKBP5 mRNA expression and ∆ methylation (%) in DMCs
located within motifs are shown. The left panel illustrates average ∆ methylation (%) of all DMCs located within GR motifs (n = 4) where each of them
is significant after 3 h and 6 h of DEX treatment. The right panel shows ∆ methylation (%) for the 2 DMCs located within CTCF motifs where 1 shows
DEX effect after 3 h and 6 h (located at + 24 bp) and the other one only after 23 h (located at + 34 bp). Plots represent mean and SEM
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difference in FKBP5 mRNA at baseline (p value > 0.05 and
fold change ≥ 1.15). In contrast to the mRNA levels, out
of the four FKBP5 CpG sites associated with MDD over
the three time points, three sites show a difference at
baseline (p value ≤ 0.05 and absolute delta methylation
(cases-controls) ≥ |1%|) with less DNAm observed in cases
(range from − 1.4 to − 2.2%, Additional file 6: Table S1).
Furthermore, we performed stepwise regression analyses
using the Akaike Information Criterion (AIC) to select the
main covariates influencing DNA methylation changes
after DEX. This analysis was performed for the 17 CpG
sites for which significant associations with DNA methyla-
tion were observed. Based on the AICs as well as the esti-
mates of DNA methylation change after 3 h, correcting
for smoking score gave the best models for all CpG sites
(AIC smaller and largest variance explained). Sixteen out
of seventeen sites remained significant (FDR < 0.05) after
correcting for smoking (Additional file 10: Table S5). Add-
ing the other covariates did not affect the significance of
these 16 sites but increased AIC for most of them.
Effects of FKBP5 genotype
We and others have previously described allele-specific
DNAm changes (lower methylation) in intron 7 of the
FKBP5 gene in peripheral blood cells associated with ex-
posure to child abuse only in carriers of the minor/risk T
allele of rs1360780 [11]. Therefore, we investigated
whether rs1360780 genotype (CC compared to CT/TT =
high mRNA induction and disease risk) had an effect on
the observed significant DEX-associated methylation
changes in both studies. Genotype effect on DEX-induced
methylation changes over time was tested using a model
testing both additive as well as interactive effects. In the
first study, we observed 17 CpGs showing significant
interaction (n = 13) or additive effects (n = 6) on DNAm
changes over time (Additional file 6: Table S1). Despite
the different timelines, 2 CpGs showed significant
genotype-dependent dynamic differences in both studies,
cg35558710 located in intron 7 GRE and cg35570224 lo-
cated in intron 5 next to the GRE (see Additional file 3:
Figure S3). We next tested whether the direction of effects
in the two different genotype conformations (CC vs CT/
TT) was the same in study 1 and 2. When investigating all
50 CpGs common to both studies, 27 showed the same
direction of effect for genotype x DEX at time point 3 h in
study 2 as compared to the effect observed overall time
points in study 1, which is more than expected by chance.
This was not the case for effects of genotype on DNAm
A
B
Fig. 3 Dexamethasone (DEX)-induced transient changes in hormonal, FKBP5 mRNA and methylation levels in an independent study. a Serum
adrenocorticotropin (ACTH) and cortisol (CORT) levels as well as whole blood FKBP5 mRNA levels after an oral dose of DEX in 89 subjects are
shown. Peripheral blood was drawn just before administration of DEX (time = 0) as well as 3 and 20–24 h thereafter. The mean and SEM are
presented for each time point. As observed in study 1, significant effect across time for ACTH (p value < 2.2e−16) and CORT (p value < 2.2e−16)
levels as well as FKBP5 mRNA levels at 3 h (p value < 2.2e−16) are observed. b Boxplots of CpG methylation levels for amplicons located in the
intronic enhancers (top), proximal enhancer (bottom left), and topologically associating domain (TAD) boundaries (bottom right) showing
replication of DEX-induced methylation changes. X axes indicate the coordinate of each site or region represented. Shaded boxes indicate sites
where significant DEX effects were observed at FDR≤ 0.05 and absolute delta methylation (Ti-baseline)≥ 1% in at least one time point
Wiechmann et al. Clinical Epigenetics           (2019) 11:83 Page 6 of 14
differences at the time point 24 h in study 2. We then sub-
divided this analysis by regulatory regions. For CpGs
within intronic and proximal enhancer GREs (n = 30), we
observed a concordance of the direction of effects for geno-
type x time interaction between the two studies significantly
more than expected chance (p = 0.049), but this was not
the case for the 20 CpGs annotated to TADs. Overall, T
carriers displayed more methylation changes over time,
with differences to CC genotype carriers ranging from 5.01
to 0.01%. This analysis supports that FKBP5 rs1360780 ge-
notypes associate with a differential DNAm sensitivity to
GR activation within GREs but not in TADs.
Usefulness of Illumina methylation array for assessing DEX-
induced DNA methylation changes in FKBP5
Most studies investigating DNA methylation in periph-
eral blood in large cohorts use Illumina methylation ar-
rays. Overlapping Illumina 450K methylation data were
available at baseline and 3 h post-DEX administration in
study 2 (n = 106 subjects, [30]) allowing to assess the ex-
tent of coverage of DEX-reactive CpGs on these arrays.
The 450K array covers 56 CpGs in the FKBP5 locus
(hg19/chr6:35487554-35718452, see Additional file 4:
Figure S4 and Additional file 6: Table S1 for further de-
tails) which are located mainly around the TSS (n = 12)
and the proximal enhancer (n = 15) with 12 CpGs in
TAD boundaries and only sparse coverage within the
gene body (11 CpGs) and 3′ end (6 CpGs). None of the
intronic GREs showing the biggest change in response
to DEX are covered by the array. Analysis of 450K CpG
sites that passed QC (52 sites) identified 13 DMCs fol-
lowing DEX (FDR ≤ 0.05 and absolute ∆ methylation ≥
|1%|) identifying 9 additional DMCs not covered by
HAM-TBS. Overlapping sites between TBS and 450K
displayed high correlation in both datasets (17 CpGs
with 0.96 mean correlation) where similar DNAm
changes following DEX were observed (Additional file 4:
Figure S4).
DEX-reactive sites reside in enhancer regions with cross-
tissue relevance
To understand whether the observed changes could have
cross-tissue relevance, as initially shown for the GRE in
intron 7 [12], we compared the chromatin state segmenta-
tions from the Roadmap Consortium (http://www.road-
mapepigenomics.org/) for blood/immune cells (n = 29
tissues), brain cells (n = 10), and fibroblasts (n = 5 tissues)
(Additional file 5: Figure S5A) for the investigated regions
within the FKBP5 locus. Common active TSS marks at the
TSS and marks indicating active transcription over the
gene body support the well-documented active transcrip-
tion of FKBP5 across these tissues. Focusing on the re-
gions in FKBP5 that showed the most prominent effects
of DEX on DNAm (GRE in intron 7, intron 5, and the
proximal enhancer), we observe that most of these regula-
tory elements show similar chromatin states, suggesting
the comparable regulatory impact of these regions across
these tissues (see Additional file 5: Figure S5B).
Discussion
Here, we investigated DNAm changes in response to GR
activation in the FKBP5 locus, a gene in which DNAm
changes have been shown in association with exposure to
childhood trauma in both children and adults [12, 14–16].
We here show that FKBP5 DNAm in specific enhancers is
highly responsive to GR activation by DEX. We observe
dynamic methylation changes over time in longitudinal
samples from two independent human studies. Significant
effects of DEX exposure were detected as early as 1 h fol-
lowing oral ingestion of DEX, with maximal effects 3–6 h
later. Most changes returned to baseline within 23 h.
These effects remained significant when correcting for im-
mune cell types as well as additional covariates such as
age, sex, BMI, and depression status.
The sites dynamically responsive to an acute DEX
challenge in blood overlap with sites correlating with
30-day cortisol load in healthy subjects [31] as well as
CpGs differentially methylated in Cushing’s syndrome
patients, a disorder characterized by excess secretion of
cortisol. This has been shown for CpGs within intronic
GREs, especially the intron 2 and 7 GREs, for which dif-
ferences were observed not only between patients with
active Cushing’s syndrome and controls but also in pa-
tients with cured Cushing’s syndrome [32]. A second
study using 450K data reported cg25114611, located in a
GRE of the proximal enhancer, to show significantly
lower methylation in patients with long-term remission
of Cushing’s syndrome [33]. In our study, this site
showed lower methylation following DEX in blood that
remained significant after 23 h. Such overlap suggests
that GR activation may—under specific circumstances—
result in lasting DNAm marks. In the above studies, pa-
tients had been in remission for 7–13 years [32, 33].
Such factors contributing to more lasting changes could
be the level and duration of GR activation as well as de-
velopmental timing. We have previously reported that
lasting changes in DNAm following DEX treatment in
hippocampal progenitor cells were observed when cells
were treated during proliferation and differentiation but
not when they were treated post-differentiation [12].
The DEX-responsive sites also overlap with those re-
ported to be demethylated in both children and adults
exposed to early trauma [11]. Although these sites do
not show durable demethylation after 23 h, the overlap
suggests that these adversity-related epigenetic changes
in FKBP5 GREs could be mediated via GR-dependent ef-
fects through prolonged exposure to GCs, as observed
in children exposed to trauma [13].
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Our results give new insight into the previously described
allele-specific methylation changes of intron 7 GRE CpGs
that may contribute to the FKBP5 x early trauma associa-
tions with risk for a number of psychiatric disorders ([10],
for review). Several studies report that lower methylation of
FKBP5 GRE intron 7 is more pronounced in child
abuse-exposed individuals carrying haplotypes tagged by
the T allele of rs1360780 [12, 15, 34]. This functional allele
has been associated with increased transcriptional activa-
tion of FKBP5 by GR [12, 35]. Here, we show that healthy
individuals carrying this allele have a different dynamic of
DNAm changes following GR activation in GREs of FKBP5.
Such a difference in epigenetic dynamics may also contrib-
ute to the fact that environmental risk factors linked to
stress hormone activation, such as early adversity, could
have more lasting effects in individuals carrying this specific
allele. Such allele-specific differences in the dynamics of
DNAm change may relate to the reported allele-specific dif-
ferences in gene transcription. As illustrated in Fig. 2c, dy-
namic DNAm changes in FKBP5 GREs inversely correlate
with changes in RNA expression.
As expected from the literature, methylation levels of
CTCF binding sites at the FKBP5 locus were low (0.57 ±
0.10%). In general, it has been shown that CTCF occu-
pancy is inversely correlated with DNA methylation and
that DNA methylation at CpGs located directly in the
core binding motif can inhibit CTCF binding [27, 36–
40]. A gain of methylation directly at CTCF binding sites
can lead to loss of CTCF binding and therefore disrup-
tion of chromatin interactions which can lead to a dys-
regulated gene expression [37]. DEX-induced DMCs
were not found directly at the core motif of the CTCF
binding sites but at close distance and show small
changes (< |2%|, Fig. 2B). The upstream and downstream
flanking regions around the CTCF core motif have been
implicated in influencing CTCF binding stability [41].
However, how such a small change in DNA methylation
at these flanking regions influences CTCF occupancy
has not yet been experimentally addressed so that their
exact role remains unknown. Overall, our data suggests
that the DEX-induced methylation effects concentrate
on GR and not CTCF binding sites. These changes in
DNA methylation may thus alter enhancer function (as
shown in reporter gene assays [12]) but will not likely
result in more profound 3D chromatin changes, such as
loop disruptions.
In addition to genetically induced altered dynamics of
DEX responsivity, other factors may also contribute to
long-term effects on FKBP5 methylation in the context of
early adversity. Factors associated with child abuse such as
smoking, BMI, and depression all had main effects on
FKBP5 methylation, including in dynamically responsive
sites (see Additional file 6: Table S1 and Additional file 2:
Figure S2). In addition, age also had a main effect on some
CpGs. The limited age range of our cohorts, however, pro-
hibits to analyze the influence of age, including childhood
and adolescence, in more depth. Whether such differences
in baseline methylation contribute to the long-term effect
of early adversity on FKBP5 methylation needs to be in-
vestigated in more detail in longitudinal cohorts. A limita-
tion of this study is the lack of information on early or
more recent adversity. Future studies will need to address
the influence of these environmental factors on
GR-induced DNA methylation dynamics.
Overall, the effects of DEX on FKBP5 methylation
were mostly in the direction of lower methylation fol-
lowing GR activation. In fact, the observation that DEX
can induce DNA methylation changes is not unique to
the FKBP5 locus and has been observed at different gen-
omic loci [42]. Several mechanisms could contribute to
differences in DNAm. One is a change in cell type com-
position, favoring cell types with no methylation at these
sites within mixed tissues. While this is a possible ex-
planation for the changes observed, the fact that these
effects withstand correction for changes in cell compos-
ition over time (see Additional file 1: Figure S1B and
Additional file 8: Table S3) and that DEX has no signifi-
cant effect on specific immune cell types estimated from
the genome-wide DNAm data suggests that at least
some of these effects likely happen within specific cells.
Re-assessing our results in sorted cells would give more
information into which cell types or cell characteristics
are associated with the highest epigenetic reactivity in
humans. A study in mice, using genome-wide bisulfite
sequencing after cell sorting, observed GC-induced
methylation changes primarily in blood T cells [43]. On
the other hand, mapping of enhancers across many tis-
sues, including different immune cells (see Additional file 5:
Figure S5), suggests that most of the GR-responsive en-
hancers exert a shared function and may thus show simi-
lar epigenetic responses to GR activation across different
cell types and tissues.
A reduction in DNA methylation following GR activa-
tion could also be mediated via a transcription factor
binding-mediated DNA demethylation which has been
reported for GR binding to GREs [5]. The mechanisms
for this targeted DNA demethylation are not fully under-
stood, but mechanisms involving DNA repair have been
proposed [9]. Similar to the GR-induced transient
changes observed here in blood, rapid cyclical pattern of
DNAm in response to estrogen stimulation in breast
cancer cells has been reported. The ERα-responsive gene
pS2 undergoes rapid demethylation and remethylation
cycles following activation of transcription with estrogen
[44]. The authors [44] implicated a coordinated binding
of DNA methyltransferases, glycosylase, and base exci-
sion repair proteins in these processes. The process of
demethylation of the pS2 promoter investigated in the
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above paper is thought to involve Dnmt3a/b that is able
to deaminate 5mC. The resulting abasic site (AP site) of
this deamination is subsequently repaired by recruiting
p68, TDG, and BER proteins (AP endonuclease, DNA
polymerase β, and DNA ligase I). The rapid GR-induced
demethylation followed by remethylation within 23 h ob-
served here in blood cells may occur via similar mecha-
nisms given the reported kinetics of this enzymatic
process. In addition, when aggregating data from our
study for all GREs and mapping DNAm changes to the
distance from the consensus GR binding site, we observe
high levels of methylation within the consensus binding
site and these central CpGs are also the ones with dy-
namic reduction following GR activation (see Fig. 2a).
These observations would support GRE-centric active
DNA demethylation. The mechanisms that would then
associate with the more lasting changes in remitted
Cushing’s patients and in individuals exposed to child-
hood trauma could relate to different actions of
DNA-methyl binding proteins such as MeCP2 and poly-
comb complexes that would interfere with DNA-driven
demethylation/remethylation [45].
Conclusions
Taken together, these data provide novel insight into pos-
sible mechanisms of stress and trauma-related changes in
DNAm and gene x stress interactions, suggesting a role of
GR-dependent methylation changes at least for a subset of
the effects. These effects are best investigated using targeted
approaches, such as HAM-TBS [25], as most of the reactive
enhancer CpGs are not covered on the current Illumina ar-
rays. The observed dynamics of these changes in peripheral
blood have consequences on epigenetic association studies
in humans, where controlling for cortisol plasma levels ap-
pears to be an important factor. Given that dynamic changes
in DNAm that can be induced by a single dose of DEX and
given their overlapping sites correlating with 30-day cortisol
load as well as with lasting changes observed in patients
with Cushing’s syndrome, critical questions arise for the
long-term epigenetic consequences of the therapeutic use of
GCs. Additional research in larger samples, with different
exposure lengths and intensity, different tissues, and differ-
ent developmental stages, will be necessary to better under-
stand this phenomenon on a genome-wide and organism-
wide level. Cataloging the moderation of these GR-induced
epigenetic effects by common gene variants may further
help in identifying genes contributing to risk and resilience
to stress-related psychiatric disorders.
Methods
Study samples
Study 1
Healthy male participants (n = 26, age 25.4 ± 2.9) were
given 1.5 mg of DEX orally at 12:00, see [46] for more
details on the study samples and [30, 47–50] for the
choice of dose. Peripheral blood was drawn just before ad-
ministration of DEX as well as 1, 3, 6, and 23 h thereafter.
Nineteen of the 26 samples were selected for TBS for a
balanced rs1360780 genotype distribution (7 subjects with
TT genotype, 6 with TC, and 6 with the CC genotype).
Study 2
The second sample consisted of 89 Caucasian subjects
and were also exposed to 1.5 mg of DEX orally as previ-
ously described in [42]. Here, DEX was administered at
6 pm and blood draws occurred immediately before the
dose of DEX and then 3 hours as well as ~ 18 hours
(from 17.5 to 21 h) later. The subset comprised of 30
healthy probands (female = 1; male = 29) and 59 inpa-
tients with depressive disorders (female = 21; male = 38)
with an age of 41.64 ± 13.96 (mean age ± SD).
The demographics of both studies are reported in
Table 1.
DNA and RNA extraction of study samples
For both studies, DNA was extracted from frozen EDTA
blood using the Elmer Chemagic 360 Instrument (Perki-
nElmer chemagen Technologie GmbH, Baesweiler,
Germany) in combination with the chemagic DNA
Blood Kit special 400 (PerkinElmer chemagen Technolo-
gie GmbH, Baesweiler, Germany). Thirty-three blood
samples of study 2 were only collected in PAXgene tubes
(PreAnalytiX GmbH, Hombrechtikon, Switzerland) for
the ~ 18 h time point. For these samples, DNA was ex-
tracted from PAXgene tubes using PAXgene Blood DNA
Kit (QIAGEN GmbH, Hilden, Germany). Blood for RNA
was stored in PAXgene tubes, and RNA was extracted
using the PAXgene Blood RNA Kit (QIAGEN GmbH,
Hilden, Germany). All samples had an RNA integrity
number of at least 7.0.
Genotyping
Study 1
All participants were genotyped for the rs1360780 allele
using hybridization probes (forward primer: CCTTATTC-
TATAGCTGCAAGTCCC, reverse primer: TCTGAATAT-
TACCAGGATGCTGAG, rs1360780_LC: Red640-AAAT
TCTTACTTGCTACTGCTGGCACAAGAGA-Phosphate,
rs1360780_FL: CAGAAGGCTTTCACATAAGCAAAGT-
TACACAAAAC-Fluorescein). Genomic DNA was ampli-
fied using the LightCycler 480 Genotyping Master mix
(Roche, Mannheim, Germany) with the following cycling
conditions: 95 °C, 10 s; 45× (95 °C, 1 s; 56 °C, 10 s; 72 °C,
10 s); 95 °C, 1min; and 40 °C, 1min, ramped up to 85 °C
using a ramp rate of 0.57 °C/s and one acquisition per °C
on a LightCycler480 II Instrument (Roche, Mannheim,
Germany).
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Study 2
Genotyping for this cohort is described in [47] and was
based on Illumina 660K genotyping arrays.
Assessment of endocrine and immune measures
Cortisol and ACTH levels were assessed as described in
[48, 51]. For the measurement of plasma cortisol con-
centrations, a radioimmunoassay kit was used (INC Bio-
medicals, Carlson, CA). Plasma ACTH concentrations
were assessed by automated electrochemiluminescence
immunoassay using Roche Cobas immunoassay analyzer
(Roche, Basel, Switzerland). In the second study, add-
itionally, plasma DEX levels were measured at the 3-h
and 20–24-h time point using mass spectrometry as de-
scribed in [48] and differential blood cell counts evalu-
ated at all three time points as reported in [51].
Gene expression analysis via quantitative real-time PCR
Study 1
FKBP5 mRNA expression levels in blood samples of the
first study were assessed as follows. The generation of
cDNA was achieved using SuperScript™ II reverse tran-
scriptase (Thermo Scientific Inc., Schwerte, Germany).
Subsequently, the cDNA was amplified in duplicates in a
LightCycler 480 Instrument II (Roche, Mannheim,
Germany) using the LightCycler 480 SYBR Green I Mas-
ter kit (Roche, Mannheim, Germany) and primer spanning
Exon 10-11 (forward primer: AAAAGGCCAAGGAGCA-
CAAC, reverse primer: TTGAGGAGGGGCCGAGTTC;
cycling conditions: 95 °C, 10 s; 45× (95°,10 s; 58 °C, 10 s;
72 °C, 10 s)). Ct values were used to calculate relative ex-
pression levels according to [52] normalized on YWHAZ
expression (Universal ProbeLibrary probe #77; cycling
conditions according to the manufacturer’s recommenda-
tions; Roche, Mannheim, Germany) for normalization and
mean assay efficiencies.
Study 2
RNA expression from study 2 was done using Illumina
HT12v4 arrays previously described in [48]. In this
study, blood RNA samples were only available for two
time points (baseline and 3 h after DEX exposure).
Assessment of DNA methylation in study samples
DNA methylation levels in both studies were analyzed
using the HAM-TBS approach, comprising an optimized
PCR panel of 28 amplicons in the FKBP5 locus [25].
These data were complemented by Illumina 450K
methylation arrays. An overview of the methylation data
obtained can be found in Additional file 6: Table S1.
Study 1
HAM-TBS [25] on the FKBP5 locus was run for all 28
amplicons on DNA from each blood sample (baseline, 1
h, 3 h, 6 h, and 23 h post-DEX administration) in a single
sequencing run with 302 CpG sites analyzed.
Study 2
FKBP5 locus DNAm levels were assessed using both
HAM-TBS [25] (10 amplicons covering 50 CpGs from
each blood sample (baseline, 3 h and 18 h post-DEX ad-
ministration)) and 450K methylation arrays (56 CpGs at
baseline and 3 h post-DEX administration).
Targeted bisulfite sequencing of the FKBP5 locus
This method has been described in detail in [25] and of-
fers good performance of amplicon bisulfite sequencing
assays in a technology comparison by the Blueprint con-
sortium [53].
Amplicon selection and amplification by PCR
We optimized the amplifications of 28 regions covering
302 CpGs within GR and/or CTCF binding sites as well
as the transcription start site of the FKBP5 locus (see
Additional file 9: Table S4 for primers and mapping of
the amplicons). In order to reduce cost and maximize
the number of samples per sequencing run, triplicate bi-
sulfite treatments were performed for each sample and
then pooled to run one PCR amplification per amplicon
[25]. Overall, 200 ng to 500 ng of DNA was used per
sample and bisulfite treated using the EZ DNA Methyla-
tion Kit (Zymo Research, Irvine, CA). Twenty nano-
grams of bisulfite-converted DNA was then used for
each PCR amplification employing Takara EpiTaq HS
Polymerase (Clontech, Saint-Germain-en-Laye, France)
and 49 amplification cycles. PCR amplicons were then
quantified with the Agilent 2200 TapeStation (Agilent
Technologies, Waldbronn, Germany) and pooled in
equimolar quantities for each sample. AMPure XP beads
(Beckman Coulter, Krefeld, Germany) were used for a
double size selection (200–500 bp) to remove primer di-
mers and high molecular DNA fragments.
Sequencing
Libraries were generated using the TruSeq DNA
PCR-Free HT Library Prep Kit (Illumina, San Diego,
CA) according to the manufacturer’s instructions. Each
library was quantified with the Qubit® 1.0 (Thermo
Fisher Scientific Inc., Schwerte, Germany), normalized
to 4 nM and pooled. Library concentration and fragment
sizes were checked via Agilent’s 2100 Bioanalyzer (Agi-
lent Technologies, Waldbronn, Germany) and quantita-
tive PCR using the Kapa HIFI Library quantification kit
(Kapa Biosystems, Wilmington, MA). Paired-end se-
quencing was performed on an Illumina MiSeq Instru-
ment (Illumina, San Diego, CA) with their MiSeq
Reagent Kit v3 (2× 300 cycles) with the addition of 30%
of PhiX Library.
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Sequencing data processing
The quality of the sequencing reads was checked with
FastQC (http://www.bioinformatics.babraham.ac.uk/pro-
jects/fastqc), and Illumina adapter sequences were re-
moved using Cutadapt v.1.9.1. Bismark v.0.15.0 was used
for the alignment to a restricted reference limited to our
PCR targets. In order to stitch paired-end reads, an
in-house Perl script has been developed to remove the
low-quality ends of the paired-end reads if they over-
lapped. The methylation levels for all CpGs, CHGs, and
CHHs were quantified using the R package methylKit.
The resulting DNAm calls were submitted to a 3-step
quality control. First, PCR artifacts introducing false
CpGs of low coverage at 0 or 100% methylation level
were removed. Second, CHH methylation levels were
analyzed, and samples with insufficient bisulfite conver-
sion rate (< 95%) were removed. Finally, CpG sites with
a coverage lower than 1000 reads were excluded.
Illumina 450K methylation arrays
Study 2
Illumina 450K arrays were processed as described in
[42]. Smoking scores were predicted from DNAm data
as described in [54] as this information was not available
for all subjects. Blood cell ratios were estimated from
the DNAm data using the Houseman algorithm [55].
Normalized beta values of 52 CpG sites located within
the FKBP5 locus (hg19/chr6:35,487,554-35,718,452) were
extracted from the 425,883 probes that passed quality
control (QC).
Statistical analysis
DEX effects in study 1 and study 2
Linear mixed models (LMMs) were used to assess the
effects of DEX treatment over time on either ACTH,
cortisol, FKBP5 expression, or DNAm levels for each
CpG sites in both studies. All models were run adjusting
for intra-individual variability as random effect using the
“lmer” function of the Lme4 package in R [56]. p values
were calculated using the Wald chi-square test from the
Car package [57]. False discovery rate (FDR) was applied
to correct for multiple testing on methylation p values.
Post hoc analysis comparing each time point to baseline
was ran using LMMs for each site showing significant
results from above (FDR ≤ 0.05) to determine at which
time point the effect was observed. Differentially methyl-
ated CpG sites (DMCs) were called when FDR from the
mixed model was ≤ 0.05 and absolute mean methylation
differences between significant time points and baseline
(p value ≤ 0.05) were ≥ 1%.
The power to detect significant DNAm changes after
DEX administration was performed using the function
“powerSim” from the R package SIMR [56] with 100
simulations for each CpG sites profiled in both studies.
These analyses used a significance (alpha) level of 0.05
and minimum effect of absolute methylation difference
≥ 1% between 3 or 6 h and baseline for study 1 (delta
T3–T0 and T6–T0) and 3 hours and baseline for study 2
(delta T3–T0). In our discovery sample (study 1), an
average power of 96.6% (bootstrap 95% CI = (94.7, 97.9))
overall the 228 CpG sites was predicted to detect a mini-
mum difference of 1% in methylation after 3 and/or 6 h
of DEX administration. Over all the 50 CpG sites profiled
in the replication cohort (study 2), an average power of
88.8% (bootstrap 95% CI = (81.2, 93.4)) was predicted to de-
tect a minimum difference of 1% in methylation after 3 h of
DEX administration. These results indicate that both co-
horts have sufficient power (> 80%) to detect a minimum
difference of 1% in methylation after DEX administration
with our repeated measures design (5 sampling times in
study 1 and 3 in study 2). Although the power in both stud-
ies is sufficient to detect a 1% change in methylation, much
of the effect observed was larger than 3% (for 66% and 62%
of the total significant sites in study 1 and 2, respectively).
In addition, parametric bootstrap using the “bootMer”
function of the “lme4 package” in R using 100 simula-
tions, for the mixed models of the 50 CpG sites profiled
in study 2, was performed. The bootstrap results includ-
ing the measures of bias and standard error as well as
confidence intervals are given in Additional file 11: Table
S6. This analysis revealed that the results are stable as
the 95% confidence intervals from the 3-h and 24-h time
points indicate a change in DNA methylation for the all
sites identified with LMM (FDR ≤ 0.05 and absolute
delta methylation ≥ 1%).
Inter-individual factors influencing DEX-induced DNAm changes
To assess inter-individual factors influencing the ob-
served changes in DNAm following DEX administration,
each CpG site showing significant DEX effects in study
2 was tested (n = 21 CpGs). LMMs were used to assess
the association between DNAm change over time and
blood cell counts, age, sex, smoking, BMI, and MDD
status for each CpG sites. All models were run adjusting
for intra-individual variability as random effect using the
“lmer” function of the Lme4 package in R [56]. p values
were calculated using the Wald chi-square test from the
Car package [57]. Stepwise regression analysis was also
performed on 17 sites showing association with either
age, sex, smoking, BMI, or MDD status to select the
main confounding variables influencing DNAm change
over time. AICs and the DNAm estimates at 3 h of these
models were used to select the best model (Add-
itional file 10: Table S5).
FKBP5 genotype effect on DEX-induced methylation
changes over time was first assessed on 44 CpG sites in
study 1 and 21 sites in study 2 showing DNAm changes
at any time point post-administration of DEX. LMMs
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were used as described above. Methylation for each CpG
was regressed against the main effect of time (DEX) and
rs1360780 risk allele (CC or CT/TT) with and without
the interaction term of genotype * time point while
adjusting for intra-individual variability. p values of the
additive and interaction effects for each time points were
calculated using the Wald chi-square test.
We assessed if the direction of effects was concordant
across studies based on the binomial distribution. Assum-
ing that a CpG site shows the same direction of effect in
both studies by chance with a probability of 0.5, we deter-
mined the probability to observe the present or even a
higher number of CpG sites with concordant directions.
Additional files
Additional file 1: Figure S1. Change in blood cell counts after DEX
administration. A) Actual blood cell counts at baseline and after DEX
administration for granulocytes, monocytes, and lymphocytes in 54
subjects from study 2. B) Boxplot of DNAm residuals from a null model
correcting for associated variance in lymphocyte counts across time in 54
subjects from study 2. Post hoc analysis correcting for lymphocyte counts
revealed significant change in DNAm after 3 h of DEX for all sites (p value
< 0.1e−18). C) Predicted blood cell proportions from 450K methylation
data in study 2 using the Houseman algorithm [55]. (PDF 260 kb)
Additional file 2: Figure S2. DEX-induced changes in DNAm are also
influenced by factors associated with early life adversity. Examples of three
CpG sites were significant associations with fixed factors including age, sex,
BMI, smoking score, and major depression were observed. (PDF 150 kb)
Additional file 3: Figure S3. CpG sites with significant genotype-
dependent dynamic methylation differences in both studies. Effects of
rs1360780 genotype on DEX-induced DNA methylation changes in 2 sites
located in intron 7 and 5 enhancers. The % methylation levels for
rs1360780 risk allele carriers CT/TT and CC carriers following DEX expos-
ure are shown for each study. Methylation of CpG 35558710 shows sig-
nificant interaction effect at 23 h in study 1 (Χ2 = 5.69, p value = 0.02) and
additive effect at 3 h in study 2 (Χ2 = 4.15, p value = 0.04) with risk allele
genotype. Significant interactions between risk allele genotype and DEX
on methylation were observed for CpG 35570224 at 6 h and 23 h post-
treatment in study 1 (Χ2 = 7.59, p value = 0.006 and Χ2 = 6.0, p value =
0.01) and at 24 h in study 2 (Χ2 = 4.36, p value = 0.04). Points and error
bars represent mean and SEM for each genotype. (PDF 101 kb)
Additional file 4: Figure S4. Replication of dexamethasone (DEX)-
induced methylation changes (n = 106 subjects) analyzed by Illumina
450K arrays. A) Genome browser shot illustrating the location of TBS
amplicons assessed as well as the location of the 450K Illumina probes
within the FKBP5 locus (hg19/chr6:35487554-35718452). CTCF-ChIA-PET
-track indicating the locations of CTCF factor mediated chromatin
interactions determined by Chromatin Interaction Analysis with Paired-
End Tag (ChIA-PET) data extracted from lymphoblastoid cell line
(GM12878, [26]). Chromatin interactions are represented by PET blocks
connected with an horizontal line; CTCF-ChIP-seq and GR-Chip-
seq—regions of transcription factor binding derived from chromatin im-
munoprecipitation (ChIP) experiments in multiple cell lines from the EN-
CODE project; blood TBS amplicons—locations of targeted bisulfite
sequencing (TBS) amplicons assessed in blood of study 1; 450K probe
locations—locations of Illumina probes from the 450K array. B) Boxplot of
DNAm levels using TBS or Illumina 450K approach for the overlapping
CpG sites showing methylation changes after DEX using TBS. p values of
linear mixed models for each time point compared to baseline or vehicle
are indicated as follows: *≤ 0.05, **≤ 0.01, ***≤ 0.001. Note that although
cg125114611 show significant DEX effect using 450K array, this site has a
methylation change after DEX of − 0.4% which did not reach our thresh-
old of |1%|. (PDF 480 kb)
Additional file 5: Figure S5. Comparison of chromatin states in FKBP5
across brain, immune/blood, and fibroblasts. A) Genome browser shot
illustrating the chromatin states of the FKBP5 locus (hg19 /
chr6:35487554-35718452) across brain, immune/blood, and fibroblasts.
FKBP5 splicing variants—visualization of two splicing variants of FKBP5; TBS
amplicons—locations of targeted bisulfite sequencing (TBS) amplicons;
450K probe locations—locations of Illumina probes from the 450K array;
CTCF-ChIP-seq and GR-Chip-seq—regions of transcription factor binding
derived from chromatin immunoprecipitation (ChIP) experiments in
multiple cell lines from the ENCODE project; CTCF-ChIA-PET and PolII-
ChIA-PET—track indicating the locations of CTCF factor or PolII mediated
chromatin interactions determined by Chromatin Interaction Analysis
with Paired-End Tag (ChIA-PET) data extracted from lymphoblastoid cell
line (GM12878, [26]). Chromatin interactions are represented by PET
blocks connected with an horizontal line; Ensembl Reg Build—overview of
the Ensembl regulatory build which represents an annotation of regions
likely to be involved in gene regulation; ChroHMM—this track displays
the chromatin state segmentation of the FKBP5 locus for selected brain,
immune/blood, and fibroblast cells from the Roadmap Consortium. The
primary core marks segmentation has been used which visualize pre-
dicted functional elements as 15 states, which are displayed at the bot-
tom of the figure. B) Quantification of the 15 chromatin states at key
regulatory regions (transcription start site (TSS), topologically associating
domains (TAD), proximal Enhancer (proxE), and intronic GREs (iGRE)) of
the FKBP5 locus. Chromatin states were averaged over brain (n = 10), im-
mune/blood (n = 29), and fibroblasts (n = 5) cells. (PDF 390 kb)
Additional file 6: Table S1. Details on the CpG sites assessed in FKBP5
locus and summary of the results obtained using HAM-TBS and Illumina
450K array in both studies. (XLSX 78 kb)
Additional file 7: Table S2. Summary statistic from linear mixed models
testing the change in methylation after DEX for each CpG sites assessed
in study 1 (n = 228) including post-hoc analysis for each time point. In
bold are sites with significant DEX-induced methylation change. (XLSX
234 kb)
Additional file 8: Table S3. Summary statistic from linear mixed models
testing the change in methylation after DEX including lymphocyte cells
counts as covariate for each CpG sites associated with change in
lymphocyte counts (n = 9) in study 2. (XLSX 50 kb)
Additional file 9: Table S4. Location of HAM-TBS amplicons and primer
sequences used to analyze FKBP5 CpGs. (XLSX 15 kb)
Additional file 10: Table S5. Results from stepwise regression analyses
comparing the LMM models without covariate, with smoking score
alone, or with all the associated covariates performed on 17 CpG sites
showing association with either age, sex, smoking, BMI, or MDD status in
study 2. (XLSX 35 kb)
Additional file 11: Table S6. Summary statistic from the linear mixed
models testing the change in methylation after DEX for 50 CpG sites
profiled in study 2 as well as the measures of bias, standard error, and
confidence intervals using bootstraps with 100 simulations. (XLSX 46 kb)
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Abstract 
The risk for developing stress-related diseases is shaped by the interaction of 
environmental and genetic risk factors. The underlying molecular mechanisms 
integrating environmental and genetic cues have not yet been fully elucidated. We 
aimed to test, whether the allele of an intronic 3.3 kb large variant esv3608688 
(insertion / deletion), located within in a disease-associated haplotype at the FKBP5 
locus, have an effect on glucocorticoid-dependent gene regulation and how this can 
be explained on a molecular level. We observed that the deletion allele was 
associated with a higher induction of FKBP5 expression after activation of the 
glucocorticoid receptor (GR) in lymphoblastoid cell lines (LCLs). Furthermore, we 
could show that the esv3608688 allele can moderate the effect on FKBP5 gene 
expression regulation of a previously described functional single nucleotide 
polymorphism rs1360780 (Klengel et al, 2013). We identified that the stabilization of 
architectural and enhancer-promoter loops is a common feature of the factors (T-
allele, deletion and GR activation) leading to increased FKBP5 mRNA expression. In 
addition, we observed differentially methylated sites depending on the allele status 
for esv3608688 within key regulatory sites of FKBP5. Our data proposes a model, 
that this gene expression response is most likely result of an increased activity of 
GRE enhancers due to the stabilization of chromatin interactions. This study 
highlights molecular mechanism how genetic and environmental factors can be 
integrated fine-tune FKBP5 expression levels, potentially involved in leading to 
FKBP5 disinhibition and therefore shape the risk for developing a stress-related 
psychiatric disease.    
 
Keywords: Chromatin structure / DNA methylation / FKBP5 / Gene by environment / 
Glucocorticoids
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Introduction  
The development of stress-related psychiatric disorders involves the integration of 
genetic and environmental factors (Caspi & Moffitt, 2006; Kendler et al, 1999; 
Kendler et al, 1995; Klengel et al, 2013; Molnar et al, 2001). It has been shown by 
epidemiological, family and molecular genetic studies that genetic predisposition as 
well as stressful or traumatic life events are important risk factors for psychiatric 
disorders (Caspi & Moffitt, 2006).   
The molecular basis of the gene x environment interactions leading to disease are far 
away form being fully understood but necessary to translate the results from genetic 
association studies to the clinic (Krijger & de Laat, 2016). However, epigenetic 
mechanisms are potentially playing a role in the etiology of various human diseases 
(Adcock et al, 2005; Esteller, 2007; Gerken et al, 2007; Handel et al, 2010; 
Varambally et al, 2008; Weksberg et al, 2002) including depression (McGowan et al, 
2009), Posttraumatic Stress Disorder (PTSD) (Klengel et al, 2013), major psychosis 
(Mill et al, 2008) and autism (Schanen, 2006). It is thought that epigenetic 
modifications and mechanisms such as DNA methylation, histone modifications, non-
coding RNA and chromatin conformation changes (Levenson & Sweatt, 2005; 
Maddox et al, 2013; Mill & Petronis, 2007; Miller et al, 2008; Mitchell et al, 2014; 
Tsankova et al, 2007) are involved in mediating these interactions between the 
genotype and the environment (GxE) by changing the expression of genes implicated 
in stress-related psychiatric diseases (Jaenisch & Bird, 2003; Yehuda & LeDoux, 
2007). Epigenetic changes due to GxE interaction effects are supposed to be 
installed during sensitive periods (e.g. early development) and remain stable over 
time (Klengel et al, 2013; Klengel et al, 2014).  
In terms of stress-related diseases, genes which have shown to be part of GxE are 
often involved in the stress hormone system such as the glucocorticoid receptor (GR, 
NR3C1), corticotropin releasing hormone receptor 1 (CRHR1) and FK506 binding 
protein 5 (FKBP5), which play a key role in the regulation of the HPA axis (Binder, 
2009; Bradley et al, 2008; Klengel et al, 2013; Klengel et al, 2014; Polanczyk et al, 
2009; Zannas & Binder, 2014). A dysregulated stress hormone system is a strong 
risk factor for developing stress-related psychiatric disorders and therefore regulating 
factors of this system display promising therapeutic targets for the treatment of 
stress-regulated diseases like PTSD or Depression (Binder, 2009; Klengel et al, 
2013). A great number of studies (comprising over 12 000 subjects) have linked 
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interactions between FKBP5 genotypes and pathological phenotypes (for review see 
Matosin et al, 2018; Zannas et al, 2016) and often reported that genotypes 
associated with higher risk for the pathological phenotypes are also associated with 
higher FKBP5 induction and prolonged cortisol responses (Zannas et al, 2016).  In 
fact, a function of the co-chaperone FKBP51 is to inactivate GR in the cytoplasm, 
constituting in an ultra-short negative feedback loop, which regulates GR signaling 
and through this modulates the actions of glucocorticoids (Zannas et al, 2016).  
To understand how genotypes can influence the complex fine-tuning process of 
FKBP5 gene expression regulation in health and disease, one has to understand the 
molecular regulatory landscape of this gene. A key study by Paakinaho et al (2010) 
highlighted that GR elements in long distance from the promoter but also in the 
introns of the FKBP5 gene, are very important to understand gene expression 
regulation and includes the consideration of the locus chromatin structure. The 
development of the C-Techniques enabled researchers to get more insights into how 
the genome folds in 3D and lead to new concepts about structural and functional 
units of chromosomes (for review see Krijger & de Laat, 2016). This development 
enabled to bring the genetic variations associated with disease, which are often 
located in the non-coding parts of the genome, into the context of the 3D regulation 
of genes (Krijger & de Laat, 2016). One of the most prominent single nucleotide 
polymorphism associated with psychiatric disorders in FKBP5 is rs1360780 (Binder 
et al, 2008; Binder et al, 2004; Matosin et al, 2018; Zannas et al, 2016). This 
polymorphism lies in close proximity to a GRE in intron 2 and alters the mRNA and 
protein production after GR activation via an altered 3D chromatin structure (Klengel 
et al, 2014).  
The T-allele of rs1360780 forms a TATA-box binding motif, which enables an efficient 
interaction of the GRE in intron 2 and the transcription start site leading to FKBP5 
mRNA induction after GR activation. The C-allele on the on the other hand 
destabilizes the enhancer-promoter interaction due to the lack of the TATA-box 
binding motif, which leads to a decreased FKBP5 induction (Klengel et al, 2013). 
Moreover, we showed evidence for a GxE interaction of rs1360780 allele and 
childhood abuse, which leads to allele-specific demethylation of CpGs in a GRE motif 
in intron 7 in T-allele carrier that were exposed to childhood abuse.  The change in 
methylation further leads to an increased inducibility of the FKBP5 gene after GC 
exposure and has long-term effects on the stress hormone system, immune cell 
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function and brain areas important for stress-regulation (Klengel et al, 2013). These 
experiments highlighted the potential that allele-specific epigenetic modifications can 
contribute to GxE interactions and moderate the long-term effects of stress and 
subsequently the likelihood of developing stress-related psychiatric phenotypes 
during the lifetime.  
In the same haplotype of FKBP5, which comprises the rs1360780 polymorphism, a 
larger structural variant can be found (Pelleymounter et al, 2011). This 3.3 kb large 
insertion / deletion (INDEL) is located in intron 1 of the FKBP5 gene. Here, we want 
to investigate if the structural variant has an influence on FKBP5 gene expression 
regulation and if the effects mediated by rs1360780 are influenced by the INDEL 
allele status. Moreover, we asked how these effects onto gene expression regulation 
can be explained on a molecular level and if the context of INDEL allele are important 
for the development of psychiatric disease phenotypes.  
To answer these questions, we investigated the effects of the allele combinations of 
the two genetic variants onto FKBP5 gene expression induction after 
Dexamethasone (DEX) treatment in LCLs using an allele-specific gene expression 
assay for FKBP5. To explore, how these transcriptional effects on FKBP5 induction 
are reflected on the DNA level we analyzed changes of the chromatin structure (4C-
Seq) and DNA methylation (HAM-TBS).  
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Results 
The INDEL alleles modulate GC-dependent FKBP5 expression induction & 
modulate rs1360780 effects  
In order to better understand the temporal pattern of the FKBP5 induction due to GR 
activation, we designed a qPCR assay to detect nascent RNA (see method section 
and supplemental table 1). We choose two LCLs cell lines (both heterozygote for 
rs1360780, GM19098 is homozygote for the insertion and GM18516 homozygote for 
the deletion) and performed a time response experiment under continuous DEX 
(100nM) stimulation for 1 h, 2 h, 3 h, 4 h, 8 h and 24 h (Figure 1 A). The treatment 
with DEX results in a fast stimulation of nascent FKBP5 RNA, which peaks at 2 to 3 h 
(Mean fold change: 4.698 ± 1.016 & 4.674 ± 0.559 respectively) and then stabilizes 
after 4 h at a fold change of 3.779 ± 0.697, which slightly decreases to 3.386 ± 0.705 
after 24 h. The mRNA of FKBP5 strongly increases after 2-4 h after continuous DEX 
treatment and stabilizes at a fold change at of 2.963 ± 0.176 and 3.336 ± 0.339 after 
4 h and 8 h respectively. As observed for the nascent RNA, FKBP5 mRNA slightly 
reduces to a fold change of 2.711 ± 0.2218 after 24 h.  
Subsequently, we asked, whether the alleles of the INDEL have the potential to 
regulate the GC-dependent induction of FKBP5 mRNA and if there is interplay of the 
INDEL and rs1360780 alleles on FKBP5 gene expression regulation. We choose to 
DEX stimulate (4 h, 100 nM DEX) 10 LCLs, which were heterozygote for rs1360780 
allele but homozygote for esv3608688 (deletion n = 5, insertion n = 5).  Using a 
hydrolysis probe qPCR assay that detects total FKBP5 mRNA expression, we 
observed as expected that GR activation via DEX leads to an induction of FKBP5 
mRNA (see Figure 1 B). Moreover, we observed that the deletion is associated with 
increased FKBP5 induction over the insertion due to the DEX treatment (Mean fold 
change difference = 1.08, P-Value < 0.01 see Figure 1 B).  We developed an allele-
specific gene expression qPCR setup to discriminate the transcripts produced from 
the rs1360780 T- or C-allele under a homozygote structural variant background.  Due 
to the fact that the rs1360780 lies within an intron of FKBP5, we designed our allele-
specific probes on rs3800373, which is in high LD with rs1360780 and located in the 
3’UTR of the FKBP5 mRNA (see method section and supplementary table 1). The 
proportions of rs1360780 allele under an insertion or deletion background were 
obtained using the allele-specific qPCR setup in the 10 LCLs and DEX treatment. We 
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found that more FKBP5 transcripts are generated from the T-allele over C-allele in 
each of the conditions (Mean Proportion Difference INS_VEH = 0.09, P-Value < 0.001; 
Mean Proportion Difference INS_DEX = 0.16, P-Value < 0.001; Mean Proportion 
Difference DEL_VEH = 0.21, P-Value < 0.001; Mean Proportion Difference DEL_DEX = 
0.22, P-Value < 0.001; see Figure 1 C).  Furthermore, the highest proportion of T-
allele transcripts is achieved under a deletion background, leading to a significant 
genotype effect under vehicle conditions (Mean Proportion Difference VEH = 0.06, P-
Value < 0.05) but not significant when treated with DEX (Figure 1 C). Subsequently, 
we analyzed the allele-specific expression levels of FKBP5 (Figure 1 D). The total 
FKBP5 transcript levels depended on the allele combination of the two variants and 
we observed an additive genotype effect (Figure 1 D). The lowest GC-induced 
FKBP5 transcript levels are detected in the combination of the C + insertion alleles, 
whereas the highest transcript levels are observed under the combination of the T + 
deletion alleles (Fold change C-INS = 2.10 ± 0.30 > Fold change T-INS = 3.00 ± 0.50 > 
Fold change T-DEL = 3.68 ± 0.79; Mean Difference T-INS vs C-INS = 0.85, P-value < 0.001; 
Mean Difference T-DEL vs C-INS = 1.58, P-value < 0.001; Mean Difference T-DEL vs T-INS = 
0.73, P-value < 0.01).  
 
 
FKBP5 responsiveness to glucocorticoids is modulated by structural variant 
allele via an altered TAD structure 
To understand how the structural variant can influence the complex fine-tuning 
process of FKBP5 gene expression regulation, one has to understand the molecular 
regulatory landscape of this gene. Therefore, we performed an in silico analysis 
comprising the key features of the FKBP5 locus structure using available literature 
and datasets (Consortium, 2004; Paakinaho et al, 2010; Rao et al, 2014; Tang et al, 
2015) (Figure 2).  The topology of the FKBP5 locus is formed by CCCTC-binding 
factor (CTCF), which generates a architectural chromatin loop, the topologically 
associating domain (TAD), in which RNAPII and other proteins like transcription 
factors (e.g. GR) further bind and substructure the locus to regulate FKBP5 gene 
expression during the development, in different tissues and in response to 
environmental influences.  In order to investigate how the esv3608688 allele can 
affect FKBP5 gene expression we used a circularized chromosome conformation 
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capture (4C) sequencing approach, to obtain high-resolution interaction profiles (van 
de Werken et al, 2012b). We designed one viewpoint on the proximal TAD boundary 
(hg19 / chr6:35704131-35704628, see Figure 3) and a second on the transcription 
start site (TSS)( (hg19 / chr6:35655866-35656827, see Figure 4 & supplementary 
Figure 2) using DpnII and NlaIII as restriction enzymes. This enabled us to obtain, 
the interaction profile from the proximal TAD boundary (to detect effects on TAD 
interactions) and TSS (to detect effects on promoter-enhancer interactions) from the 
same 4C DNA samples. We choose to generate high-resolution interaction profiles in 
triplicates of the two viewpoints from GM18516 (homozygote deletion, heterozygote 
SNP) and GM19098 (homozygote insertion, heterozygote SNP) under vehicle (EtOH) 
and DEX treatment (100nM, 4h) conditions. The 4C profiles from the TAD boundary 
and TSS are reproducible between replicates and specific interactions descripted in 
the literature are detected (for further details see supplementary Figure 1). Due to the 
fact that we can use the same restriction enzymes for the definition of the viewpoints, 
we detect aligned interaction frequency peaks between both viewpoints. As an 
example, the interactions at the intragenic TAD boundary and intronic GRE at intron 
5 are observable in both viewpoints (Supplemental Figure 1). This indicates that the 
TAD boundary and the TSS are linked to some degree through the 3D conformation 
of the locus, highlighting the finding from Tang et al (2015) that RNAPII transcription 
factories are spatially associated with the CTCF / Cohesin foci. 
FKBP5 is known to be a pre-poised locus (Paakinaho et al, 2010), therefore the 
chromatin structure of the locus is already established before the stimulation with 
glucocorticoids, which is reflected with a visible interaction profile in the VEH samples 
(Supplemental Figure 1). To identify INDEL allele and DEX treatment effects onto 
FKBP5 interaction profiles we used the 4C-cker pipeline (Raviram et al, 2016). In our 
quantitative analysis we especially focused on aggregates of differentially interacting 
regions (DIRs) at an FDR = 0.05 to less likely interpret false positive regulates sites 
as being regulated. The reason is that interacting regions to the viewpoint are 
reflected by an increase and decrease of interaction frequencies (shape of Gaussian 
distribution) and therefore, if the FDR is not to stringent, called DIRs of true regulated 
interactions should also appear in an aggregate shape of a Gaussian distribution. As 
expected, we detect differentially interacting regions (DIRs) at the INDEL position in 
both viewpoints and conditions. The 4C interaction profiles of the insertion allele 
show an interaction frequency peak at the position of the INDEL position in both 
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viewpoints (Figure 3 & 4). This indicates that the region of the INDEL allele is in 
proximity to the TSS and the CTCF foci due to the 3D conformation of the locus. 
Moreover, aggregates of DIRs are detected at the intronic CTCF to the TAD 
viewpoint, which are significantly increased under the deletion allele (Figure 3, 
Quantification – Genotype tracks). Additionally, DIRs in the same direction are 
detected from the intronic CTCF binding site over the gene body to the TAD 
viewpoint (Figure 3, Quantification – Genotype tracks). This indicates a more intense 
TAD forming CTCF interaction from the locus proximal to the intronic site under the 
deletion allele in comparison to the interaction profile of the insertion allele. A similar 
distribution of DIRs was found when comparing the interaction profiles of the two 
genotypes of the TSS viewpoint (Figure 4, Quantification – Genotype tracks). But in 
this viewpoint, no clear aggregates of DIRs at the intronic CTCF binding site are 
observable, indicating that the DIRs detected by the TSS viewpoint may originate 
from the increased TAD forming CTCF interaction under the deletion allele which is 
detected by the TAD viewpoint. The DEX treatment leads to an increase of 
interaction frequencies from the TAD viewpoint to the intronic GRE binding site in 
intron 5, irrespectively from the INDEL allele status (Figure 3, Quantification – 
Treatment tracks). Aggregates of DIRs are observable due to the DEX treatment at 
the proximal long-range GRE enhancer when quantifying the interaction profiles of 
the TSS viewpoint (Figure 4, Quantification – Treatment tracks). 
In summary, the quantification of the high resolution interaction profiles of the TAD 
boundary and TSS viewpoint showed that the INDEL allele have the potential to 
modulate the TAD forming CTCF interaction (deletion allele increased the interaction 
frequencies) and that the DEX treatment leads to and increase of interacting 
frequencies over the whole gene body (TAD viewpoint) and specifically at the long-
range GRE enhancer (TSS viewpoint). 
 
The allele of the structural variant affect the methylation levels of key 
functional sites in the FKBP5 locus 
To further characterize the influence of the structural variant onto the DNA level, we 
aimed to investigate the DNA methylation levels of CpGs in key functional sites (TAD 
boundaries, TSS, intronic GREs and proximal GRE enhancer; see Figure 5 & 
supplementary table 3) in the FKBP5 locus and regions within and around the 
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structural variant. Therefore, we analyzed the methylation levels of these regions in 
10 LCLs carrying the insertion or deletion (n = 5, INDEL = INS / INS, rs1360780 = T / 
C; n = 5, INDEL = DEL / DEL, rs1360780 = T / C) with and without a DEX treatment 
(4h, 100 nM). We found that the allele of esv3608688 had an effect on the 
methylation level of 36 CpGs under the VEH (Total: 33 CpGs, 23 CpGs 
hypermethylated & 10 CpGs hypomethylated under the insertion allele) and DEX 
(Total: 27 CpGs, 17 CpGs hypomethylated & 10 CpGs hypomethylated under the 
insertion allele) condition with an overlap of 24 CpGs between both conditions 
(Figure 5, see Δ Methylation track). We observed a mean genotype effect size of 
⏐19.5 ± 6.8⏐% (Max: 41.65, Min: -23.32 when ΔMethgenotype = INSVEH-DELVEH) and 
⏐20.2 ± 7.2⏐% (Max: 39.6, Min: -25.7 when ΔMethgenotype = INSDEX-DELDEX) under the 
VEH and DEX condition, respectively.   
The CpGs within the insertion allele (h19 / chr6:35626434-35629744) and the distal 
flank (hg19/chr6:35625879-35626155) showed a high level of methylation 
(InsertionVEH = 90.7 ± 8.5 %, n = 33; Distal flank InsertionVEH = 94.6 ± 2.0 %, n = 14), 
whereas at the proximal flank (hg19/chr6:35630048-35631736) the methylation 
levels were more variable (Proximal flank InsertionVEH = 80.7 ± 20.4 %, n = 14). At 
the flanking regions of the INDEL, we found 4 CpGs (1 CpG at the distal flank & 3 
CpGs at the proximal flank), which showed increased methylation levels in the 
presents of the insertion allele in comparison to the deletion allele (Mean effect size 
VEH= 24.0 ± 9.7, n = 4; Mean effect size DEX= 28.9 ± 9.4, n = 3). One region between 
the INDEL and TSS (hg19 / chr6:35635518-35636055) included in our methylation 
analysis showed an array of CpGs located next to each other to be regulated by the 
INDEL allele (see Figure 5 B).  9 out of 10 CpGs in this regions showed a significant 
higher methylation levels under the insertion allele and VEH conditions with a mean 
effect size of 16.6  ±  2.9 %. When treating with DEX the number of CpGs with a 
genotype effect reduced to 5 out of 10 CpGs with a mean effect size of 18.3 ± 3.1 %. 
Further genotype effects on methylation were found close or at GREs in intron 5 (a 
total of 3 CpGs hypomethylated under the insertion allele (Mean effect size VEH = 19.0 
± 1.1 % (n = 2) & Mean effect size DEX = 17.3 ± 2.8 % (n = 3)) and proximal Enhancer 
(a total of 3 CpG hypermethylated (Mean effect size VEH = 16.9 ± 0.6% (n =3) & Mean 
effect size DEX = 15.7 ± 1.2 (n = 2)) and 8 CpGs hypomethlyated  (Mean effect size 
VEH = 19.0 ± 3.0 (n = 7)  & Mean effect size DEX = 18.6  ± 3.7 (n = 6)) under the 
insertion allele (see Figure 5 A & B). Interestingly, 10 out of the total 11 CpGs 
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showing lower methylation levels due to the insertion allele in both treatment 
conditions are located in regions in with known GR binding sites. Before TSS we 
found 1 CpG, which showed a hypermethylation of 14.4% under the insertion when 
treated with DEX but not in the VEH condition. Moreover, we found genotype effects 
onto the methylation of 8 CpGs close to CTCF binding sites at the proximal TAD 
boundary (a total of 2 CpGs hypermethylated under the insertion allele (Mean effect 
size VEH = 18.0 ± 5.7 % (n = 2) & Effect size DEX = 20.6 % (n = 1)) & distal TAD 
boundary (a total of 2 CpGs; 1 CpG hypomethylated and 1 CpGs hypermethylated 
under the insertion allele (Mean effect size VEH = ⏐15.7 ± 2.5⏐% (n = 2) & Mean effect 
size DEX = ⏐16.1 ± 0.1⏐% (n = 2)), after the TSS (a total of 2 CpGs hypomethylated 
under the insertion allele (Mean effect size VEH = 39.1 ± 3.6 % (n = 2) & Mean effect 
size DEX = 37.7 ± 2.7 % (n = 2)) and after the 3’UTR (a total of 2 CpGs 
hypomethylated under the insertion allele (Mean effect size VEH = 15.0 ± 0.1 % (n = 2) 
& Mean effect size DEX = 15.6 ± 2.3 % (n = 2)) (see Figure 5 A). We did not detect any 
significant DEX treatment effects onto the DNA methylation within the FKBP5 locus.    
Overall, we observed genotype effects onto DNA methylation at key functional sites 
in the FKBP5 locus (proximal & distal TAD boundaries, TSS, GRE in intron 5 and 
GREs at the proximal enhancer), around the position of the INDEL and in between 
the region of the INDEL and TSS. This indicates that the allele of the INDEL have the 
potential to lead to adaptations on the DNA methylation level in close proximity to the 
INDEL position but also in greater distance within the FKBP5 locus.  
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Discussion 
Here we provide evidence that the alleles of a 3.3 kb large INDEL within a disease-
associated haplotype in the FKBP5 locus can modulate FKBP5 expression response 
due to GC excess and therefore potentially to shape the risk for developing stress-
related psychiatric disorders. Our data suggest that the INDEL allele not only affect 
the gene expression regulation of FKBP5 (Figure 1 B) but also modulates the effect 
of the polymorphism rs1360780 under glucocorticoid exposure in LCLs (Figure 1 C). 
By using allele-specific gene expression assays and heterozygote LCLs for 
rs1360780 allele we could show that a higher proportion of mRNA is generated from 
the T-allel in comparison to the C-allele. This is in line with the results from Klengel et 
al (2013), who showed that the T-allel has a higher potential to induce gene 
expression in gene reporter assays. Interestingly, this differential gene expression 
response of rs1360780 allele is only observed in cells carrying the insertion allele. 
Moreover, we monitored the highest proportions of transcripts from the T-allele under 
the background of the deletion allele. In addition, the highest levels of total FKBP5 
transcripts under the excess of GCs were observed in LCLs combining the T- and 
deletion allele (Figure 1 D). These data indicate that the INDEL allele do not only 
moderate the differential effect of rs1360780 allele on FKBP5 expression, moreover 
both variants affect total FKBP5 transcript levels in an additive manner upon GC 
stimulation. The effects of rs1360780 allele onto FKBP5 expression can be explained 
on a molecular level by the establishment of an enhancer-promoter loop due to the 
formation of a TATA-box binding motif by the T-allele (Klengel et al, 2013). This leads 
to higher proportions of mRNA at baseline and even higher mRNA proportions from 
the T-allele under GC stimulation.  
In order to better understand how the large INDEL allele can modulate the rs136780 
effects on a molecular level, we obtained high-resolution interaction profiles of the 
FKBP5 locus TSS and TAD applying a 4C approach. A benefit of our 4C viewpoint 
design was the simultaneous monitoring of interaction profiles of both viewpoints in 
the same sample. This was achieved by choosing the same 4 base pair restriction 
enzymes for the definition of both viewpoints. The interaction profiles obtained from 
LCLs showed locus interactions that are in line with the reference literature and 
revealed architectural loops mediated by CTCF but also enhancer-promoter loops 
between the proximal GR and intronic GR-associated enhancers to the TSS (Klengel 
and Binder (2013); Paakinaho et al (2010), CTCF-ChiA-PET, PolII-ChiA-PET from 
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Tang et al (2015), Hi-C data from Rao et al (2014), see supplemental Figure 1). A 
comparison of the interaction profiles from cells carrying the insertion or deletion 
allele showed by interaction frequency peaks at position of the INDEL that the variant 
can be in close proximity to the TSS and TAD boundary (Figure 3 & 4). This 
involvement in the FKBP5 locus architectural and functional loop network indicates a 
potential ability to modulate gene expression, which is a first explanation for the 
INDEL expression effects monitored in these cells. Moreover, using the 4C-cker 
pipeline (Raviram et al, 2016) and DESeq2 (Love et al, 2014) were able to quantify 
the differences between the interaction profiles between the INDEL allele and DEX 
stimulation (Figure 3 & 4). The stimulation with DEX did not change the overall 
FKBP5 interaction profiles indicating the described pre-established nature as a pre-
poised gene (Jaaskelainen et al, 2011; Paakinaho et al, 2010). However, we 
quantified an increase of interaction frequencies from the TSS to the proximal GR-
associated enhancer. This most likely indicates the observed gene expression 
induction due to GC excess through the long-range GR enhancer. In addition to the 
specific stabilization of promoter-enhancer looping, we detect an increase of 
interaction frequencies from the proximal TAD boundary over the FKBP5 locus upon 
DEX stimulation (Figure 3). Together with the observation of increased interaction 
frequencies of the proximal TAD to the intronic TAD boundary in cells harboring the 
deletion allele, we conclude that the INDEL allele and GC excess may affect the 
stability of the architectural CTCF mediated-loop linking genotype and environmental 
signal. This interaction of genotype and environmental on the level of chromatin 
architecture could explain the FKBP5 expression results monitored in (Figure 1 B). In 
fact, the concept that the stability of loops is important for regulating gene expression 
has been described (Hakim et al, 2011; Le Dily et al, 2014) and that pre-existing 
loops favor the response to external stimuli (Grbesa & Hakim, 2017; Jin et al, 2013). 
In regard to the idea that a disregulation of architectural proteins / loops could lead to 
changes in the stability of promoter-enhancer interactions and lead to an altered 
response in gene expression (Antony et al, 2015; Quintin et al, 2014; Seitan et al, 
2013), we reason the following model for the integration of INDEL allele and GC 
excess to modulate FKBP5 gene expression (Figure 6). 
The structural basis of FKBP5 gene expression regulation is shaped by CTCF 
generating architectural loopings, which are described as TAD structure observed in 
Hi-C data (Lieberman-Aiden et al, 2009; Tang et al, 2015), see Figure 2). These TAD 
	 - 85 -   
loopings aid the formation of promoter-enhancer interactions, by restricting the 
promoter-enhancer looping within the TAD boundaries. For FKBP5 pre-existing 
proximal & intronic GR enhancer loopings to the promoter (Paakinaho et al, 2010) 
are important to mediate the gene expression response after GR activation by GCs. 
The GC-induced expression changes are associated with increased interaction 
frequencies between long-range promoter-enhancer loops but also from the proximal 
TAD boundary to the body of the FKBP5 gene. Genetic variants in FKBP5 locus can 
modulate the response to GR activation by affecting either GR-associated promoter-
enhancer loops or architectural CTCF mediated interactions. For rs1360780 a loop 
between a GR enhancer in intron 2 and the promoter is established due to the 
formation of an additional TATA-box binding motif of the T-allele, which can increase 
the GC-regulated FKBP5 induction. The 3.3 kb INDEL on the other hand is 
associated to moderate the stabilization of the architectural loop between the 
proximal TAD and intronic TAD boundary. In this scenario, the deletion is associated 
to lead to increased interaction frequencies between TAD boundaries and production 
of FKBP5 transcripts. The common feature in this model is that genetic variants and 
GR activation are associated to stabilizing loops within the FKBP5 locus which is 
reflected by increased interaction frequencies and additive effects onto gene 
expression. In other words, the activity of the GR enhancers responsible for FKBP5 
gene expression regulation is on the on hand regulated by the activation of the 
hormone receptor itself but also their probability to find the FKBP5 promoter. This 
probability is regulated by genetic variants modulating the stability of the architectural 
interactions (esv3608688 allele) but also promoter-enhancer interactions (rs1360780 
allele). Indications for the concept that the enhancer activity is regulated by the 
overarching TAD stability have been found by Simonis et al (2007) by manipulating 
the Shh locus. To prove the causality of this concept for the FKBP5 locus similar 
locus manipulation experiments using the CRISPR/Cas9 system need to be 
performed.  
The involvement of other chromatin features defining of the activity of enhancers is 
plausible and DNA methylation levels have been proposed to be instructive for the 
activity of GR enhancers (Wiench et al, 2011). Using the HAM-TBS workflow we 
assessed the DNA methylation levels of 46 sites (see Figure 5) covering key 
functional regions of the FKBP5 locus (TSS, TAD boundaries, proximal and intronic 
GR enhancer), the region of the INDEL and other sites between TSS and INDEL of 
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LCLs. The CpGs within the insertion allele show high methylation levels (InsertionVEH 
= 90.7 ± 8.5 %, n = 33). We observed significant genotype effects onto DNA 
methylation levels of 36 CpGs at proximal & distal TAD boundaries, TSS, GRE in 
intron 5 and GREs at the proximal enhancer. Effects onto methylation levels due to 
the INDEL allele have been monitored in both directions and depend on the location 
of the respective CpGs. Moreover, we detected a genotype effect onto methylation 
levels in an array of CpGs located in intron 1 (hg19 / chr6:35635518-35636055). This 
region showed increased methylation levels in the background of the insertion allele 
and has not yet been described to include important regulatory sites. However, a 
potential role as an enhancer of this region in LCLs is implicated by the chromatin 
states of the ENCODE project (Consortium, 2012) using multiple epigenetic 
information and hidden markov models (Figure 5 A, ENCODE ChromHMM Genome 
segmentation track, Ernst and Kellis (2010); Hoffman et al (2012); Hoffman et al 
(2013). No DEX-induced methylation changes have been detected in the LCLs. 
Overall, next to genotype effects of the INDEL allele onto chromatin interactions we 
detect DNA methylation levels changes at key functional sites involved in the 
formation of architectural and promoter-enhancer loops indicating a potential 
integration of both epigenetic layers. The absence of DEX-inducible methylation 
changes in the LCLs could be explained on the one hand by the chosen treatment 
conditions or tissue-specific inability of the LCLs to respond to GR activation. To 
further dissect the importance of the INDEL allele onto chromatin interactions and 
DNA methylation levels to regulate FKBP5 expression, experiments combining the 
manipulation of the DNA sequence but also the methylation levels of key regulatory 
sites of FKBP5 should be applied. Moreover, the observation of eRNA being 
produced from active enhancers (Mikhaylichenko et al, 2018) could be used to detect 
in vivo enhancer activity instructed by the production of eRNA from the respective 
enhancer in FKBP5. This would help to fine map the contribution of each specific 
GR-associated enhancer and better understand which manipulations of the DNA 
sequence or DNA methylation levels affect the activity of the FKBP5 enhancers. 
Although, there are preliminary data in PTSD patients that the INDEL allele moderate 
the symptom severity in a GxE manner (not shown here), further analyses need to be 
performed to enhance the evidence for the INDEL allele to moderate the 
development of stress related disease phenotypes. Due to the development of the 
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HAM-TBS (Roeh et al, 2018) workflow, there is now the possibility to investigate the 
INDEL effect onto the methylation level in patients. 
In summary, the data presented in this chapter extends the proposed molecular 
mechanism (Klengel et al, 2013) integrating genetic and environmental factors at the 
FKBP5 locus. We identified that the stabilization of architectural and enhancer-
promoter loops is a common feature of the factors (T-allele, deletion and GR 
activation by GCs) leading to increased FKBP5 mRNA expression. We and others 
(Symmons et al (2016) and discussed by Beagrie and Pombo (2016); Hakim et al 
(2011); Le Dily et al (2014)) find indications that this gene expression response is 
most likely result of an increased activity of enhancers due to the stabilization of 
chromatin interactions. However, further experiments manipulating the DNA 
sequence and DNA methylation levels of FKBP5 key regulatory sites will be 
necessary to obtain causality. Moreover, further analysis in patients will help to clarify 
the role of INDEL allele in the development of stress-related phenotypes.  
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Materials and Methods 
Cell culture of LCLs 
LCLs (GM20356, GM20278, HG00634, HG00442, HG00114, HG00140, GM18516, 
GM19098, GM19371, GM19317) were purchased from the Coriell Institute for 
Medical Research (Camden, New Jersey, USA) and grown in RPMI 1640 medium 
(FG-1385, Biochrom GmbH, Berlin, GER) with 10 % FCS (Thermo Fisher scientific 
Inc., Schwerte, Germany) and 1% Antibiotic/Antimycotic (Thermo Fisher scientific 
Inc., Schwerte, Germany) in an incubator under 37 °C and 5 % CO2 conditions. RNA 
and DNA was extracted from 0.8 million of cells. For RNA extraction, cells were 
pelleted and lyzed in 750 µl Trizol and RNA was isolated using the RNeasy mini kit 
(Qiagen GmbH, Hilden). DNA was extracted using the NucleoSpin® Tissue Kit 
(Macherey-Nagel GmbH & Co.KG, Dueren, GER) following manufacturer 
instructions. 
 
Detection of FKBP5 gene expression  
Allele-specific FKBP5 gene expression: The design of the allele-specific gene 
expression setup (see table 1 for primer sequences) was inspired by Soldner et al 
(2016). In order to obtain the ratio of mRNA generated from the rs1360780 allele (G / 
T) of heterozygote cells, we desgined hydrolysis probes on the SNP rs3800373 (C / 
A) which is located in the 3’UTR of the FKBP5 mRNA and in full LD with rs1360780 
allele (rs1360780 G – rs3800373 C, rs1360780 T – rs3800373 A) (Binder et al, 
2004). RNA was isolated using Qiazol (QIAGEN GmbH, Hilden, Germany) in 
combination with the RNeasy Mini Kit (QIAGEN GmbH, Hilden, Germany). 
Subsequently, DNA contamination in the RNA samples was removed by DNase 
digestion using the RNase-Free DNase set (QIAGEN GmbH, Hilden, Germany) and 
purified with the RNeasy MinElute Cleanup Kit (QIAGEN GmbH, Hilden, Germany). 
After bringing the RNAs to the same concentration with RNase-free water, cDNA was 
generated using the Superscript II reverse transcriptase (Thermo Scientific Inc., 
Schwerte, Germany). In order to test for DNA contamination some samples 
underwent an additional cDNA generation without adding reverse transcriptase (RT), 
these samples are referred as no RT controls. cDNAs were amplified in triplicates via 
real-time PCR using double-quenched hybridization probes (IDT PrimeTime® 
assays) with Taqman® fast advanced master mix (Thermo Scientific Inc., Schwerte, 
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Germany). All reactions were performed in a final volume of 10 µl on the LightCycler 
480 Instrument II (Roche, Mannheim, Germany).  Allele-specific multiplexing assays 
contained of a primer pair (final concentration of each primer = 0.5 µM) and two 
double-quenched hydrolysis probes (final concentration of each probe = 0.125 µM, 
Primer to Probe ration = 2:1) conjugated to different fluorophores (FAM / HEX) 
dependent on the rs3800373 allele (FAM = C; HEX = A). Cycling condition for the 
allele-specific multiplexing assay was: 50 °C – 2 min, 95 °C – 20 s and 65x (95 °C – 
3 s, 65 °C – 30 s). Cycling conditions for predesigned IDT PrimeTime® assays 
(Hs.PT.58.20523859 (FKBP5), Hs.PT.39a.22214836 (GAPDH) and 
Hs.PT.58.4154200 (YWHAZ)) were: 50 °C – 2 min, 95 °C – 20 s and 65x (95 °C – 3 
s, 60 °C – 30 s). Each amplification plate included non-template controls for each 
assay (cDNA substituted by water in amplification mix used as negative control to 
detect cross-contamination). 
For the analysis of relative quantification of allele-specific FKBP5 expression after 
DEX treatment we used - similar to Soldner et al (2016) - the Pfaffl method (Pfaffl, 
2001) that incorporated the following information: Total FKBP5 expression 
(Hs.PT.58.20523859 used as reference assay for total FKBP5 mRNA), allele-specific 
FKBP5 multiplexing assay (target assay to determine proportion of mRNA species 
from each allele), two stable calibrator genes (Hs.PT.39a.22214836 (GAPDH) and 
Hs.PT.58.4154200 (YWHAZ)) and a 1 to 10 dilution of a RNA sample (to generate 
standard curve and calculate assay efficiencies). Cp values were extracted using the 
LightCycler 480 Instrument II analysis software. Optionally, we also included two 
DNA samples with known allele status for rs3800373 / rs1360780 to increase the 
reproducibility of setting the thresholds for each run within the LightCycler 480 
Instrument II analysis software. Mean Cp values were calculated for each sample 
and assay. Allele-specific FKBP5 expression proportions were calculated as follows: 
First, Cp values from Target assay (Cps from FAM (rs1360780 T) and HEX 
(rs1360780 C)) were subtracted from Cp values of reference assay. Second, the 
relative change is computed using the respective assay efficiencies. Third, relative 
changes are calculated for single alleles and normalized to obtain the allele-specific 
FKBP5 expression proportions. Finally, to calculate allele-specific gene expression 
the total FKBP5 expression (relative to the vehicle samples and normalized on mean 
calibrator genes) was computed and multiplied with allele-specific FKBP5 expression 
proportions.  
	 - 90 -   
      (1) !"#$%& ! !" ! −  !"#"$"%&" !" =  Δ !" ! !" !  
(2) !""#$ !""#$#%&$'!∆!" (! !" ! !""#") = !"#$%&'" !ℎ!"#$ (! !" !) 
(3) !"#$%&'" !ℎ!"#$ ! !" ! ∗ 0.5 = !"#$%&'" !ℎ!"#$ !"#$%& !""#"  (! !" !) 
(4)  !"#$%&'" !ℎ!"#$ !!"#$% !""#"  (! !" ! !""#")!"#$%&'" !ℎ!"#$ !"#$%& !""#"  ! +  !"#$%&'" !ℎ!"#$ !"#$%& !""#"  (!)
= !"#$%&'()* !""#" !"#!#"$%#& (! !" !) 
 (5) !"#$%&'" !ℎ!"!"!"!#$ !"#$! ∗ !"#$%&'()* !""#" !"#!#"$%#& ! !" !
=  !""#"# !"#$%&%$ !"#$5 !"#$!%%&'( (! !" !) 
 
Nascent FKBP5 RNA: In order to detect nascent FKBP5 RNA transcripts we 
designed primer and a double-quenched-probe targeting the intron carrying the SNP 
rs1360780 (see supplementary table 1 for primer sequences). RNA extraction and 
cDNA generation was achieved as described in the section allele-specific FKBP5 
gene expression. cDNAs were amplified in duplicates via real-time PCR using 
Taqman® fast advanced master mix (Thermo Scientific Inc., Schwerte, Germany). All 
reactions were performed in a final volume of 10 µl on the LightCycler 480 Instrument 
II (Roche, Mannheim, Germany). Cycling condition for the nascent FKBP5 RNA 
assay was: 50 °C – 2 min, 95 °C – 20 s and 65x (95 °C – 3 s, 60 °C – 30 s). Each 
amplification plate included non-template controls for each assay (cDNA substituted 
by water in amplification mix used as negative control to detect cross-contamination) 
and a 1 to 10 dilution of a RNA sample (to generate standard curve and calculate 
assay efficiencies). For the analysis of nascent FKBP5 RNA expression after a DEX 
treatment in comparison to the FKBP5 mRNA expression (Hs.PT.58.20523859) we 
used the Pfaffl method (Pfaffl, 2001). 
 
Circularized chromosome conformation capture (4C-Seq) 
In order to investigate the effects of the INDEL allele onto the FKBP5 chromatin 
structure we applied the high-resolution 4C-Seq approach developed by the de Laat 
group (Splinter et al, 2012; van de Werken et al, 2012a; van de Werken et al, 2012b), 
which uses 4bp cutter restriction enzymes to generate 4C template DNA. The 4C-ker 
method was used to analyze 4C-Seq data (Raviram et al, 2016). 
	 - 91 -   
Design of FKBP5 viewpoints: We designed primer for two viewpoints according to 
van de Werken et al (2012a) (see supplementary table 2). The first viewpoint was 
designed on the FKBP5 transcription start site (hg19 / chr6: 35655865 - 35656827) 
and the second on proximal TAD boundary (hg19 / chr6: 35704130 - 35704628). Due 
to the fact that both viewpoints are defined by the same restriction enzymes DpnII 
and NlaIII, we are able to monitor the interaction profiles from both viewpoints of the 
same 4C DNA template.   
4C template DNA generation and library preparation: The 4C DNA was generated 
with some slight adjustments according to Splinter et al (2012). In brief, 10 Mio. cells 
re-suspended in PBS/10% FCS (Thermo Scientific Inc., Schwerte, Germany), were 
fixated with formaldehyde (2% final concentration, (Thermo Scientific Inc., Schwerte, 
Germany) for 10 min on RT while tumbling. The cross-linking reaction was quenched 
on ice using glycine. After re-suspending fixed cells in cold lysis buffer, 50 strokes 
were applied with a cell douncer (Pestle A). DpnII (New England Biolabs GmbH, 
Frankfurt am Main, Germany) was used for the first restriction digestion and digestion 
efficiency was checked via qPCR using the LightCycler 480 Instrument II and 
LightCycler480 SYBR Green I Master Mix (Roche, Mannheim, Germany) according 
to Hagege et al (2007) (for primer sequences see table 1; Cycling condition: 95 °C – 
5 min, 45x (95 °C – 10 s, 60 °C – 10 s, 72 °C – 10 s), 40°C – 10s). After in-solution 
ligation using T4 DNA ligase (New England Biolabs GmbH, Frankfurt am Main, 
Germany), cross-links and RNA were removed with Proteinase K (Merck KGaA, 
Darmstadt, Germany) and RNase A (Merck KGaA, Darmstadt, Germany) 
respectively. 3C DNA was cleaned up using Phenol-chloroform and DNA 
precipitation. Nlalll (New England Biolabs GmbH, Frankfurt am Main, Germany) was 
used for a second round of digestion to trim DNA circles and ligated in solution again. 
After DNA precipitation 4C DNA was cleaned up using the nucleotide removal kit 
(Qiagen GmbH, Hilden). The Expand Long Template Polymerase (Roche, 
Mannheim, Germany) was used to amplify 3.2 µg 4C DNA with viewpoint-specific 
primer introducing Illumina adapter sequences (single-indexed) in 16 separate 
reactions. The cycling condition for the TSS viewpoint was: 94 °C – 2 min, 29x (94 °C 
– 10 s, 64.9 °C – 60 s, 68°C – 3 min), 68°C – 5 min, 4 °C – ∞. The cycling condition 
for the proximal TAD viewpoint was: 94 °C – 2 min, 29x (94 °C – 10 s, 62.8 °C – 60 s, 
68°C – 3 min), 68°C – 5 min, 4 °C – ∞. After pooling the 16 PCR reactions, AMPure 
XP beads (1.2x beads, Beckman Coulter, Krefeld, Germany) were used to clean up 
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PCR products. The purity and average amplicon size was obtained using a 
bioanalyzer (Agilent Technologies, Waldbronn, Germany) and DNA 7500 Chips. The 
Kapa Library qPCR quantification kit (Kapa Biosystems, Wilmington, MA) was used 
to calculate the molarity of 4C libraries. 4C libraries adjusted to 4 nM and pooled for 
sequencing. 
Sequencing: Single-end sequencing (125 bp) was performed on an Illumina HiSeq 
2500 Instrument (Illumina, San Diego, CA).  
Sequencing data processing: The quality of the sequencing reads was checked with 
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). The sequence 
reads contained the primer sequence until the primary restriction enzyme recognition 
sequence (DpnII) and the captured fragments to the bait. The primer sequence until 
the DpnII recognition sequence was trimmed away from the read. The sequence of 
the capture fragments was kept until the appearance of the first (DpnII) or second 
(NlaIII) restriction enzyme recognition sequence. Afterwards the capture sequences 
were aligned to a reduced DpnII digested 4C reference genome of hg19 using 
Bowtie2 (Dryden et al, 2014). Each experiment needed to consist of  > 1 million 
reads and > 40% of the capture sequences needed to align in cis (chromosome 6). 
All reads within 1000 bp around the viewpoints were discarded. Subsequently 
capture fragments were used to perform the near-bait analysis of the 4C-ker pipeline 
using default parameters (Raviram et al, 2016). Normalized read counts and 
quantitative analysis of the 4C signal were obtained using DESeq2 (Love et al, 
2014). An FDR cut-off of 0.05 was used for the quantitative analysis.  
 
Targeted bisulfite sequencing 
Method development of the HAM-TBS approach has been described in detail in 
Roeh et al (2018). Below is a brief summary of the most salient methodological 
features. 
Amplicon selection and amplification by PCR: We assessed in the 10 LCLs the 
methylation levels of 46 regions covering 306 CpGs within GR and/or CTCF binding 
sites as well as the around the INDEL of the FKBP5 TAD (see Figure 5 & 
supplementary table 3) using the HAM-TBS approach (Roeh et al, 2018). Overall, 
200 ng to 500 ng of DNA was used per sample and bisulfite treated using the EZ 
DNA Methylation Kit (Zymo Research, Irvine, CA). 20 ng of bisulfite converted DNA 
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were then used for each PCR amplification employing Takara EpiTaq HS 
Polymerase (Clontech, Saint-Germain-en-Laye, France) and 49 amplification cycles. 
PCR amplicons were then quantified with the Agilent 2200 TapeStation (Agilent 
Technologies, Waldbronn, Germany) and pooled in equimolar quantities for each 
sample. AMPure XP beads (Beckman Coulter, Krefeld, Germany) were used for a 
double size selection (200-500 bp) to remove primer dimers and high molecular DNA 
fragments. 
Sequencing: Libraries were generated using the TruSeq DNA PCR-Free HT Library 
Prep Kit (Illumina, San Diego, CA) according to the manufacturer’s instructions. Each 
library was quantified with the Qubit® 1.0 (Thermo Fisher Scientific Inc., Schwerte, 
Germany), normalized to 4 nM and pooled. Library concentration and fragment sizes 
were checked via Agilent’s 2100 Bioanalyzer (Agilent Technologies, Waldbronn, 
Germany) and quantitative PCR using the Kapa HIFI Library quantification kit (Kapa 
Biosystems, Wilmington, MA). Paired-end sequencing was performed on an Illumina 
MiSeq Instrument (Illumina, San Diego, CA) with their MiSeq Reagent Kit v3 (2 x 
300-cycles) with the addition of 15% of PhiX Library.   
Sequencing data processing: The quality of the sequencing reads was checked with 
FastQC (http://www.bioinformatics.babraham.ac.uk/projects/fastqc) and Illumina 
adapter sequences were removed using Cutadapt v.1.9.1. Bismark v.0.15.0 was 
used for the alignment to a restricted reference limited to our PCR targets. In order to 
stitch paired-end reads, an in-house Perl script has been developed to remove the 
low-quality ends of the paired-end reads if they overlapped. The methylation levels 
for all CpGs, CHGs and CHHs were quantified using the R package methylKit. The 
resulting DNAm calls were submitted to a quality control. PCR artifacts introducing 
false CpGs of low coverage at 0 or 100% methylation level were removed. CHH 
methylation levels were analyzed, and samples with insufficient bisulfite conversion 
rate (< 95%) were removed.  
 
Genotyping 
Genotyping PCR INDEL: The allele of the 3.3 kb large INDEL in intron 1 of the 
FKBP5 gene were detected by separate PCR reactions using two primer pairs (see 
supplementary table 1 & supplementary Figure 4). The primer of the first pair were 
designed left (del10left1F) and right (del10span1R) from the INDEL position. 
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Amplification was carried out using LongAmp Taq polymerase (New England Biolabs 
GmbH, Frankfurt am Main, Germany) on a GeneAmp PCR System 9700 (Thermo 
Fisher Scientific Inc., Schwerte, Germany) with 50 ng genomic DNA as template 
under the following cycling conditions: 94°C – 6 min, 30x (94°C – 30s, 58°C – 45s, 
65°C – 6 min); 65°C – 15 min. The second pair of primer consisted of the same right 
primer (del10span1R) but a left primer (del10right2F), which binds within the insertion 
allele. Amplification was carried out as described above and the following conditions: 
94°C –6 min, 30x (94°C – 30s, 58°C – 45s, 65°C – 4 min), 65°C – 15 min.  Both PCR 
reactions of each sample were loaded next to each other onto an 0.8% agarose gel, 
separated by electrophoresis and visualized with an E-Box VX2 (Vilber Lourmat 
Deutschland GmbH, Eberhardzell, Germany)(see supplementary Figure 1). Thus, a 
sample carrying the deletion allele homozygously, result in a 2275 bp amplicon in the 
first PCR reation and no band in the second PCR. A sample, heterozygote for the 
INDEL allele, displays two amplicons for the first PCR, one at 2275 bp and another 
band at 5588bp. For the second PCR this heterozygote sample shows a band at 
1732 bp.  
 
Statistical analysis 
Nascent & allele-specific qPCR: GraphPad Prism 5 was used to calculate statistical 
analyses. To assess genotype and treatment effects onto gene expression, a one-
way or two-way ANOVA followed by bonferroni correction for multiple comparisons 
has been used with replicate normalized gene expression fold changes or allele 
proportions form each sample as input. 
Targeted Bisulfite Sequencing: GraphPad Prism 5 was used to calculate statistical 
analyses. To assess genotype and treatment effects onto DNA methylation, a two-
way ANOVA followed by a bonferroni correction for multiple comparisons has been 
used with replicate methylation values form each sample as input. 
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Figures 
 
Figure 1: Glucocorticoid-dependent FKBP5 expression and its modulation by 
esv3608688 and rs1360780 allele in Lymphoblastoid cell lines. 
(A) FKBP5 expression of nascent (nasRNA) and mature RNA (mRNA) over a time 
period of 24 h under continuous Dexamethasone treatment (DEX, 100 nM) of two 
Lymphoblastoid cell lines (LCL; GM19098 & GM18516). (B) Comparison of FKBP5 
mRNA expression after DEX treatment (4 h, 100 nM) of 10 LCLs carrying the 
insertion or deletion. ** indicates a genotype effect onto FKBP5 expression after DEX 
treatment (p-value = 0.01). (C) Proportions of FKBP5 mRNA produced from the 
rs1360780 alleles under the background of the insertion or deletion in 10 LCLs. *** 
indicate a genotype effect onto FKBP5 mRNA of the rs1360780 allele (p-value = 
0.001); # indicates a genotype effect of the INDEL allele onto the FKBP5 proportions 
produced from the rs1360780 allele (p-value = 0.05). (D) Allele-specific FKBP5 
mRNA expression for rs1360780 under the background of the insertion or deletion 
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obtained in 10 LCLs. *** indicate a genotype effect of rs1360780 allele onto FKBP5 
expression levels under the same INDEL background (p-value = 0.001). ## indicates 
a genotype effect of the INDEL allele onto the FKBP5 mRNA expression levels 
generated from the T-allele of rs1360780 (p-value = 0.01).  
 
 
Figure 2: In silico analysis of the 3D structure of the FKBP5 locus. 
Genome browser shot and HI-C profile illustrating the FKBP5 locus 3D structure 
(hg19 / chr6:35487554-35718452) and the location of the genetic variants rs1360780 
& esv3608688 in relevance to key functional sites using reference data. ChiP-Seq – 
The binding of the Glucocorticoid receptor (GR; ENCODE GR HAIB TFBS track from 
A549 cells), CTCF and Cohesin (indicated by its subunit Rad21)(both ENCODE 
SYDH TFBS tracks from GM12878) at the FKBP5 locus. ChIA-PET – Chromatin 
interactions mediated by PolII and CTCF at the FKBP5 locus (data from Tang et al 
(2015)). CTCF interactions are classified in convergent (loop formed by CTCF sites 
with opposing motif directions), complex convergent (loop formed by CTCF sites with 
opposing motif directions, between the interaction CTCF sites are other CTCF sites 
forming chromatin interactions) and tandem loops (loop formed by CTCF sites with 
the same motif directions) according to Tang et al (2015). HI-C – The FKBP5 locus 
	 - 107 -   
topologically associated domain structure (TAD) in GM12878 using data from Rao et 
al (2014) (visualized by Juciebox from the Aiden-Lieberman lab (Durand et al (2016), 
in situ MboI primary + replicate). 
 
 
Figure 3: 4C interaction profiles and quantification of LCLs carrying the 
insertion or deletion allele for esv3608688 using the TAD boundary as 
viewpoint. 
Genome browser shot illustrating the FKBP5 locus structure (hg19 / chr6:35247364-
35946252) and highlighting the location of the INDEL esv3608688 and intronic CTCF 
interaction involved in forming the FKBP5 topologically associated domain structure 
(TAD). The reference data was obtained from the ENCODE project (GR & CTCF 
peaks from Txn Factor ChiP track, for CTCF peaks green indicates CTCF motif in 
forward or red in reverse orientation; ChiA-PET from CTCF and PolII was derived 
from the GIS ChIA-PET track). The 4C Signal was generated from a viewpoint 
designed on the TAD boundary, in order to obtain the interaction structure of the 
FKBP5 TAD under vehicle and Dexamethasone treatment (4h, 100 nM) of the 
GM19098 (insertion) and GM18516 (deletion) LCLs. The triplicate 4C data of the two 
LCLs were processed and quantified using the near-bait cis analysis with standard 
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parameter of the 4C-ker pipeline (Raviram et al, 2016) and FDR cut-off of 0.05 for the 
quantification with DESeq2 (Love et al, 2014). The quantification data is displayed in 
a log2 transformation.  
 
 
Figure 4: 4C interaction profiles and quantification of LCLs carrying the 
insertion or deletion allele for esv3608688 using the TSS as viewpoint. 
Genome browser shot illustrating the FKBP5 locus structure (hg19 / chr6:35247364-
35946252) and highlighting the location of the INDEL esv3608688 and the proximal 
long-range enhancer containing multiple GR binding sites. The reference data was 
obtained from the ENCODE project (GR & CTCF peaks from Txn Factor ChiP track, 
for CTCF peaks green indicates CTCF motif in forward or red in reverse orientation; 
ChiA-PET from CTCF and PolII was derived from the GIS ChIA-PET track). The 4C 
Signal was generated from a viewpoint designed on the transcription start site (TSS), 
in order to obtain the interaction structure to the TSS under vehicle and 
Dexamethasone treatment (4h, 100 nM) of the GM19098 (insertion) and GM18516 
(deletion) LCLs. The triplicate 4C data of the two LCLs were processed and 
quantified using the near-bait cis analysis with standard parameter of the 4C-ker 
pipeline (Raviram et al, 2016) and FDR cut-off of 0.05 for the quantification with 
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DESeq2 (Love et al, 2014). The quantification data is displayed in a log2 
transformation.  
 
Figure 5: INDEL esv3608688 effect on FKBP5 methylation in LCLs   
(A) Genome browser shot illustrating the FKBP5 locus structure (hg19 / 
chr6:35479489-35729448) and the location of the genetic variants rs1360780 & 
esv3608688. The reference data was obtained from the ENCODE project (GR & 
CTCF peaks from Txn Factor ChiP track; ChiA-PET from CTCF and PolII was 
derived from the GIS ChIA-PET track, GM12878 WGBS data was obtained from 
GSM2308632, low methylation levels are in by cold colors and high methylation 
levels by warm colors; ENCODE ChromHMM displays the Genome segmentation 
track of GM12878, summarizing 15 chromatin states which e.g. indicate active 
promoters (red), enhancer (yellow/orange), transcription (green) but also repression 
by polycomb (grey). 4C Signal - The 4C Signal was generated from a viewpoint 
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designed on the TAD boundary, in order to obtain the interaction structure of the 
FKBP5 TAD under vehicle conditions of the GM19098 (insertion) and GM18516 
(deletion) LCLs. 4C quantification -  The 4C quantification data is displayed in a log2 
transformation and a FDR cut-off of 0.05 was used. TBS amplicons - indicate the 
localization of the amplicons for the assessment of DNA methylation levels at the 
FKBP5 locus. TBS Methylation – Displays the assessed DNA methylation levels of 
CpGs at selected sites for FKBP5 of 10 LCLs which carry the insertion or deletion 
(mean methylation level of each group, n = 5). Low methylation levels are in by cold 
colors and high methylation levels by warm colors Δ Methylation – Difference of DNA 
methylation levels between LCLs carrying the insertion / deletion. Significant 
methylation levels (p > 0.05, two-way ANOVA followed by bonferroni correction for 
multiple testing) are indicated in blue (significant reduced methylation levels in 
insertion LCLs) or red (significant increased methylation levels in insertion LCLs). (B) 
Detailed Plot of methylation differences due to the INDEL allele of aggregates CpGs 
in all amplicons distributed over the FKBP5 locus.   
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Figure 6: A model how glucocorticoids and INDEL esv3608688 influence 
FKBP5 expression by modulating its underlying chromatin structure  
The structural basis of FKBP5 gene expression regulation is shaped by CTCF 
generating architectural loopings, which are described as TAD structure. These TAD 
loopings aid the formation of promoter-enhancer interactions, by restricting the 
promoter-enhancer looping within the TAD boundaries. For FKBP5 pre-existing 
proximal & intronic GR enhancer loopings to the promoter are important to mediate 
the gene expression response after GR activation by GCs. The GC-induced 
expression changes are associated with increased interaction frequencies between 
long-range promoter-enhancer loops but also from the proximal TAD boundary to the 
body of the FKBP5 gene. Genetic variants in FKBP5 locus can modulate the 
response to GR activation by affecting either GR-associated promoter-enhancer 
loops or architectural CTCF mediated interactions. The 3.3 kb INDEL is associated to 
moderate the stabilization of the architectural loop between the 5´TAD and intronic 
TAD boundary. In this scenario, the deletion is associated to lead to increased 
interaction frequencies between TAD boundaries and production of FKBP5 
transcripts. The common feature in this model is that genetic variants and GR 
activation are associated to stabilize loops within the FKBP5 locus which is reflected 
by increased interaction frequencies and additive effects onto gene expression. In 
other words, the activity of the GR enhancers responsible for FKBP5 gene 
expression regulation is on the on hand regulated by the activation of the hormone 
receptor itself but also their probability to find the FKBP5 promoter. This probability is 
regulated by genetic variants modulating the stability of the architectural interactions 
(INDEL allele) but also promoter-enhancer interactions (rs1360780 allele). 
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Supplementary Figure 1: Triplicate 4C interaction profiles from the TSS and 
TAD viewpoint under vehicle conditions. 
Genome browser shot illustrating the FKBP5 locus (hg19 / chr6:35237870-
35899266) and the location of the genetic variants rs1360780 & esv3608688 in 
relevance to key functional sites using reference data. The reference data was 
obtained from the ENCODE project (GR & CTCF peaks from Txn Factor ChiP track, 
for CTCF peaks green indicates CTCF motif in forward or red in reverse orientation; 
ChiA-PET from CTCF and PolII was derived from the GIS ChIA-PET track). The 4C 
Signal was generated from two viewpoints designed on the transcription start site 
(TSS) and topologically associated domain (TAD) boundary. The triplicate 4C data of 
the two LCLs were processed using the 4C-ker pipeline (Raviram et al, 2016). 
Examples of regions known to interact with the viewpoints or are important in this 
study are highlighted in different colors.   
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Tables and their legends 
Supplemental Table 1: Primer used for qPCR 
Allele-specific FKBP5 gene expression 
rs3800373_F: GCAACTGCGTGTCAAACC 
rs3800373_R: GAACTTTATTTACACTCCTCTATCATGC 
rs3800373_FAM: 
/56-FAM/AG AAG AGC A/ZEN/A CTA TTT ATT TGT CAA CCC 
TAC AGA T/3IABkFQ/ 
rs3800373_HEX: 
/5HEX/AG AAG AGC A/ZEN/A CTA TTT ATT TGT CAA CAC 
TAC AGA T/3IABkFQ/ 
Nascent FKBP5 RNA 
FK5hnR_F: GTA AAC AGA GGC AGG GAG ATG 
FK5hnR_R: AGG CTT CTC AAC CTT GTA GC 
FK5hnR_Probe: 
/56-FAM/ACA GCC TGC /ZEN/AAA GTC TCC ACT GTT 
/3IABkFQ/ 
4C RE efficiency 
DpnII_P1_F: ACGTCCCAGAACAGAAGAGC 
DpnII_P1_R: CAGCGCCGTCTAACAGGT 
DpnII_P2_F: ATTCTATAGCTGCAAGTCCC 
DpnII_P2_R: GAAAGCCTTCTGTGCCTG 
NlaIII_P1_F: GTAAGCCTTATTCCACTGGA 
NlaIII_P1_R: GTTCAGGACAGTGTGTTCA 
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Supplemental Table 2: 4C-Seq primers used in this study 
Viewpoint 
First 
RE 
Second 
RE Reading Primer Non-reading primer 
FKBP5 
TSS 
DpnII NlaIII GCGCCGTCTAACAGGT
GAT 
CCCATCTCCGTGGCCA
TG 
FKBP5 
5’TAD 
DpnII NlaIII GGCCCTCCCATATGTG
ATC 
AGTACAGTGGCGTGTC
AG 
 
Supplemental Table 3: TBS PCR information 
Please see separate File.  
 
Supplemental Table 4: Primer used for qPCR 
INDEL allele genotyping PCR 
Del10left1F: CCCAGGATAATCTCCCCATT 
Del10span1R: GGTCCTCTTTGTGCTCTTGC 
Del10right2F: CACTGCTATGAACATTTTTGTGC 
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6 Discussion 
The development of stress-related psychiatric disorders involves the complex 
integration of genetic and environmental factors (Zannas and Binder, 2014). There 
are a large number of studies (31 independent studies comprising 39 cohorts with 
more than 31000 individuals) linking common genetic variants within a haplotype 
spanning the FKBP5 locus and environmental impacts with diverse psychiatric 
phenotypes such as MDD or PTSD (Matosin et al., 2018; Zannas et al., 2016). 
Interestingly, only a few studies detect a main genotype effect of FKBP5 variants with 
increased risk for psychiatric disorder, but most of them show evidence that the risk 
is shaped by an interaction of FKBP5 variants and early life adversity. The molecular 
mechanisms of such statistical gene by environment interaction, are far from being 
fully understood, and improved understanding of these molecular mechanism and 
their contribution to pathogenesis would have strong implications for decreasing the 
burden on individuals and societies suffering from psychiatric diseases. A first 
indication for a molecular mechanism integrating FKBP5 variants and early childhood 
adversity was described by Klengel et al. (2013), highlighting that the SNP rs136780 
is the functional variant in the disease associated haplotype, which can modulate 
enhancer-promoter chromatin contacts and is accompanied by allele-specific local 
demethylation of CpGs in a specific GRE enhancer. This thesis aims to further 
elaborate our understanding of this molecular mechanism integrating genetic and 
environmental factors by enabling new possibilities to investigate how environmental 
impacts are embedded into FKBP5 DNA methylation patterns and how other more 
complex variants in the disease associated haplotype of FKBP5 can impact the 
response to stressors. First, a new method - High accurate methylation 
measurements via targeted bisulfite sequencing (HAM-TBS) - was established to 
accurately and robustly measure DNAm levels in key regulatory sites of FKBP5 in 
larger cohorts of patients (Paper I and further discussed in Chapter 6.1). Second, the 
new possibilities of this method have been used to better understand the underlying 
dynamics of GC-induced DNAm changes in FKBP5 in healthy individuals upon a 
DEX challenge (Paper III) and preterm infants (Paper II, implications from Paper II & 
Paper III are further discussed in Chapter 6.2). Third, lymphoblastoid cell lines 
carrying different alleles for a 3.3 kb large INDEL in intron 1 within the FKBP5 gene 
have been used to identify if and how this structural variant in the disease-associated 
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haplotype contributes to shape GC-induced FKBP5 gene expression changes 
(Manuscript I and further discussed in Chapter 6.3). Finally, thoughts on future 
perspectives and potential translations into the clinical routine of the mechanistic 
insights of FKBP5 gene expression regulation are discussed in Chapter 6.4.  
 
6.1 Accurate and robust measurement of DNAm levels 
within the FKBP5 locus in patient cohorts 
A requirement to investigate epigenetic mechanisms and their contribution to 
common disease is the ability to accurately and robustly detect epigenetic marks 
such as DNAm. This is especially important for complex diseases, which involve 
multiple genetic and environmental factors. Therefore effect sizes of the single 
factors contributing to the development of complex diseases are rather small and 
pathological situations favorably emerge due to the interplay of these factors. In 
addition, mixed tissues like peripheral blood or saliva are often the only material 
available in larger patient cohorts. In mixed tissues, cell type specific methylation 
effects can appear and be masked due to the high abundance of DNA from non-
responsive cell types and therefore lead to small changes in methylation levels. In 
the light of this realization and the need of DNAm measurement in large human 
cohorts for research in epidemiology and medicine (Joubert et al., 2016), we 
developed the HAM-TBS method that assesses DNAm levels at a high accuracy and 
cost-efficient manner. Moreover, due to the high interest in the field of psychiatry for 
FKBP5, we established and validated a PCR panel for monitoring methylation levels 
of important regulatory regions within the FKBP5 locus.   
We chose a TBS (bisulfite conversion of DNA and subsequent target enrichment via 
PCR) workflow coupled with high-throughput sequencing since this enables the 
detection of methylation levels at base-pair resolution. Furthermore, TBS workflows 
have shown to be one of the best techniques to obtain comparable results between 
laboratories (consortium, 2016). The HAM-TBS is placed between whole genome 
bisulfite sequencing, which is cost intensive and due to the coverage needed (>60x) 
to detect differentially methylated sites (Ziller et al., 2015), and Pyrosequencing (Tost 
and Gut, 2007), which enables the assessment of DNA methylation levels accurately 
but lacks the throughput capabilities to assess multiple regions in larger cohorts. 
Illumina DNA methylation arrays are an example to obtain methylation levels at base 
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pair resolution in a cost-efficient manner but lack the coverage in key enhancer 
regions which are important for FKBP5 gene expression regulation and epigenetic 
mechanisms contributing to the development of psychiatric diseases (Klengel and 
Binder, 2013; Matosin et al., 2018; Zannas et al., 2016). 
In order to clarify which steps within the TBS workflow introduce the most variability 
onto the DNA methylation measurement we performed a validation experiment using 
in vitro methylated control DNA and different workflow conditions (replicates at the 
bisulfite treatment, PCR or library preparation step of the workflow). The results of 
this experiment indicate that each of the conditions were suitable to detect 
methylation levels at a high accuracy. Due to the experience that sample-to-sample 
variation of non-in vitro generated control samples (e.g. patient samples) can not be 
excluded, we recommend to use triplicate bisulfite treatment of each patient DNA 
which can be pooled and further processed as a pooled sample. Next, we compared 
the technical accuracy of the HAM-TBS workflow to Pyrosequencing, the gold 
standard method for assessing DNA methylation via targeted bisulfite sequencing. 
We found that the accuracy of the HAM-TBS workflow was higher than 
Pyrosequencing (Pyrosequencing mean SD = 4.68%, max. SD = 14.56% and HAM-
TBS mean SD = 0.72%, max. SD = 1.83%). To our knowledge, this accuracy for the 
measurement of DNA methylation is the highest reported so far in the literature. This 
level of accuracy for DNA methylation measurement could not only be useful for 
investigating small differences in patient samples but also be beneficial other fields 
like forensics (Vidaki and Kayser, 2018). The differences in accuracy can potentially 
be explained by the underlying detection principles of both techniques per se. TBS 
using Pyrosequencing deducts methylation levels by comparing the intensities of 
fluorescence signals under consideration of other reference intensities within the 
sequencing run. Over the length of the sequencing, the enzyme and nucleotides are 
consumed which leads to a decrease in signal intensities over the length of the run. 
We observe that this affects the accuracy of the methylation measurement and 
therefore we only use short sequencing (<30 dispensions) runs when using 
Pyrosequencing. It has to be noted that there are also further considerations to be 
aware of when designing Pyrosequencing assays to accurately obtain methylation 
levels such as long stretches of T-nucleotides that can affect the performance of the 
sequencing run after the long T-stretch. On the other hand, using the sequencing by 
synthesis technology from Illumina, methylation levels are calculated by comparing 
Discussion	
	 - 118 - 
the read counts of T´s and C´s at a distinct position. While the detection of the base 
itself is also based on a fluorescent signal the actual methylation level is not. In order 
to obtain suitable sequencing quality of the read, we filter out reads with a Phred 
score lower than 30. Moreover, to ensure an accurate detection of the methylation 
levels we established a three step quality control. First, we ensure a sufficient 
bisulfite conversion rate of 95 % per sample and amplicon. Second, PCR artifacts are 
removed and potential SNPs are monitored. Third, we and others found that a 
minimum coverage of 1000 reads per CpG is recommended for accurate methylation 
quantification (Masser et al., 2013). In comparison to other TBS workflows (Bernstein 
et al., 2015; Chen et al., 2017; Masser et al., 2013; Masser et al., 2015), we belief 
that reducing the amount of PCR steps within the workflow (we only use one PCR 
step for target amplification but eliminate the PCR step during the library preparation 
by ligating the adapters to the amplicons) helps to increase the accuracy of the 
methylation measurement due to the avoidance of potential amplification biases.  
Another benefit of using the sequencing by synthesis technology is the upscaling 
potential. Our HAM-TBS workflow currently allows to analyze 96 samples of targeted 
regions (about 10 kb) in one MiSeq run. This is only possible due to the 
implementation of the Agilent Tape station for amplicon quantification and the use of 
a liquid handling robot for amplicon pooling into the workflow. The use of the Tape 
station enables to quantify amplicon band concentrations without the detection of 
other DNA contaminants such as Primer dimer or unspecific bands in the PCR 
reaction. Therefore samples can be pooled using a pipetting robot prior to clean up of 
the PCR products with paramagnetic beads. This saves the amount of cost intensive 
beads. Furthermore, using a pipetting robot does not only free hands-on time but 
also avoids the problem of potential mis-pipetting and therefore increases the 
robustness of the workflow.     
Current limitations of the HAM-TBS are the need of PCR for target amplification but 
also the need to sequence longer reads to cover all CpGs within PCR amplicons. 
Performing single PCR reactions for each loci of interest in a large amount of 
samples is time and cost intensive. Furthermore, we observe PCR design limitations 
and amplification biases especially in CpG rich regions of the genome. Due to the 
harsh bisulfite treatment amplifying in target loci over 400 bp is challenging and 
introduces undesirable sample-to-sample variability. In addition, up to now Illumina 
sequencer allow a maximal read length of 300 bp (MiSeq which is limited to 25 
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million reads), which ideally would enable to cover 600 bp amplicons. Possible 
solutions to overcome some of these limitations are the optimization of multiplex PCR 
reactions or the use of other enrichment strategies such as capture-based methods 
(Brinkman et al., 2010; Sun et al., 2015).      
Due to the importance of FKBP5 in the field of psychiatry we designed and validated 
a PCR panel to accurately measure DNA methylation levels of key regulatory sites 
within the FKBP5 locus. We designed 29 amplicons that cover the TSS, TAD 
boundaries, intronic and proximal enhancers as well as GR and CTCF binding sites. 
Not only does the panel include sites that are potentially important gene expression 
regulation and have shown to be implicated in disease mechanisms (Klengel and 
Binder, 2013; Yehuda et al., 2013) but also a control PCR (h19, imprinted region 
should show a DNA methylation level around 50%, (Boissonnas et al., 2010)) which 
serve as an control for the DNA measurement of each sample. Each PCR was 
validated by an initial gradient PCR run to find robust cycling conditions. Moreover, 
using in vitro methylated control DNA we checked the PCRs in the panel for 
amplification biases.  
In summary, the HAM-TBS workflow is a versatile tool to accurately and cost 
efficiently measure DNA methylation levels of target loci which has the potential not 
only to enhance research of epigenetic mechanisms but also may influence other 
fields like forensics (Vidaki and Kayser, 2018). In this regard, the ability to detect 
small effects onto DNA methylation levels can lead to a more in deep analysis of 
disease mechanism including DNA methylation marks. On the other hand, the 
increased throughput of this method enables to measure methylation levels in larger 
patient cohorts and longitudinal studies. The community interested in the FKBP5 will 
benefit from the FKBP5 PCR panel since it enables the investigation of key 
regulatory sites which are not covered by the widespread commercial DNA 
methylation arrays used to cost efficiently assess methylation levels in cohorts.  
 
6.2 Embedding of environmental signals into FKBP5 DNAm 
levels 
The concept that environmental signals especially during sensitive phases can have 
an impact onto the phenotype and are mediated by epigenetic marks such as DNAm 
is well established (Szyf, 2013) and prominent examples are the agouti mouse model 
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(Jirtle, 2014; Waterland and Jirtle, 2003) or twin studies in humans (Fraga et al., 
2005). Although it has been thought that the DNAm patterns in cells are set after 
dynamic changes during embryogenesis, it now becomes clear that postnatal 
methylation changes can occur due to environmental signals (Dor and Cedar, 2018). 
Postnatal changes of DNAm has for example been shown in liver as a result of 
nutritional changes after birth (Cannon et al., 2016; Ehara et al., 2015), male liver 
through testosterone secretion (Reizel et al., 2015) and breast tissue after the first 
pregnancy (Dos Santos et al., 2015). The common conclusion in these examples is 
that DNAm changes are installed by hormone exposure and maintained to serve as a 
kind of memory of hormone exposure even after hormone levels are normalized 
again (Dor and Cedar, 2018).  A similar link is potentially observed when individuals 
are exposed to ELS. In regard of this concept, the release of GCs into the blood 
circulation after stress exposure could integrate the response including DNAm 
changes in many tissues, including the brain (Szyf, 2013). In fact, the embedding of 
ELS into the epigenetic layer in central and peripheral tissues has been described in 
rodents and humans for several genes of the HPA axis (NR3C1, Crh, Avp, Crfr2, 
FKBP5) but also for candidate genes outside the stress axis (SLC6A4, rRNA 
promoter, BDNF, Reelin, Gad1) (Klengel and Binder, 2013; Roth et al., 2009) and 
reviewed in Jawahar et al. (2015). Epidemiological studies find associations that 
early adversity can impact the susceptibility to develop a psychiatric disorder later in 
life and that the sensitivity to ELS can be mediated by FKBP5 genotypes (Matosin et 
al., 2018; Zannas et al., 2016). Moreover, the combination of ELS and FKBP5 has 
been associated with the occurrence of long-term stable alterations in methylation 
levels in distinct enhancer regions of FKBP5 (Klengel et al., 2013). The open 
question is whether the methylation changes in FKBP5 are already established 
directly after stress exposure in childhood, similarly as discussed above for other 
hormones, or if these are installed later in life when pathological phenotypes 
manifest. The observation that FKBP5 methylation differences between preterm 
infants and term babies at birth were resolved later in life (Paper II) are an indication 
for dynamic methylation changes after ELS. Dynamic changes have also been 
observed by an epigenome-wide association study (EWAS) (Cruickshank et al., 
2013) that highlighted many differences in DNAm (1555 sites) that were resolved at 
the age of 18 years, but did also show that the methylation level difference of CpGs 
at some loci persisted (PCSK9, TRIM71, SLC44A4, GPC6, NFYA and EGR1). In this 
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EWAS, CpGs at FKBP5 did not reveal any difference between preterm and term 
babies. This can on the one hand be explained by missing probes for important 
regulatory sites within FKBP5 such as inton 7 CpGs on the Illumina methylation array 
used in the EWAS study but, on the other hand, the use of DNA from different tissue 
(Paper II used buccal DNA and the EWAS study by Cruickshank et al. (2013) blood 
spots). Therefore the question arises how cells memorize the early exposure to high 
levels of stress in light of the dynamic methylation changes. In fact, we know very 
little about the variation of methylation marks in specific loci within the same 
individual (Zhang et al., 2013), especially under the influence of an environmental 
impact. One factor making it difficult to understand how early adversity can impact 
the susceptibility to develop a psychiatric disorder later in life is that this impact is 
influenced by a number of factors such as the nature of stressor, exposure in 
sensitive phases, severity, cumulative exposure effects but also biological factors as 
gender, age and genotypes (Jawahar et al., 2015). In this regard, using 
pharmacological challenges to mimic native GC exposure during stressful situations 
can be a valuable model to better understand the physiology of the embedding of 
environmental input into epigenetic layers. Therefore, to investigate the underlying 
dynamics of GC-induced methylation changes in FKBP5 we exposed healthy 
individuals to a DEX challenge (Paper III). 
The development of the HAM-TBS workflow enabled us to investigate GC-induced 
methylation changes at the FKBP5 locus at a higher accuracy and coverage of key 
regulatory sites (TSS, TAD boundaries, intronic and proximal Enhancer, and GR and 
CTCF binding sites). Due to the increased throughput we were able to test the 
methylation patterns (302 CpGs covered by 28 amplicons) in peripheral blood of 19 
healthy individuals after an acute DEX treatment (single oral dose of 1.5 mg DEX) for 
5 timepoints (baseline, 1 h, 3 h, 6 h, 23 h) and validated the DEX-induced effects in a 
larger independent sample (n = 89, baseline and 3 h after DEX). We detected GC-
induced methylation changes at 44 CpGs within the FKBP5 locus including CpGs in 
intron 7 and intron 5 which where shown to be associated with ELS (Harms et al., 
2017; Klengel et al., 2013) but also in healthy individuals after a 30-day cortisol load 
(CpGs in intron 2 & intron 7; Lee et al. (2018). The effects sizes ranged from -17% to 
+10% methylation difference, however, 74% of the CpGs analyzed showed 
decreased methylation levels after the exposure to DEX, which tend to co-localize 
with GR binding sites at the proximal and intronic GR enhancers. Similarly, studies in 
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rodents using continuous GC excess and DEX treatment of HPCs also observed 
reduced methylation levels in FKBP5 co-localizing with GR binding sites (Klengel et 
al., 2013; Lee et al., 2010; Seifuddin et al., 2017). Interestingly, we monitored GC-
induced DMCs after 1 h of the DEX exposure, which peaked between 3 h to 6 h and 
returned to baseline within 23 h and are inversely correlated with FKBP5 expression. 
Only 8 of the 44 DMCs, which revealed these dynamics remained significant after 
23 h and showed a much smaller effect size (mean absolute Δ methylation = 
⏐1.8%⏐). Moreover, we were able to show that allele of rs1360780 could moderate 
these methylation level dynamics supporting the idea that FKBP5 genotypes 
associate with differential sensitivity to GR activation as observed for differential 
effects of rs1360780 allele onto disease symptom severity (Klengel et al., 2013; Lee 
et al., 2010; Seifuddin et al., 2017), response to antidepressant treatment and 
recurrence of depressive episodes (Binder et al., 2004) but also neuroendocrine 
endophenotypes and other clinically relevant outcomes (reviewed in Matosin et al. 
(2018); Zannas et al. (2016)).  
Several mechanisms could contribute to the dynamics in DNAm observed in blood of 
(Paper III). On the one hand by controlling for cell type composition before and after 
DEX treatment we could show that at least some of the methylation changes were 
likely to appear within specific cells. Sorting cells and re-assessing our results in the 
sorted cells would give more information, which cells types contribute to the effects 
monitored. In fact, a study in mice could show by cell sorting and genome-wide 
bisulfite sequencing that the observed GC-induced methylation changes were 
observed primarily in blood T-cells (Seifuddin et al., 2017). On the other hand, 
mapping enhancers within the FKBP5 locus across many tissues, using chromatin 
states analyzed by the ENCODE project, suggest that most of the GR-responsive 
enhancers exert a shared function and thus may show a similar epigenetic response 
to GR activation across different cell types and tissues.  Due to the observation that 
many of the methylation changes appeared within or very close to GR binding motifs, 
a reduction in methylation following GC exposure could be mediated by a 
demethylation pathway involving transcription factor binding of the GR to GREs 
which has been reported by Thomassin et al. (2001) and Wiench et al. (2011). The 
mechanisms of this targeted demethylation remain unknown, but the involvement of 
DNA repair has been proposed (Kress et al., 2006). Interestingly, similar to the 
transient GC-induced methylation changes at the FKBP5 locus in blood rapid cyclical 
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methylation patterns have been reported for the pS2 gene in response to estrogen 
stimulation in breast cancer cells (Metivier et al., 2008). This study implicated that for 
the de- and remethylation processes at pS2 DNA methyltransferases, glycosylases 
and base excision repair proteins are involved. Given the similar reported kinetics of 
DNAm changes due to hormone exposure, the same enzymatic processes could be 
involved in GR-induced demethylation. We and others detected hormonal-induced 
methylation changes at specific CpGs which can appear transiently and be partially 
remethylated (Wiench et al., 2011) but also long lasting (Cannon et al., 2016; Dos 
Santos et al., 2015; Ehara et al., 2015; Klengel et al., 2013; Reizel et al., 2015). The 
question of how the dynamics of de- and remethylation are regulated remains open, 
but the importance of timing (e. g. development) and the local chromatin structure of 
the CpGs (e.g tissue specific binding of TF next to hormone receptor) has been 
discussed by Luo et al. (2018); Wiench et al. (2011). Therefore, hormone-induced 
methylation changes associated to different TF e.g. GR or STAT5 (Dos Santos et al., 
2015) could involve different processes of de- and remethylation, but also similar 
pathways, which lead to other dynamics. The processes of de- and remethylation 
could potentially be interfered by DNA-methyl binding proteins such as MeCP2 and 
polycomb complexes (Murgatroyd and Spengler, 2014) changing the methylation 
dynamics due to hormones from transient to long-term stable.  
In summary, the data presented in this thesis favor the hypothesis that environmental 
impacts can be embedded into epigenetic layers through the action of hormones, 
which have the potential to mediate the response to the environment across central 
and peripheral tissues. The processes involved in this embedding of environmental 
signals are not yet fully understood but several lines of evidence exist that these are 
active enzymatically driven that can lead to dynamic epigenetic changes and have to 
be seen in the light of temporal & spatial factors that can lead to transient but also 
long term stable epigenetic adjustments. However, to understand how an 
environmental signal - such as childhood stress - together with other important 
factors - like genotypes - can prime the underlying epigenetic processes to lead to 
disease phenotypes later in life, further research on these epigenetic processes has 
to be done. Essential in this regard will be the ability to model environmental signals 
on a molecular level, but also an animal or cell model to observe the embedding into 
epigenetic layers and manipulate the implicated processes.  
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6.3 Molecular mechanisms of GxE interactions in the 
FKBP5 locus  
In the same disease-associated haplotype of FKBP5 that comprises the SNP 
rs1360780, which is involved in a GxE mechanism shaping the risk for stress-related 
psychiatric disorders (Klengel et al., 2013), a larger structural variant can be found 
(Pelleymounter et al., 2011). This 3.3 kb INDEL (esv3608688) is located in intron 1 of 
the FKBP5 gene. The aim of this thesis was to better understand, how the 
combination of rs1360780 and INDEL allele in intron 1 influence the chromatin 
structure and therefore the potentially affect FKBP5 gene expression under basal 
and stress conditions. Moreover, the aim is to investigate which allele combination is 
more responsive to induction by glucocorticoids and possibly induce other epigenetic 
changes like DNAm levels of functional elements in the FKBP5 locus. 
By using allele-specific gene expression assays and heterozygote LCLs for 
rs1360780 allele we could show that a higher proportion of mRNA is generated from 
the T-allele in comparison to the C-allele. This is in line with the results from Klengel 
et al. (2013), who showed that the T-allele has a higher potential to induce gene 
expression in gene reporter assays. Furthermore, under the excess of GCs the 
proportion of mRNA generated from the T-allele is further increased in the LCLs.  
Interestingly, this differential gene expression response of rs1360780 allele is only 
observed in cells carrying the insertion allele. Moreover, we monitored the highest 
proportions of transcripts from the T-allele under the background of the deletion 
allele. In addition, the highest levels of total FKBP5 transcripts under the excess of 
GCs were observed in LCLs combining the T- and deletion allele. These data 
indicate that the INDEL allele does not only moderate the differential effect of 
rs1360780 allele on FKBP5 expression, but moreover both variants affect total 
FKBP5 transcript levels in an additive manner upon GC stimulation. The effects of 
rs1360780 allele onto FKBP5 expression can be explained on a molecular level by 
the establishment of an enhancer-promoter loop due to the formation of a TATA-box 
binding motif by the T-allele (Klengel et al., 2013). This leads to higher proportions of 
mRNA at baseline and even higher mRNA proportions from the T-allele under GC 
stimulation. In order to better understand how the large INDEL allele can modulate 
the rs136780 effects on a molecular level, we obtained high-resolution interaction 
profiles of the FKBP5 locus TSS and TAD applying a 4C approach. A benefit of our 
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4C viewpoint design was the simultaneous monitoring of interaction profiles of both 
viewpoints in the same sample. This was achieved by choosing the same 4 base pair 
restriction enzymes for the definition of both viewpoints. The interaction profiles 
obtained from LCLs showed locus interactions that are in line with the reference 
literature and revealed architectural loops mediated by CTCF but also enhancer-
promoter loops between the proximal GR and intronic GR-associated enhancers to 
the TSS ((Klengel et al., 2013; Paakinaho et al., 2010), CTCF-ChiA-PET, PolII-ChiA-
PET from Tang et al. (2015), Hi-C (Rao et al., 2014)). A comparison of the interaction 
profiles from cells carrying the insertion or deletion allele showed by interaction 
frequency peaks at position of the INDEL that the variant can be in close proximity to 
the TSS and TAD boundary. This involvement in the FKBP5 locus architectural and 
functional loop network indicates a potential ability to modulate gene expression, 
which is a first explanation for the INDEL expression effects monitored in these cells. 
Moreover, using the 4C-cker pipeline (Raviram et al., 2016) and DESeq (Love et al., 
2014), we were able to quantify the differences between the interaction profiles 
between the INDEL allele and DEX stimulation. The stimulation with DEX did not 
change the overall FKBP5 interaction profiles indicating the described pre-
established nature as a pre-poised gene (Jaaskelainen et al., 2011; Paakinaho et al., 
2010). However, we quantified an increase of interaction frequencies from the TSS to 
the proximal GR associated enhancer. This most likely indicates the observed gene 
expression induction due to GC excess through the long-range GR enhancer. In 
addition to the specific stabilization of promoter-enhancer looping, we detect an 
increase of interaction frequencies from the proximal TAD boundary over the FKBP5 
locus upon DEX stimulation. Together with the observation of increased interaction 
frequencies of the proximal to the intronic TAD boundary in cells harboring the 
deletion allele, we conclude that the INDEL allele and GC excess may affect the 
stability of the architectural CTCF mediated loop linking genotype and environmental 
signal. This interaction of genotype and environment on the level of chromatin 
architecture could explain the FKBP5 expression results monitored. In fact, the 
concept that the stability of loops is important for regulating gene expression (Hakim 
et al., 2011; Le Dily et al., 2014) and that pre-existing loops favor the response to 
external stimuli (Grbesa and Hakim, 2017; Jin et al., 2013) has been described. In 
regard to the idea that a dysregulation of architectural proteins / loops could lead to 
changes in the stability of promoter-enhancer interactions and altered response in 
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gene expression (Antony et al., 2015; Quintin et al., 2014; Seitan et al., 2013), we 
reason the following model for the integration of INDEL allele and GC excess to 
modulate FKBP5 gene expression (Figure 5).  
 
 
 
 
 
The structural basis of FKBP5 gene expression regulation is shaped by CTCF 
generating architectural loopings, which are described as TAD structure observed in 
Hi-C data (Lieberman-Aiden et al., 2009; Tang et al., 2015). These TAD loopings aid 
the formation of promoter-enhancer interactions, by restricting the promoter-
enhancer looping within the TAD boundaries. For FKBP5 pre-existing proximal & 
intronic GR enhancer loopings to the promoter (Paakinaho et al., 2010) are important 
to mediate the gene expression response after GR activation by GCs. The GC-
induced expression changes are associated with increased interaction frequencies 
between long-range promoter-enhancer loops but also from the proximal TAD 
boundary to the body of the FKBP5 gene. Genetic variants in FKBP5 locus can 
modulate the response to GR activation by affecting either GR-associated promoter-
Intronic CTCF interaction 
Proximal GRE enhancer 
INDEL 
TSS 
Intronic GREs 
GC exposure  Deletion Allele 
ü  Stabilization of long-range GRE interactions 
 
ü  Increased interactions from the proximal 
TAD boundary to the gene body 
ü  Stabilization of TAD architectural interaction 
 
ü  Increased interactions from the proximal 
TAD boundary to the gene body  
CTCF 
GRE  
The INDEL allele in FKBP5 affect GRE enhancer activity through the modulation of TAD 
interaction frequencies and regulate the responsiveness to glucocorticoid exposure  
Figure 5: A model how glucocorticoids and INDEL esv3608688 influence FKBP5 expression by modulating its 
underlying chromatin structure 
Source: Tobias Wiechmann, 2019 
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enhancer loops or architectural CTCF mediated interactions. For rs1360780, a loop 
between a GR enhancer in intron 2 and the promoter is established due to the 
formation of an additional TATA-box binding motif of the T-allele, which can increase 
the GC regulated FKBP5 induction (Klengel et al., 2013). The 3.3 kb INDEL on the 
other hand is associated to moderate the stabilization of the architectural loop 
between the proximal TAD and intronic TAD boundary. In this scenario, the deletion 
is associated to lead to increased interaction frequencies between TAD boundaries 
and production of FKBP5 transcripts. The common feature in this model is that 
genetic variants and GR activation are associated to stabilizing loops within the 
FKBP5 locus which is reflected by increased interaction frequencies and additive 
effects onto gene expression. In other words, the activity of the GR enhancers 
responsible for FKBP5 gene expression regulation is on the on hand regulated by the 
activation of the hormone receptor itself but also their probability to find the FKBP5 
promoter. This probability is regulated by genetic variants modulating the stability of 
the architectural interactions (INDEL esv3608688 allele) but also promoter-enhancer 
interactions (rs1360780 allele). Indications for the concept that the enhancer activity 
is regulated by the overarching TAD stability have been found by (Symmons et al., 
2016) by manipulating the Shh locus. To prove the causality of this concept for the 
FKBP5 locus similar locus manipulation experiments using the CRISPR/Cas9 system 
need to be performed.  
The involvement of other chromatin features defining of the activity of enhancers is 
plausible and DNAm levels have been proposed to be instructive for the activity of 
GR enhancers (Wiench et al., 2011). Using the HAM-TBS workflow we assessed the 
DNAm levels of 46 sites covering key functional regions of the FKBP5 locus (TSS, 
TAD boundaries, proximal and intronic GR enhancer), the region of the INDEL and 
other sites between TSS and INDEL of LCLs. The CpGs within the insertion allele 
show high methylation levels (InsertionVEH = 90.7 ± 8.5 %, n = 33). We observed 
significant genotype effects onto DNAm levels of 36 CpGs at proximal & distal TAD 
boundaries, TSS, GRE in intron 5 and GREs at the proximal enhancer. Effects onto 
methylation levels due to the INDEL allele have been monitored in both directions 
and depend on the location of the respective CpGs. Moreover, we detected a 
genotype effect onto methylation levels in an array of CpGs located in intron 1 (hg19 
/ chr6:35635518-35636055). This region showed increased methylation levels in the 
background of the insertion allele and has not yet been described to include 
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important regulatory sites. However, a potential role as an enhancer of this region in 
LCLs is implicated by the chromatin states of the ENCODE project using multiple 
epigenetic information and hidden markov models (Ernst and Kellis, 2012). No DEX-
induced methylation changes have been detected in the LCLs. Next to genotype 
effects of the INDEL allele onto chromatin interactions we detect DNA methylation 
levels changes at key functional sites involved in the formation of architectural and 
promoter-enhancer loops indicating a potential integration of both epigenetic layers. 
The absence of DEX-inducible methylation changes in the LCLs could be explained, 
on the one hand, by the chosen treatment conditions or tissue specific inability of the 
LCLs to respond to GR activation. To further dissect the importance of the INDEL 
allele onto chromatin interactions and DNA methylation levels to regulate FKBP5 
expression, experiments combining the manipulation of the DNA sequence but also 
the methylation levels of key regulatory sites of FKBP5 should be applied. Moreover, 
the observation of eRNA being produced from active enhancers (Mikhaylichenko et 
al., 2018) could be used to detect in vivo enhancer activity instructed by the 
production of eRNA from the respective enhancer in FKBP5. This would help to fine-
map the contribution of each specific GR-associated enhancer and better understand 
which manipulations of the DNA sequence or DNA methylation levels affect the 
activity of the FKBP5 enhancers. 
Although, there are preliminary findings from data obtained from PTSD patients that 
the INDEL allele moderate the symptom severity in a GxE manner, further analyses 
need to be performed to enhance the evidence for the INDEL allele to moderate the 
development of stress related disease phenotypes. Due to the development of the 
HAM-TBS workflow, there is now the possibility to investigate the INDEL effect onto 
the methylation level in patients. 
In summary, the data presented in this chapter extends the proposed molecular 
mechanism (Klengel et al., 2013) integrating genetic and environmental factors at the 
FKBP5 locus. We identified that the stabilization of architectural and enhancer-
promoter loops is a common feature of the factors (T-allele, deletion and GR 
activation by GCs) leading to increased FKBP5 mRNA expression. We and others 
(Symmons et al. (2016) and discussed by Beagrie and Pombo (2016), (Hakim et al., 
2011); Le Dily et al. (2014)) find indications that this gene expression response is 
most likely result of an increased activity of enhancers due to the stabilization of 
chromatin interactions. However, further experiments manipulating the DNA 
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sequence and DNA methylation levels of FKBP5 key regulatory sites will be 
necessary to obtain causality. Moreover, further analysis in patients will help to clarify 
the role of INDEL allele in the development of stress-related phenotypes.  
 
6.4 Future perspectives towards translation 
The syndrome-based disease classification has been identified to be one of the 
major challenges in psychiatry (Stephan et al., 2016). In order to enable the 
translation of the rapidly increasing knowledge of our genome and the regulation of 
its output into the clinical routine, we need to overcome the over-dependency of 
subject questionnaires and favor an integrative classification system that is also 
based on biological information of the individuals. Promising approaches to establish 
such integrative systems are the Research Domain Criteria (RDoC) Initiative of the 
National Institute of Mental Health (NIH) or the BeCOME study (Biological 
Classification of mental disorders) of the Max-Planck Institute for Psychiatry 
(https://www.psych.mpg.de/become). The work of Consortia is especially important to 
enable the integration of multi-omics data and promote its availability to better 
investigate complex diseases. In the context of psychiatry the PsychENCODE 
Consortium recently developed a comprehensive functional genomic resource for the 
adult human brain (Wang et al., 2018a). This resource includes various epigenomic 
datasets highlighting the importance of understanding epigenetics in psychiatry.    
Biomarkers enabling patient stratification developed by molecular and biological 
insights of disease mechanisms could have a beneficial impact onto clinical decision-
making and improve prevention and personalized treatment of individuals. The only 
U.S. Food and Drug Administration (FDA)-approved genetic biomarkers in the field of 
psychiatry is the genotyping of CYP2D6 and CYP2C19 allele (Winner et al., 2013). In 
this case the biomarker is used to detect inter-individual differences of antidepressant 
metabolization and therefore the choice and dose of antidepressant can be reflected 
by the clinician accordingly. Other promising candidate genes to serve as a 
biomarker in the context of stress-related disorders are FKBP5, DDX6, B2M, LAIR1, 
RTN4 and NUB1 (Le-Niculescu et al., 2019). FKBP5 gene expression regulation has 
been shown to involve complex interactions of genetic variants but also 
environmental stressors that can lead to FKBP5 disinhibition. This disinhibition has 
been shown to co-occur in a great amount of aberrant phenotypes in rodents and 
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humans (Matosin et al., 2018; Zannas et al., 2016). Therefore, a promising treatment 
intervention for at least a subset of patients suffering from stress-related disorders 
would be the blockage of FKBP5. The development of selective FKBP51 antagonist 
(Gaali et al., 2015) showed first encouraging results in rodents by reducing anxiety 
and increasing stress-coping (Gaali et al., 2015; Hartmann et al., 2015) as well as 
increasing GR sensitivity and promoting the negative feedback of HPA axis 
regulation (Gaali et al., 2015). A caveat for the use of FKBP51 antagonist is the 
pleiotropic function of this chaperone in several signaling pathways (Zannas et al., 
2016). However, FKBP51 blockage may also lead to adverse consequences owing to 
the association that FKBP5 genotypes leading to the increased response might also 
favor antidepressant responses (Binder et al., 2004; Zou et al., 2010) and that 
FKBP51 can promote antidepressant activity (Gassen et al., 2016; Gassen et al., 
2014). In this regard, the same alleles but in different environmental contexts can act 
negatively but also positively, therefore the term  “risk” or “protective” FKBP5 allele 
have to be seen in context of the specific environmental setting and may be better 
termed “environmental sensitive” or “plasticity” alleles (Klengel and Binder, 2013). An 
example of this is the observation that rs1360780 T-allel carriers, which were 
exposed to childhood and adult trauma revealed an increased likelihood to exhibit a 
psychiatric disease phenotype. However, when T-allele carriers were exposed to 
adult trauma only, this likelihood was decreased (Klengel and Binder, 2013; Klengel 
et al., 2013). Key questions are, if the environmental sensitivity of these alleles in can 
be mediated by epigenetic changes and if we can steer those to achieve beneficial 
outcomes for individuals. The described GC-induced dynamic methylation changes 
and the moderation by rs1360780 allele (Paper III) can be seen as an indicator for 
the potential of epigenetic marks being involved in the differential response to the 
environmental context. The ability to manipulate the environmental sensitivity to favor 
the response to the environment onto trajectories of beneficial outcomes could be a 
great opportunity for the treatment of patients. FKBP5 genotypes and DNA 
methylation levels could serve as a marker for the current status of the sensitivity to 
the environment and help to monitor the effectiveness of interventions to steer the 
sensitivity to facilitate beneficial outcomes. To translate the concept of steering 
environmental sensitivity of individuals, one has to gain further insights into the 
epigenetic molecular mechanisms involved. Further experiments should address, if 
the environmental sensitivity can be modulated in animal models linking the changes 
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in environmental sensitivity to behavioral outputs. In addition, delivering the tools for 
biomarker research to apply this concept in a clinical setting.  
Potential FKBP5 biomarker for a biologically-based stratification of patients to enable 
an enhanced personalized treatment of patients with stress-related diseases will 
probably include the detection of multiple FKBP5 variants but also epigenetic 
markers like DNA methylation levels of distinct CpGs (Figure 6). The future progress 
of tools for biomarker research such as HAM-TBS and the FKBP5 panel will be 
essential to enable the development of epigenetic-based biomarkers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biological-based disease classification 
FKBP5 disinhibition Other 
FKBP5 biomarker 
Treatment A Treatment B 
G à E sensitivity 
DNAm à Memory of E  
Figure 6: A biological-based disease classification system and potential FKBP5 biomarker have a great potential 
to enhance translation in psychiatry  
In order to enable the translation of the increasing knowledge of our genome and the regulation of its output, a shift from a 
syndrome-based disease classification system to an integrated biological-based system seems promising. This 
classification system will potentially include FKBP5 disinhibition to indicate a substructure of patients in which the 
blockage of FKBP5 or manipulation of environmental sensitivity is promising. FKBP5 biomarker should include genotypes 
but also DNA methylation levels to instruct the best treatment choice for patients displaying FKBP5 disinhibition.       
Source: Tobias Wiechmann, 2019 
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